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Abstract 
Prostate cancer is the most common male cancer in the UK and USA, with a 1/13 chance of 
diagnosis and a 1/30 lifetime risk of death from the disease. Current treatment options 
include radiotherapy, surgery and hormone therapy, however 1/3 patients escape from all 
therapies and novel therapies are urgently required for this patient group. The University of 
Birmingham gene therapy group constructed two oncolytic adenovirus vectors, CRAd-NTR 
and vNR6, both of which contained the E1B-55K deletion and expressed the transgene 
nitroreductase for combined oncolytic virotherapy and enzyme/prodrug gene therapy. The 
latter of these two vectors, vNR6, expressing nitroreductase from the pIX virus promoter 
demonstrated the greatest cytotoxicity at low virus concentrations however also showed 
some lytic activity to non-transformed human fibroblasts. Our collaborators at the Institut 
Català d'Oncologia designed a panel of oncolytic adenovirus vectors with the E1A CR2 24 
deletion and the E1A promoter replaced by an insulated E2F-1 promoter. The latest two in 
this series of vectors, termed ICOVIR-5 and ICOVIR-7, provide potential oncolytic 
backbones for the introduction of the therapeutic transgene nitroreductase. The aim of this 
thesis was therefore to „arm‟ the ICOVIR based vectors with nitroreductase for combined 
oncolytic virotherapy and enzyme/prodrug therapy. At the beginning of this study no 
reports were published with either ICOVIR-5 or ICOVIR-7 based vectors. It was therefore 
first decided to construct both vectors expressing the marker transgene eGFP. These vectors 
were characterised in terms of cytotoxicity, transgene expression, DNA replication and E1A 
expression. Furthermore, these vectors were compared to the vNR3, an E1B-55K deleted 
virus similar to vNR6, but the eGFP ORF replacing that of pIX. The ICOVIR-7 based 
vectors were identified as being the most tumour selective vectors and demonstrated no 
cytotoxicity to non-transformed human fibroblasts, and were therefore chosen for the 
 III 
introduction of the therapeutic transgenes. The new ICOVIR-7 based vectors were 
constructed to express either wildtype, double mutant or triple mutant nitroreductase. 
Double and triple mutant nitroreductase are two previously characterised mutant 
nitroreductases, which show enhanced catalytic activity for the prodrug CB1954. The new 
nitroreductase expressing ICOVIR-7 vectors were characterised in terms of virus mediated 
cytotoxicity, tumour selectivity, E1A and NTR expression and cytotoxicity with the 
prodrug CB1954. One vector, expressing double mutant nitroreductase, showed the highest 
tumour selectivity and greatest combined cytotoxicity with the prodrug CB1954. 
Furthermore, this vector showed greater tumour selectivity and combined cytotoxicity than 
the E1B-55K deleted vector vNR6. 
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CHAPTER 1   
 
Introduction 
 2 
1.1 Gene Therapy 
Gene therapy is the therapeutic delivery of exogenous genetic material including DNA, 
RNA or oligonucleotides, into the cells of an organism for the treatment of a disease. Over 
the past 50 years gene therapy has progressed from a theoretical principle into clinical trials, 
with over 1000 clinical trials completed to date [www.wiley.co.uk, Dec. 09]. In 2004 China 
became the first country to approve a commercial gene therapy product for the treatment of 
cancer patients [Peng, 2005].  
 
The primary objective of this study is the development of adenovirus vectors for cancer 
gene therapy. However initial gene therapy attempts focused on treating single gene 
defects, an approach which is still in trial and has had impact on the gene therapy of cancer. 
This introduction will therefore briefly review some key examples of gene therapy of single 
gene defects, before discussing some of the viral vectors used for cancer gene therapy. The 
biology of adenoviruses will be discussed in greater detail, before reviewing the application 
of adenoviruses for cancer gene therapy. 
1.1.1 Monogenic Diseases 
The single gene defects that give rise to monogenic diseases provide a relatively easy target 
for gene therapy by simply introducing the wildtype gene into the cells with the mutant 
version. Thus monogenic diseases were the first targets for gene therapy. This next section 
will cover some of the efforts to treat monogenic diseases, which have had implications for 
the treatment of more complex diseases such as cancer. 
 3 
1.1.1.1 Cystic Fibrosis 
With a prevalence of approximately 1 in 2000, cystic fibrosis (CF) is the most common 
lethal hereditary disease among Caucasians. The disease presents itself as chronic lung 
inflammation, chronic pulmonary infection and digestive problems and at best reduces life 
expectancy to 45 years [Bobadilla et al, 2002; FitzSimmons, 1993]. CF is the result of a 
mutation within the cystic fibrosis transmembrane conductance regulator (cftr) gene, which 
produces a mutant CFTR protein with a defective cAMP-regulated chloride channel 
function [Bear et al, 1992; Riordan et al, 1989]. This is located on the long arm of 
chromosome 7 [Knowlton et al, 1985] and the most common mutation was shown to be a 
whole codon deletion resulting in the loss of phenylalanine at position 505 [Kerem et al, 
1989]. 
CF is a good target for gene therapy as the single gene defect makes it easy to replace, the 
mutant cftr gene is recessive suggesting gene dose is not critical and the accessibility of the 
lung should make it easy to treat. Furthermore the progressive nature of the disease means 
that a normal phenotype is present at birth, providing a window for treatment [Lee et al, 
2005]. 
Gene therapy has focused on using adenovirus (Ad), adeno-associated virus (AAV) or 
cationic liposomes to deliver the entire 6.5kb wildtype cftr gene or 4.45kb cftr cDNA 
[reviewed by Lee et al,  2005]. 
The first gene therapy trial for CF was conducted in 1993 using a replication deficient Ad 
vector [Wilson et al, 1994] and many subsequent trials using Ad vectors have been 
conducted. Unfortunately multiple groups have identified several limitations with Ad based 
delivery. The thick bacterially infected mucus that covers the CF airway presents a barrier 
for gene delivery [Stern et al, 1998]. Inflammatory responses have consistently been 
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identified with Ad vectors due to innate immunity, cell-mediated immunity and humoral 
immune responses [Lee et al,  2005; Schwiebert, 2004]. Poor cftr gene transduction has 
been observed with Ad vectors, in part due to the lack of the primary adenovirus receptor 
CAR, on the luminal surface of respiratory cells. However CF still remains one of the 
primary targets for gene therapy and different strategies are being investigated to overcome 
the limitations and setbacks identified so far [review by Mueller and Flotte, 2008]. 
1.1.1.2 SCID-X1 
X-linked severe combined immunodeficiency (SCID-X1) disease is caused by mutations 
within the cytokine receptor common gamma chain (c). The c cytokine receptor subunit 
forms part of the receptor complex for cytokines such as interleukins 2, 4, 7, 9, 15 and 21, 
and its functional loss is characterised by a complete block in T and NK lymphocytes 
differentiation. Patients with SCID-X1 or so-called „Bubble babies‟ suffer severe clinical 
infections and have exceptionally low life expectancies [Cavazzana-Calvo and Fischer, 
2007; Fischer, 2000]. 
Gene therapy trials of SCID-X1 commenced in 1999 in London and Paris, using a non-
replicating retroviral vector expressing the c cDNA from the long terminal repeat (LTR) in 
CD34+ haematopoietic cells. Nine out of 10 patients from the Paris trial showed emergence 
of gene-corrected T and NK cells, with 7 of these 9 patients reaching normal T cell counts. 
Even after 8 years these patients remain immunocompetent [Cavazzana-Calvo and Fischer 
2007; Hacein-Bey-Abina et al, 2002]. 
Unfortunately 4 patients from this trial have developed lymphoproliferative disease from 
clonal T cell proliferation, leading to the death of one patient, with the remaining 3 under 
chemotherapy and in complete remission. In three of the 4 patients the disease was the 
result of a single retroviral integration event, causing aberrant expression of the LIM 
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domain only 2 (LMO2) proto-oncogene. From the London trial one of ten patients 
developed leukaemia post treatment, also associated with insertional activation of the 
LMO2 gene, but is now in complete remission. Unfortunately LMO2 mediated oncogenesis 
is poorly understood and it is not clear whether retroviral insertion alone accounts for the 
malignant transformation [Hacein-Bey-Abina et al, 2003; reviewed by Qasim et al, 2009]. 
Extensive efforts have been made by researchers to improve the safety of viral vectors that 
function by genome insertions, such as inhibiting unwanted expression and promoting site 
directed integration (see section1.1.3.1.2.1). However the use of integrating vectors may be 
essential for the long-term expression of therapeutic genes. 
1.1.1.3 Adenosine Deaminase (ADA) Deficiency 
ADA deficiencies contribute to approximately 20% of all severe combined 
immnodeficiencies (SCID). The ubiquitous enzyme ADA reversibly converts adenosine 
and 2‟-deoxyadenosine to inosine and 2‟-deoxyinosine, respectively. ADA patients have 
mutations within the ADA gene, resulting in a build-up of adenosine and deoxyadenosine 
both of which are indirectly toxic to lymphocytes. In most cases ADA deficiency results in 
very low T and B cell counts, which can be accompanied by skeletal abnormalities and 
neurological problems [Fischer 2000]. 
Gene therapy trials have been conducted for the treatment of ADA deficiency, through the 
ex vivo transduction of autologous T cells and haematopoietic stem cells with a retrovirus 
expressing ADA followed by re-infusion [Cavazzana-Calvo and Fischer 2007]. In general, 
gene therapy trials using this system in conjunction with replacement ADA (either bovine 
ADA or PEG-ADA) were not greatly successful. It would seem that the treatment with 
replacement ADA negated the selective advantage of transduced cells over un-transduced 
cells. However no toxicity was observed, and in many patients the transduced T cells 
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persisted for several years. Since the initial attempts clinical trials have been more 
successful by using improved gene transfer protocols and no PEG-ADA. Combined results 
from three trials treating over 20 patients have shown limited toxicity and at least a partial 
recovery of immune function. Taken together these trials demonstrate direct clinical benefit 
from gene therapy of ADA deficiency. In comparison to previous SCID-X1 trials no 
patients in ADA deficiency trails showed problems from retroviral integration into known 
oncogene sequences, demonstrating the future potential of ADA gene therapy [reviewed by 
Gaspar et al, 2009]. 
1.1.2 Other Gene Therapy Targets 
Following the initial gene therapy trial for ADA deficiency in 1990 it was quickly realised 
gene therapy held potential for the treatment of a wide range of diseases. Since then clinical 
trails have been initiated for cardiovascular, infectious, neurological and ocular diseases 
plus 17 other monogenic disease (summarised in Figure 1-1), all of which are outside the 
scope of this work, but have been extensively reviewed previously [Edelstein et al, 2004]. 
Over recent years the greatest effort has been focused on gene therapy of cancer diseases. 
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Figure 1-1. Gene therapy trials by target 
Worldwide gene therapy trials by disease. [www.wiley.co.uk, Dec. 09]. 
 
1.1.3 Cancer Gene Therapy 
Over the past three decades worldwide efforts have led to an increase in our understanding 
of the molecular mechanisms and pathogenesis of cancer. Whereas cancer incidence rates 
have increased over the past 38 years, mortalities due to all cancers have decreased. Still 
more than 155,000 (>30% of the total deaths) people died from cancer in 2007 in the UK 
alone [www.statistics.gov.uk/statbase/, Dec. 09]. 
Current treatments for cancer comprise surgery, chemotherapy, radiotherapy and hormone 
therapy. However, current treatments often have unwanted side effects and do not guarantee 
a cure. This emphasises the need for new cancer therapies, reflected in the fact that over 
60% of all gene therapy trials conducted to date are for the treatment of cancer (Figure 1-1). 
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Currently several gene therapy strategies have been investigated for the treatment of cancer. 
All gene therapy strategies require a vector to deliver the therapeutic nucleic acids into 
target cells. This next part covers some vectors that have been investigated for cancer gene 
therapy; briefly addressing non-viral vectors before reviewing the more frequently used 
viral gene delivery vectors. Following this general introduction adenovirus will be 
discussed in more detail, first by summarising the adenovirus lifecycle before focusing on 
how these viruses are used for cancer gene therapy. 
1.1.3.1 Cancer Gene Therapy Vectors 
Two thirds of all ongoing gene therapy clinical trials use viral vectors for the delivery of 
genetic material. This can be sub-divided into 6 main virus vectors, summarised in Figure 
1-2, demonstrating the wide range of vectors, which have been used for the delivery of 
therapeutic genes. In addition to these vectors several non-viral methods have been 
investigated, including physical, chemical and bacterial vectors.  
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Figure 1-2. Vectors used in gene therapy clinical trials 
Gene therapy trials by vector. [www.wiley.co.uk, Dec. 09]. 
 
1.1.3.1.1 Non-Viral Vectors 
The non-viral gene delivery vectors can be divided into three sub-groups; physical gene 
delivery, chemical gene delivery and non-viral biological gene delivery. Numerous studies 
have investigated methods for non-viral gene delivery, all of which are outside the scope of 
this thesis, however the more advanced ones have been reviewed previously [Gao et al, 
2007; Niidome and Huang, 2002; Seow and Wood, 2009]. 
1.1.3.1.2 Viral Vectors 
1.1.3.1.2.1 Retrovirus 
Retroviridae are a large family of viruses split into two subfamilies; Orthoretrovirinae 
which contains 6 recognised genera (alpharetrovirus, betaretrovirus, deltaretrovirus, 
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epsilonretrovirus, gammaretrovirus and lentivirus) and Spumaretrovirinae which only 
contains one recognised genera (spumavirus) [www.ictvonline.org, Dec. 09]. All 
retroviruses are lipid enveloped single-stranded RNA viruses with a genome of 7-13kb and 
contain long terminal repeat sequences (LTR), which flank retroviral genomes of varied 
complexity. The simplest retroviral genomes encode just 3 genes: gag, pol and env, which 
can be found in all retroviral genomes. More complex retroviruses, such as the lentivirus 
HIV-1, can encode multiple accessory proteins, which have added functions in the viral life 
cycle [Hu and Pathak, 2000]. 
Retroviral infection starts with entry of the virion core into the host cell. The viral RNA 
genome is reverse-transcribed into a linear dsDNA genome by the viral encoded reverse 
transcriptase. The dsDNA genome is transported to the nucleus where it is integrated into 
the host cell genome. The integrated virus, termed provirus, is transcribed by cellular RNA 
polymerase II. A fraction of transcribed viral RNA is translated by cellular machinery to 
produce the viral proteins. The remaining full length viral RNA assemble with viral 
proteins to form the progeny virions, which bud out of host cells [Hu and Pathak 2000]. 
Many of the initial cancer gene therapy studies used retroviral vectors. To date retroviruses 
remain the second most used vector for gene therapy (see Figure 1-2). Most cancer gene 
therapy studies use non-replicating retroviruses, in which up to 8kb of transgenes are 
flanked by LTR sequences. Virion packaging is enabled by the packaging sequences, 
generally located within or near the LTR. Production of such gutted vectors requires the 
essential viral genes (gag, pol and env) to be supplied in trans, normally from a packaging 
cell line. 
Most early studies used the Moloney murine leukaemia virus (MoMuLV), with transgene 
expression from the promoter/enhancer elements present in the U3 region of the 5‟ LTR, 
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which is copied from the 3‟ LTR upon reverse transcription. Self inactivating or SIN 
vectors were developed, which have the promoter/enhancer elements within the U3 region 
of the 3‟ LTR deleted, thus upon reverse transcription and provirus formation, the resulting 
5‟ LTR also lacks these transcriptional regulatory sites. Transgene expression is then driven 
from specific promoter/enhancer elements inserted upstream of the transgene, but outside 
the LTR regions. SIN vectors therefore allow greater regulation of transgene expression and 
also greater safety by reducing the possibility of activating adjacent cellular oncogenes [Yu 
et al, 1986]. 
MoMuLV cannot cross the nuclear membrane and therefore can only transduce dividing 
cells. This can be a significant disadvantage since at any one time not all tumour cells will 
be dividing. It is worth noting that some groups have found this an advantage, when the 
requirement is to target dividing cells [Liu and Deisseroth, 2006]. 
To overcome this problem new generations of lentivirus vectors were created, generally 
based around human immunodeficiency virus 1 (HIV-1). These vectors are able to 
transduce both dividing and non-dividing cells, greatly widening the target cell types. 
Extensive work has since been performed using lentiviral vectors to improve production, 
transduction and transgene expression [review by Delenda, 2004; and Liu and Deisseroth 
2006]. 
Multiple studies have used pseudotyped lentiviral vectors to expand upon the natural 
cellular tropism. Pseudotyping is achieved by incorporating heterologous viral 
glycoproteins into the viral envelope and has been performed with both lentiviral and non-
lentiviral glycoproteins [reviewed by Cronin et al, 2005]. 
All retroviral vectors are able to support long-term transgene expression, often a 
requirement for a gene therapy vector. However, retrovirus integration favours 
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transcriptional active gene regions, leading to the possibility oncogenesis [Ciuffi et al, 
2005; Ciuffi et al, 2006]. However by using SIN and non-integrating vectors these dangers 
can be reduced. 
Retroviral vectors have been used extensively in vitro with several different strategies for 
cancer gene therapy [and by Dalba et al, 2007; reviewed by Kafri, 2004]. These have 
translated into over 20 phase II trials using different strategies, however only the thymidine 
kinase – ganciclovir system has been put into phase III clinical trails [www.wiley.co.uk, 
Dec. 09]. 
1.1.3.1.2.2 Herpes Simplex Virus 
There are two types of herpes simplex virus, type 1 (HSV-1) and type 2 (HSV-2), which are 
part of the large family of Herpesviridae and fall into the genus Simplexviruses 
[www.ictvonline.org, Dec. 09]. HSV-1 is a large enveloped virus, with a dsDNA genome of 
approximately 150kb, and can undergo both a lytic and latent life cycle. HSV-1 lytic 
infection begins with entry into the host cell, where the viral dsDNA enters the nucleus 
along with the viral structural protein VP16. Following entry a cascade of gene expression 
is activated, starting with immediate-early gene expression that is activated by VP16. 
Immediate-early gene expression is followed by expression of early and late genes, which 
encode the proteins required for DNA replication and the viral structural proteins. New 
virions are assembled and released by lysis of the host cell [Burton et al, 2001; Shen and 
Nemunaitis, 2006]. 
Upon entry into neuronal cells, HSV-1 can undergo lytic infection, but can alternatively 
enter a latent infection. In latent infection the viral genome persists as a stable episomal unit 
that adopts a chromatin-like structure. During latency no immediate early, early or late 
genes are expressed, but a set of nontranslated RNA species termed the latency-associated 
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transcripts (LATs) are synthesised from the inverted repeat sequences. Latency can persist 
for many years, and sometimes the entire lifetime of the host. Alternatively latent infection 
can revert to lytic infection, typically following environmental stresses and immuno-
suppression [Burton et al,  2001; Shen and Nemunaitis 2006]. The exact mechanism behind 
the latent to lytic transition is unknown, however recent studies have implicated chromatin 
as an important factor in the switch from latent to lytic infection [reviewed by Knipe and 
Cliffe, 2008]. 
Gene therapy vectors based on HSV-1 were primarily developed for targeting the central 
nervous system. Initially HSV-1 vectors were developed into 2 different vector systems: 
recombinant and amplicon. More recently a third system has been developed using 
oncolytic HSV-1 vectors. 
Recombinant HSV-1 are non-replicating vectors, which contain deletions in genes essential 
for virus replication. Use of packaging cell lines to complement the removal of essential 
genes allow relatively high titres of virus to be produced [Dobson et al, 1990]. Large 
deletions in essential genes can allow them to accommodate 30kb of transgenes inserts. 
Recombinant vectors retain most of the viral genome, leaving the possibility of low level 
viral gene expression, leading to an immune response and subsequent cytotoxicity [Burton 
et al,  2001]. 
HSV amplicons are non-replicating vectors, which contain no viral genes. Their genome 
consists of a circular DNA element, which contains one copy of the origin of replication 
and packaging sequences, leaving up to 130kb free for insertion of large or multiple 
transgenes. Production of amplicon vectors requires all the viral genes to be supplied in 
trans, since they contain no viral genes themselves. This can be achieved by using non-
replicating helper viruses, which yield amplicon vector stocks contaminated with helper 
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viruses [Spaete and Frenkel, 1982]. Helper virus contamination can give rise to an 
unwanted HSV helper virus directed immune response, along with some associated toxicity. 
Helper virus contamination can be overcome by using a packaging defective, replication-
defective helper HSV-1 genome. Alternatively, all the genes essential for virus replication 
can be supplied in trans from overlapping cosmid vectors or bacterial artificial 
chromosomes [Fraefel et al, 1996; Sena-Esteves et al, 2000]. Removal of helper virus 
contamination eliminates most of the associated immune response and toxic side effects. 
However, such methods are more complicated and yield lower virus titres [all reviewed by 
Epstein, 2005]. 
The first replication competent oncolytic herpes viruses were developed in 1991 and tested 
using subcutaneous and subrenal malignant gliomers in nude mice [Martuza et al, 1991]. 
Since then many conditionally replicating HSV-1 vectors have been constructed, for the 
treatment of a wide range of human cancers [reviewed by Varghese and Rabkin, 2002]. The 
first generation vectors contained single deletions or mutations in genes essential for viral 
replication in normal cell, but which could be partially substituted in cancer cells, (e.g. 
deletion of the HSV encoded thymidine kinase). These vectors were selective for 
replication in dividing cells, and were unable to replicate in non-dividing cells. However 
these vectors were found to be non-specific in their replication and showed associated 
neurotoxicity. Subsequent second and third generation conditionally replicating vectors 
were created which contained multiple deletions/mutations in viral genes. 
More recently tumour or tissue targeted vectors have been engineered, by the insertion of 
tumour/tissue specific promoters and insulator elements. These vectors showed better 
tumour specificity and reduced neurovirulence [Ring, 2002; Varghese and Rabkin 2002]. 
All HSV-1 oncolytic vectors are able to carry very large transgene insertions (up to 30kb), 
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due to the large number of non-essential genes that can be removed. Furthermore many 
non-essential genes are associated with neurovirulence; hence their deletion can increase 
the safety of the vector, while also increasing the transgene capacity. These facts, coupled 
with their ability to replicate in a large range of tumour cell types, make them ideal for 
oncolytic cancer gene therapy. 
HSV vectors have been tested in clinical trials for the treatment of a variety of cancers 
including glioma, melanoma, head-and-neck cancer, prostate cancer and mesothelioma, 
which have been previously reviewed [reviewed by Shen and Nemunaitis 2006]. 
1.1.3.1.2.3 Adeno-Associated Virus 
Adeno-associated virus (AAV) was initially discovered in 1965 contaminating stocks of 
simian adenoviruses [Atchison et al, 1965]. Since then human AAV has emerged as a small 
collection of viruses, numbering only 7 species (11 serotypes) that belong to the genus of 
Dependovirus, within the family of Parvoviridae [Choi et al, 2005; www.ictvonline.org, 
Dec. 09]. AAV is one of the smallest viruses, with a non-enveloped capsid 22-26nm in 
diameter. AAV has an ssDNA genome, of approximately 4.7kb that contains two open 
reading frames (ORF) and inverted terminal repeat (ITR) sequences flanking either end of 
the genome. The two ORF, rep and cap, encode for all the 7 AAV proteins, through the use 
of alternative promoters and differential splicing. The rep ORF produces 4 proteins that are 
involved in viral DNA replication (Rep proteins), while the cap ORF produces the 3 viral 
capsid proteins (VP1-3) [Goncalves, 2005]. The ITR elements contain the minimal cis-
acting sequences required for DNA replication and packaging. AAV can undergo two 
separate lifecycles: a lytic and a lysogenic [reviewed by Goncalves 2005]. 
AAV lytic growth requires co-infection with helper viruses such as adenovirus (mediated 
by the E1, E2A, VA RNA and E4orf6 proteins) or herpes simplex virus (mediated by the 
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Helicase/primase complex, DNA binding protein, ICP0, ICP4 and DNA polymerase 
complex). Helper virus infection activates the AAV gene expression cascade, which leads 
to Rep mediated provirus excision. Viral DNA replication and packaging follow, both of 
which require the viral ITR sequences. Stress conditions such as metabolic inhibitors and 
DNA damage have also been shown to induce low level AAV lytic growth, in the total 
absence of helper virus, demonstrating AAV is not absolutely replication defective 
[Yalkinoglu et al, 1988]. 
In absence of a helper virus AAV normally undergoes lysogenic infection. Within lysogenic 
infection minimal AAV gene expression acts to auto-repress full AAV gene expression and 
the genome is integrated into the host genome as a provirus. Viral genome integration 
preferentially targets a 2kb region on the long arm of human chromosome 19 [Kotin et al, 
1990; Samulski et al, 1991]. Site specific integration requires cis components supplied by 
the ITRs and two viral encoded Rep proteins, Rep78 and Rep68; without these integration 
is random. 
AAV are attractive gene therapy vectors because they can infect a wide range of cell types, 
both dividing and non-dividing, and can persist over several years, allowing long-term gene 
expression. 
AAV vectors have all viral genes deleted, containing only transgenes flanked by the viral 
ITRs. Due to the comparatively small genome size up to 4.7kb of transgenes can be 
inserted, in comparison to other vectors that can carry much large inserts (such as herpes 
simplex virus) [Flotte, 2000]. Furthermore, transgene expression takes substantially longer 
than other vectors, requiring several weeks to months in certain situations [Fisher et al, 
1997]. However studies using so called „self-complementary‟ vectors, which form dimeric 
genomes to alleviate the requirement of host cell mediate second strand viral DNA 
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synthesis, have been shown to greatly reduce this time [McCarty et al, 2001]. Because AAV 
vectors are essentially „gutted‟, vector production requires all viral genes to be supplied in 
trans, and can be done through co-infection with helper virus such as adenovirus. AAV 
vectors need to be separated from helper virus, bringing the possibility of helper virus 
contamination. Alternatively the AAV viral genes and essential helper viral genes can be 
expressed on plasmids. Whereas this method can eliminate helper virus contamination, it is 
substantially more complicated and harder to scale up for clinical applications [Goncalves 
2005]. Removal of all viral genes leaves open the possibility of insertional mutagenesis, as 
site direct integration requires the Rep proteins. Indeed integration seems to prefer 
transcriptionally active regions, however much also seems to remain as episomal 
concatemers [Nakai et al, 2003; Tenenbaum et al, 2003]. 
 
Several cancer gene therapy strategies have been tested in vitro and in mouse animal 
models, and such strategies have been reviewed several times previously [Coura and Nardi, 
2007; for reviews see Li et al, 2005; and Park et al, 2008]. As yet no cancer gene therapy 
trials using AAV have been reported, but 15 clinical trials from phases I-III are ongoing for 
the treatment of prostate cancer [www.wiley.co.uk, Dec. 09]. A recent series of studies have 
used AAV vectors in in vivo mouse and rat models to treat retinitis pigmentosa and leber 
congenital amaurosis, both of which cause progressive visual loss and are caused by defects 
in AIPL1. This series of studies used AAV in gene replacement therapy and have 
demonstrated long-term rescue of these photoreceptor-specific defects, with a minimal 
immune response that allow repeat vector administration [Barker et al, 2009; Sun et al, 
2010; Tan et al, 2009]. 
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1.1.3.1.2.4 Adenovirus 
To date over three hundred gene therapy trials have used adenovirus based vectors. These 
account for almost a quarter of all gene therapy clinical trials conducted worldwide (see 
Figure 1-2). Adenovirus vectors have been used in the gene therapy of many simple and 
complex diseases such as ornithine transcarbamylase deficiency, coronary heat disease, 
angina and cystic fibrosis. However, most adenovirus gene therapy has focused on the 
treatment of cancer, giving rise to several alternative strategies. 
To further elaborate on how adenoviruses have been used in gene therapy, the next section 
will cover adenovirus in detail. The basic structure, gene expression and life cycle of 
adenovirus will be reviewed, before discussing adenovirus vectors for cancer gene therapy. 
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1.2 Adenovirus 
Adenoviruses were first discovered over 50 years ago by two groups simultaneously. Rowe 
et al, investigating spontaneously degrading adenoids tissue, showed a transmissible agent 
was present in 62% of adenoid specimens [Rowe et al, 1953] . A second group studying an 
epidemic of respiratory disease in American army recruits recovered a new unidentified 
transmissible agent [Hilleman and Werner, 1954]. It soon became clear that both agents 
belonged to the same family, and the name of adenovirus (Ad) was put forward [Enders et 
al, 1956]. It was soon discovered that human adenoviruses form part of a large family of 
viruses, which are present in a range of vertebrates including primates, birds, reptiles, 
amphibians and fish. 
Currently the Adenoviridae family is divided into five main genera, of which human 
adenoviruses fall into the Mastadenoviridae genus. The other main genera are 
Aviadenoviridae, Atadenoviridae, Ichtadenovirus and Siadenoviridea with recent 
suggestions to add other minor genus [Davison et al, 2003; www.ictvonline.org, Dec. 09]. 
To date there are 52 serotypes of human adenoviruses which fall into 7 species, named A-
G, many of which cause a range of disease, summarised in Table 1-1. 
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Species Types Typical Associated Diseases 
A 12, 18, 31 Gastroenteritis, hepatitis (Ad31) 
B1 3, 7, 16, 21, 50 
Acute respiratory infections, 
conjunctivitis (Ad3 and 7) 
B2 11, 14, 34, 35 
Renal infections (Ad11, 34 and 35) and 
some acute respiratory tract infections 
C 1, 2, 5, 6 Respiratory tract infections 
D 
8, 9, 10, 13, 15, 17, 19, 20, 22-
30, 32, 33, 36-39, 42-49, 51 
Keratoconjunctivitis (Ad8, 19, 37) 
E 4 Respiratory disease 
F 40, 41 Infantile gastroenteritis 
G 52 Gastroenteritis? 
Table 1-1. Adenovirus type classification and associated disease 
[Fields, 2007; www.ictvonline.org, Dec. 09] 
 
1.2.1 Capsid Structure and Organisation 
Adenoviruses are non-enveloped icosahedral shaped viruses measuring approximately 
100nm in diameter. Their outer capsid has three principle components; hexon, penton base 
and fibre, along with several copies of 4 minor capsid components IIIa, VI, VIII and IX 
[recently reviewed by Russell, 2009]. The location of each capsid component can be seen in 
Figure 1-3. 
Each capsid has 252 principle subunits; 240 of which are hexons that form the 20 facets 
with 12 hexons per facet. The remaining 12 subunits are comprised of penton base and 
fibre, which together form the pentons [Ginsberg et al, 1966], located at the apex of five 
facets, with the fibre projecting from the structural vertex. 
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Figure 1-3. Organisation of adenovirus capsid  
Diagrammatic representation of the adenovirus capsid structure. The outer capsid contains 3 
major capsid proteins and 4 minor capsid proteins. The core structure contains 4 structural 
proteins as well as two non structural proteins: protease and IVa2 [taken from Russell 
2009]. 
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Each hexon protein consists of three closely associated molecules of polypeptide II (II) and 
each penton base consists of 5 copies of polypeptide III (III) [Boudin et al, 1979; Russell 
2009]. Three copies of polypeptide IV (IV) form each fibre protein, which bind non-
covalently via the N-terminus onto the top surface of penton base to form the pentons. A 
sequence near the N-terminus of each fibre polypeptide (FNPVYPY) has been shown to lie 
in a hydrophobic groove on the top surface of penton base. This interaction together with a 
number of hydrogen bonds and a salt bridge has been suggested to stabilise the fibre – 
penton base interaction [Zubieta et al, 2005]. All human adenoviruses encode one fibre 
protein which they use as the primary cell surface receptor, with the exception of species F 
adenoviruses that encode two separate fibres [Kidd et al, 1993]. 
Each capsid contains several copies of 4 minor capsid components, IIIa, VI, VIII and IX, 
the primary function of which is thought to be in stabilising the capsid structure [reviewed 
by Vellinga et al, 2005]. 
The minor capsid proteins IIIa, VI and VIII (along with the core proteins VII, TP and Mu) 
are first synthesised as precursor proteins, designated with a p prefix (i.e. pIIIa is cleaved 
into polypeptide IIIa). The precursor proteins are cleaved into their mature forms by the 
adenovirus encoded protease upon virion assembly, discussed further in section 1.2.3. 
Each viral particle contains 240 copies of polypeptide IX (IX), which is thought to stabilise 
hexon-hexon interactions. Following mild dissociation conditions, virions break apart 
producing groups of nine (GON) hexon proteins, each of which derives from the central 
region of the capsids icosahedral facets [Colby and Shenk, 1981]. The current model 
positions the N-terminus of IX as a trimer in the centre of each facet, with the C termini 
forming a 4 helical bundle consisting of 3 copies of IX from the same facet but different 
trimers, and one copy of IX from the adjacent facet (see Figure 1-4). Some debate still 
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(A) 
remains as to the exact position of IX C-terminus, however it has recently been shown 
using peptide tagging the IX C-termini associates in an antiparallel manner, most likely 
within the 4 helical bundles [Fabry et al, 2009; Marsh et al, 2006; Saban et al, 2006]. 
 
 
Figure 1-4. Cryo-electron microscopy of polypeptide IX location 
Cryo-electron microscope location of polypeptide IX location in the Ad capsid. A region of 
a cryo-EM difference map (red) and pseudoatomic capsid showing hexons (green, cyan, 
blue, magenta), roughly corresponding to one icosahedral facet. Four trimeric density 
regions and three helix bundles of IX are observed in red (A). Diagram showing the 
interoperation of the difference map. The four trimeric density regions were assigned to the 
N-terminal domain of protein IX (blue), the weak density regions were assigned to the 
midsection of IX (green) and the helical bundles are assigned to the C-terminal α helix 
region of IX. The black dotted lines indicated presumed extended connections between 
central trimeric region and helical bundles. Note, one of the 4 helices in each bundle 
appears to come from a copy of IX in an adjacent facet (B) [adapted from Saban et al,  
2006]. 
 
It was shown that when pIX is deleted, virion particles are more heat sensitive and do not 
form GON under mild dissociation [Colby and Shenk 1981]. Polypeptide IX has also been 
shown to have additional minor functions in transcriptional regulation (see section 1.2.2.2.). 
Polypeptide IIIa (IIIa) was found to be an elongated monomer with 5 copies positioned  
below the penton base at each apex (thus 60 copies altogether) [Saban et al,  2006]. The N-
(B) 
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terminal region associates with penton base, hexons and VI, and has been shown to be 
positioned beneath the vertex complex, and in wedges at the interface between the penton 
base and peripentonal hexons [San Martin et al, 2008]. Older co-immunoprecipitation 
experiments showed that IIIa was in direct contact with the inner capsid protein V and VII 
[Boudin et al, 1980; Stewart et al, 1993]. It is thought that IIIa has a role in stabilising 
hexon assembly, and possibly a minor role in the splicing of late gene produces, [Molin et 
al, 2002; Stewart et al,  1993]. However more recent data has pointed to a role in 
stabilisation of the vertex and the packaged genome. 
The exact location of VI in the capsid is still not fully known. However it appears to be in 
direct contact with the hexon inner cavity, IIIa and penton base, and core protein V [Fabry 
et al, 2005; Matthews and Russell, 1998; Stewart et al,  1993]. When the virion particle is 
internalised into the endosome the acidic environment causes a conformational change in 
virion structure, which allows release of VI from the partially disassembled virus particle. 
Free VI mediates disruption of the endosomal membrane, releasing the virus for nuclear 
transport [Wiethoff et al, 2005]. Furthermore, the VI precursor protein (pVI) facilitates the 
nuclear import of newly synthesised hexon protein [Wodrich et al, 2003] and the C-terminal 
domain of cleaved pIV acts as a cofactor for the Ad protease, allowing full protease activity 
[Honkavuori et al, 2004] (discussed in section 1.2.3.). 
Polypeptide VIII (VIII) is the least studied minor viral capsid protein. Polypeptide VIII is a 
15kDa protein located on the inner capsid surface, both as a ring around peripentonal 
hexons connecting them to the GONs and in rings stabilising the GONs. In this manner VIII 
is though to help stabilize the viral capsid [Liu et al, 1985; Stewart et al,  1993]. 
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1.2.2 Core Structure and Genome Organisation 
Adenovirus has a double stranded DNA genome of approximately 36kb, which is located 
within the virion capsid with 4 virus proteins; VII, V, Mu, and TP (plus also IVa2 and the 
adenovirus protease) (see Figure 1-3) 
Polypeptide VII (VII) is the major core protein and acts like a histone protein, around which 
the viral genome is wrapped [Chatterjee et al, 1986]. Polypeptide V has been shown to 
associate loosely with VII and virus DNA and tightly with VI and is thought to be a bridge 
between core and capsid [Everitt et al, 1975; Russell 2009]. Polypeptide X, also known as 
Mu, has no clear function. The Mu precursor, pMu, was shown to be required for 
expression of the pre-terminal protein (pTP) from the E2B region [Lee et al, 2004]. The 
least abundant protein constituent in the viral core is the Terminal Protein (TP). This protein 
is present in two copies that are covalently attached to the 5‟ ends of the viral genome. The 
TP is essential for viral DNA replication (discussed in section 1.2.3), but also can assist in 
attachment of the viral genome to the nuclear matrix [Schaack et al, 1990]. 
The Ad5 genome produces over 50 proteins via convergent transcription from both strands 
of the viral genome as illustrated in Figure 1-5. 
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Figure 1-5. Ad 5 genome schematic 
Adenovirus transcription map. Arrows indicate the direction of transcription [adapted from 
Wold and Gooding, 1991] 
 
The genome is flanked by inverted terminal repeat (ITR) sequences of 93-371bp (103bp for 
Ad2 and Ad5), which are essential in viral DNA replication (see section 1.2.3). Adenovirus 
gene expression is divided into 3 stages; early, intermediate and late, each one of which is 
discussed in the following sections. 
1.2.2.1 Early Gene Expression 
Early adenovirus gene transcription is divided into 5 transcription units E1A, E1B, E2, E3 
and E4. 
1.2.2.1.1 E1 
The E1A region is the first to be expressed upon viral entry into a cell, from a promoter 
found immediately downstream of the left ITR. The E1A region is transcribed into 5 
mRNA species through differential splicing, two of which are found from early times of 
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infection with the remaining three accumulating at later times [Chow et al, 1979; Stephens 
and Harlow, 1987]. The two early expressed mRNA species, 13S and 12S, encode proteins 
of 289 and 243 amino acids, respectively, commonly referred to as E1A-13S and E1A-12S. 
A third mRNA species 9S encodes for the E1A-9S protein, which accumulates later in 
infection. 
Upon comparing E1A proteins from a variety of adenovirus serotypes, it became clear that 
they contain four conserved regions (CR1, 2, 3 and 4, respectively). Further analysis also 
revealed the N terminus to be important for a wide variety of E1A functions [Berk, 2005]. 
The 12S and 13S-E1A proteins have identical CR1, 2, 4 and N terminal regions, with only 
the 13S protein possessing CR3 (see Figure 1-6). The 9S protein only contains the N-
terminus and CR1 [Spector et al, 1978]. 
To date E1A has not be shown to bind any DNA elements, however it has been 
demonstrated to bind to an extensive range of viral and host proteins, which are mostly 
involved in modifying gene expression [and Berk 2005; reviewed by Gallimore and 
Turnell, 2001], summarised in Figure 1-6. 
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Figure 1-6. Ad E1A protein-protein interactions 
Linear representation of the Ad2/5 E1A 13S protein showing the 13S, 12S and 9S splice 
variants. Know regions of conservation between serotypes are shaded in grey and some of 
the known E1A-interacting proteins are shown [and Berk 2005; adapted from Gallimore 
and Turnell 2001]. 
 
Both E1A 12S and 13S proteins can bind to the retinoblastoma (pRb) family of proteins 
through interactions with the CR1 and CR2 regions [Dyson et al, 1992; Whyte et al, 1988]. 
The pRb family of tumour suppressor proteins act to regulate gene expression and the cell 
cycle by sequestering the E2F family of transcription factors. E2F upregulates expression of 
proteins essential for cell cycle progression (such as DNA polymerase A and c-myc), and 
facilitates the transition from late G1 phase into S phase. The CR1 and CR2 regions bind to 
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pRb, allowing the release of E2F and progression of the cell cycle [Bagchi et al, 1990; 
Bagchi et al, 1991]. 
Interactions between the CR3 region of E1A-13S and the TATA-binding protein (TBP) 
have been shown to modulate gene expression. TBP is an important part of TFIID, a 
transcription factor that can bind the TATA box and up-regulate transcription of many viral 
and cellular genes [Lee et al, 1991]. The tumour suppressor protein p53 can bind to and 
inactivate TBP and in doing so suppress transcription. Binding of E1A-13S to TBP blocks 
the repression by p53, allowing increased transcription [Horikoshi et al, 1995]. 
E1A can further modulate cellular gene expression through interactions with a wide range 
of cellular proteins, including: p300/CBP, TBP-associated factors (TAFs), TFIIF rap30 
subunit, Sug1, Dr1 and Sur-2 proteins [Berk 2005; Gallimore and Turnell 2001; Turnell et 
al, 2005]. Early viral gene transcription is highly regulated by E1A. For example, the E2 
promoter can be directly activated by E1A through its TATA site, ATF sites or E2F binding 
sites [reviewed by Shenk, 2001]. 
The N-terminal region of Ad5 E1A has been shown to directly subvert the host immune 
response. Signal transduction and activation of transcription (STAT) proteins represent an 
integral part of the intra-cellular pathway activated by the interferon (IFN) immune 
response. Upon IFN stimulation STATs activate transcription of cellular immune response 
genes, partly through recruitment of the p300/CBP complex [reviewed by Goodbourn et al, 
2000]. Not only does E1A exhibit p300/CBP interactions, it has been shown to directly bind 
STATs and downregulate the IFN response [Look et al, 1998]. 
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The E1B region encodes two proteins, 19kDa (E1B-19K) and 55kDa (E1B-55K), produced 
via differential splicing [Virtanen and Pettersson, 1985]. Embedded within the E1B region 
is the pIX gene, which is activated from a separate promoter, discussed in section 1.2.2.2. 
E1B-19K was initially reported to have both a positive and negative effect on early viral 
gene transcription. It has since been discovered that E1B-19K is a Bcl-2 homologue, and 
has a role in blocking both p53-dependent and p53-independent apoptosis [Chiou et al, 
1994a; Chiou et al, 1994b; Subramanian et al, 1995]. Bcl-2 is located in the outer 
mitochondrial membrane and blocks the translocation of cytochrome c from the 
mitochondrion to the cytoplasm. Upon translocation, cytochrome c activates caspase-9 
leading to an apoptotic response [Chiou et al,  1994a; Cuconati et al, 2002]. 
E1B-55K binds to the amino-terminal activation domain of p53 and in conjunction with 
E4orf6 blocks p53 dependent apoptosis, relieves a p53 cell cycle block and blocks p53 
activated transcription [Ornelles and Shenk, 1991]. In doing so E1B-55K helps create an 
environment primed for viral DNA replication and gene expression. Further investigation 
revealed that E1B-55K interacts with E4orf6 along with cellular proteins to form an E3 
ubiquitin ligase complex [reviewed by Blackford and Grand, 2009]. This complex targets 
cellular proteins including p53 and Mre11 for proteasomal degradation and is important in 
mediating the E1B-55K protein functions. E1B-55K can also form a complex with E4orf3 
which re-localises the Mre11 complex to cytoplasmic aggregates. Mre11 is part of the 
Mre11-Rad50-Nbs1 (MRN) complex responsible for the recognition and repair of DNA 
double strand breaks. The ends of adenovirus DNA would normally be recognised by the 
MRN complex as double strand breaks and subsequently “repaired” to form viral DNA 
concatemers. Thus E1B-55K in complexes with E4orf3 and E4orf6 stops the formation of 
viral DNA concatemers during infection [Stracker et al, 2002].  
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Late in infection the E1B-55K-E4orf6 E3 ubiquitin ligase complex is required for the 
export of late viral mRNA, while also blocking the export of cellular messages, thereby 
resulting in a cytoplasmic accumulation of late viral mRNA [review by Blackford and 
Grand 2009]. 
1.2.2.1.2 E2 
The E2 region consists of the E2A gene, which codes the DNA binding protein (DBP), and 
the E2B genes, which codes for the pTP and DNA polymerase (Pol). The E2 transcription 
unit is driven by two promoters; early and late. The E2 early promoter is trans-activated 
early in infection by E1A. Basal activity of this promoter requires the transcription factors 
TBP, E2F and ATF. TBP and ATF bind their respective binding regions, found within the 
E2 early promoter at position -23 to -29 and -69 to -76 relative to the transcriptional start 
site. Located between these sites is the E2F binding palindrome, which binds two 
heterodimeric complexes of E2F/DP-1 which are dimerised by E4orf6/7. E1A targets all 
four transcription factors (TBP, ATF, E2F and DP-1) to greatly upregulate transcription 
[Kovesdi et al, 1987; Schaley et al, 2000; Swaminathan and Thimmapaya, 1996]. During 
intermediate times of infection the E1A trans-activation of the early E2 promoter is 
blocked, probably by E4orf4-PP2A mediated dephosphorylation of E1A, and the E2 late 
promoter is activated [Mannervik et al, 1999]. The E2 late promoter contains a TBP binding 
site, two SP-1 recognition sites and three CAAT boxes. Two CAAT boxes located at 
positions of -71 and -135 relative to the E2 late transcriptional start site are sufficient for 
promoter activity and bind the transcription factor YB-1 [Goding et al, 1987; Holm et al, 
2002]. 
All three E2 proteins are primarily involved in viral DNA replication and can be mainly 
found associated with viral replication centres as infection proceeds (localized nuclear sites 
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of Ad transcription and DNA replication). The 80kDa pTP is found covalently attached to 
the 5‟ end of viral DNA, and is cleaved by the adenovirus protease to a 50kDa mature form 
(TP) upon viral assembly [Mangel et al, 2003]. The E2B encoded Pol is a distinct DNA 
polymerase which uses pTP as a protein primer and possesses both 5‟-3‟ polymerase 
activity and 3‟-5‟ exonuclease activity. The E2A encoded DBP unwinds dsDNA and is 
required for chain elongation and to stabilise the pTP-DNA interaction. A full description 
of the pTP, Pol and DBPs roles in the viral lifecycle will be discussed later in section 1.2.3. 
 
Late in infection (following DNA replication) a novel transcription unit is activated, which 
runs in the same direction as the E2 and E4 early regions. The unit codes for the U exon 
protein (UXP), from an ORF overlapping with DBP and a small part of L4-100K. UXP 
expression is from a yet unidentified promoter; however there is a presumed promoter near 
the 5‟ end of the UXP mRNA. UXP localises to the nucleolus where it is localised with 
viral replication centres as infection proceeds. Aberrant DBP localization upon UXP 
deletion suggests UXP is required for establishment of viral replication centres. The exact 
function of UXP is currently not known, however deleting UXP seems to cause a mild 
growth defect and lower yields of progeny virions [Tollefson et al, 2007].  
1.2.2.1.3 E3 
The E3 region encodes for proteins involved in evading the host immune system and 
controlling apoptosis, summarised in Figure 1-7 [reviewed by Horwitz, 2004; and by 
Lichtenstein et al, 2004b]. The E3 region within species C adenoviruses can be divided into 
two parts; E3A and E3B, dependant on poly(A) site usage, and produces 7 proteins via 
differential splicing. At early times post infection expression of the E3 region is from the 
same E3 promoter region, which like the other early regions is activated by E1A. Several 
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binding regions for cellular transcription factors including ATF, AP-1 and NF-1 have been 
identified in the E3 promoter region. E1A can interact with the multiple components of the 
E3 basal promoter to upregulate E3 transcription [Garcia et al, 1987; Hurst and Jones, 1987; 
Kornuc et al, 1990]. During late times of infection E3 promoter activity is downregulated 
and expression of one E3 protein termed adenovirus death protein (ADP) is upregulated 
from the major late promoter (discussed further in section 1.2.2.3) [Tollefson et al, 1992]. 
 
 
Figure 1-7. Function of the E3 region 
Schematic representation of the E3 region with the approximate position in the Ad5 genome 
in kb (not to scale). The E3 region is divided into E3A and E3B, based on poly(A) usage, 
and is differentially spliced to produce 7 proteins. Proteins are shown as open boxes 
labelled with the primary functions. Late in infection the E3 promoter is downregulated and 
ADP is upregulated from the major late promoter. 
 
Two E3 encoded genes, RIDα and RIDβ (also known as E3-14.5K and E3-10.4K, 
respectively) form a complex termed the receptor internalisation and degradation or RID 
complex [Tollefson et al, 1991]. The RID complex stimulates the internalisation and 
degradation of specific cell surface death receptors such as Fas and tumour necrosis factor 
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(TNF)-related apoptosis-inducing ligand (TRAIL) (including both TRAIL receptor one and 
two, TR1 and TR2 respectively) [Elsing and Burgert, 1998; Lichtenstein et al, 2002; 
Tollefson et al, 2001]. This prevents ligand-receptor binding and so blocks apoptosis. E3-
6.7K has been shown to block apoptosis both independently and also in conjunction with 
the RID complex. E3-6.7K localises mainly to the endoplasmic reticulum (ER), with a 
small amount reaching the plasma membrane [Wilson-Rawls and Wold, 1993] and has been 
proposed to act in the ER as a general inhibitor of apoptosis, possibly by helping maintain 
cytosolic calcium homeostasis [Moise et al, 2002]. Furthermore, E3-6.7K can associate 
with the RID complex to assist in TR2 and possibly TR1 RID mediated degradation, but not 
Fas or EGFR degradation [Benedict et al, 2001; Lichtenstein et al, 2004a].  
The two genes positioned at the ends of the E3 region encode for the distantly related E3-
12.5K and E3-14.7K proteins. These are thought to have arisen via gene duplication at an 
early stage of Mastadenoviridae evolution and were subsequently lost in some lineages 
[Davison et al,  2003]. E3-14.7K can directly block TNFα and TRAIL induced apoptosis 
and has been linked to blocking Fas induced apoptosis [Chen et al, 1998; Horton et al, 
1991; Schneider-Brachert et al, 2006; Tollefson et al,  2001]. More recent studies have 
suggested E3-14.7K can inhibit NF-B transcriptional activity, by direct and selective 
targeting of NF-B p50 [Carmody et al, 2006]. It is possible this interaction influences the 
E3-14.7K mediated anti-apoptotic response and expression of inflammatory cytokines such 
as IL-6 and IL-12. 
E3-19K binds to cellular HLA class I molecules in the ER and in doing so prevents their 
translocation to the cell surface, thus avoiding cytotoxic T cell activated cell death [Burgert 
and Kvist, 1987; Burgert et al, 1987]. 
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The E3 adenovirus death protein (ADP) or E3-11.6K is only produced in small amounts at 
early times of infection. ADP production is upregulated approximately 400-fold in late 
times of infection by expression from the major late promoter [Tollefson et al,  1992]. ADP 
deleted viruses are typically characterised by a small plaque phenotype, a feature that led to 
the discovery of ADP function [Tollefson et al, 1996a]. As the name suggests, ADP 
promotes cell death late in infection and thus aids in the release of progeny virions 
[Tollefson et al, 1996b]. ADP is a membrane glycoprotein that accumulates in the Golgi 
body and ER and eventually the nuclear membrane late in infection [Tollefson et al, 2003]. 
To date the exact mechanism of ADP action is unknown, however ADP must interact with 
membranes in order to function. Using yeast two hybrid screens ADP has been linked to 
MAD2B, a protein similar to the spindle assembly checkpoint protein MAD2, and suggests 
that this interaction is somehow relevant [Ying and Wold, 2003]. Furthermore, ADP can 
work in both a caspase-dependent and caspase-independent manner [Zou et al, 2004]. 
1.2.2.1.4 E4 
The E4 region is located at the right hand end of the Ad genome and is transcribed in a 
leftward direction. This region produces at least 18 distinct mRNA from the same promoter 
through differential splicing [Virtanen et al, 1984]. These were predicted to produce 7 
proteins, named after their corresponding open reading frame (E4orf1, E4orf2, E4orf3, 
E4orf4, E4orf3/4, E4orf6 and E4orf6/7), six of which have been identified in infected cells 
(shown in Figure 1-8). 
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Figure 1-8. Functions of the E4 proteins 
Schematic representation of the E4 region with the approximate position in the Ad5 genome 
in kb (not to scale). The primary E4 transcript is spliced to produce 7 predicted proteins, 
shown as open boxes labelled with the known function of each protein. Proteins whose 
coding regions are split by intron sequences are shown as boxes linked by a line. 
Overlapping proteins have different polypeptide sequences unless they share the same 
number [adapted from Leppard, 1997]. 
 
Transcription of the E4 region occurs early in infection and is activated by the E1A-13S 
protein. The E4 promoter region contains binding sites for the transcription factors ATF and 
E4F. E1A interacts with both ATF and E4F to upregulate transcription, seemingly via two 
separate pathways. E4F mediated activation involves interaction with the E1A CR3 region, 
plus two C-terminal regions termed auxiliary regions 1 and 2 (AR-1 and AR-2) [Bondesson 
et al, 1992; Raychaudhuri et al, 1987]. The AR-1 and AR-2 regions have been suggested to 
be required for the phosphorylation of E4F, which in turn is required for E4F dependent 
upregulation [Raychaudhuri et al, 1989]. In contrast ATF mediated upregulation does not 
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seem to be AR dependent. However conflicting evidence has also demonstrated ATF alone 
can upregulate transcription independent of E1A [Jones and Lee, 1991; Liu and Green, 
1990; Rooney et al, 1990; Strom et al, 1998]. Some of the E4 proteins have functions that 
are required for lytic growth in tissue culture, whereas others have no clear function 
[reviewed by Leppard 1997]. 
E4orf1 was discovered to be a major oncogenic factor of Ad9 in the presence of the E1 
region [Javier, 1994]. Further investigations have suggested that E4orf1 from a variety of 
Ad serotypes has the ability to transform cells in the presence of the E1 region [Weiss and 
Javier, 1997; Weiss et al, 1997]. The C-terminal PDZ binding domain of E4orf1 was found 
to be responsible for the transforming activity, by interaction with phosphatidylinostiol 3-
kinase (PI3K), triggering a downstream signalling cascade to effectors such as protein 
kinase B (Akt) and mTOR. Through these effectors PI3K alters protein synthesis and cell 
survival [Frese et al, 2003; O'Shea et al, 2005]. A recent study has also demonstrated 
E4orf1 limits late viral mRNA translation in cells in G1 phase, and as a result reduces the 
progeny virus production in an E1B-55K deleted virus [Thomas et al, 2009]. 
The E4orf2 protein has been shown to be present in Ad infected cells [Dix and Leppard, 
1995]. However as of yet no function has been defined for this protein. 
The E4 products E4orf3 and E4orf6 are the most studied E4 proteins and can compensate 
for each other in vitro. Both proteins use post-transcriptional mechanisms to cause a 
cytoplasmic accumulation of late viral mRNAs, resulting in increased viral late proteins. 
Both proteins have also been shown to alter RNA splicing patterns thus modulating gene 
translation [Ohman et al, 1993]. E4orf6 interacts with the E1B-55K gene to form an E3 
ubiquitin ligase complex which targets cellular proteins such as Mre11 and p53 for 
degradation. This complex helps to stop viral DNA concatemer formation, blocks the 
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export of cellular mRNA and increases the export of late viral mRNA [Gonzalez and Flint, 
2002; Ornelles and Shenk 1991; Querido et al, 2001a; Querido et al, 2001b]. Older reports 
have also shown E4orf6 can directly bind p53, in the absence of E1B-55K, and in doing so 
repress p53 function as a transcriptional activator and block p53 dependent apoptosis 
[Dobner et al, 1996]. 
E4orf3 interacts with E1B-55K to relocalise the Mre11 complex to cytoplasmic aggregates 
to help stop viral concatemer formation [Araujo et al, 2005]. E4orf3 has been shown to 
reorganise an important group of nuclear transcription/replication factors [Carvalho et al, 
1995; Evans and Hearing, 2005]. E4orf3 dependent relocalisation of these factors to virus 
replication centres helps modulate late viral transcription. Other studies have implicated 
E4orf3 in the enhancement of S-phase replication and in the repression of the interferon 
immune response, again by rearrangements of nuclear transcription bodies [Shepard and 
Ornelles, 2003; Ullman et al, 2007]. 
E4orf4 has been linked to several functions in the viral life cycle [reviewed by Branton and 
Roopchand, 2001]. E4orf4 interacts with the Bα subunit of protein phosphatase 2A (PP2A), 
which result in the selective hypophosphorylation of viral and non-viral proteins 
[Kleinberger and Shenk, 1993; Muller et al, 1992], and it is this interaction which is thought 
to be responsible for all E4orf4 functions. E4orf4 has been shown to downregulate E1A 
transcription as well as inhibit E1A mediated transcriptional activation of E4, 
demonstrating an E1-E4 regulatory feedback loop [Bondesson et al, 1996]. E4orf4 can 
regulate alternative splicing of adenoviral L1 proteins [Estmer et al, 2001; Kanopka et al, 
1998]. E4orf4 can induce p53-independent apoptosis, in both a caspase-dependent and 
caspase-independent manner, which is dependent on the interaction with the Bα subunit of 
PP2A [Lavoie et al, 2000; Lavoie et al, 1998; Marcellus et al, 2000; Marcellus et al, 1996]. 
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More recent work demonstrated E4orf4 induced a G2/M cell cycle arrest, resulting in cell 
death, by blocking the PP2A dependent dephosphorylation of proteins involved in cell cycle 
progression [Li et al, 2009a]. It also appears E4orf4 is targeted to the nucleus and localises 
primarily in viral replication centres, in nucleoli and in perinuclear bodies. Furthermore this 
targeting is important in E4orf4 induced cell death and export of late viral mRNAs [Li et al, 
2009b; Miron et al, 2009; Miron et al, 2004]. 
E4orf6/7 is involved in the control of the cellular transcription factor E2F. E4orf6/7 
dimerises to link two E2F molecules, which stabilises the binding to specific E2F DNA 
binding elements [Huang and Hearing, 1989; Obert et al, 1994]. Palindromic E2F binding 
motifs have been located within the Ad E2 early promoter as well as within the E2F-1 
promoter itself. In this way E4orf6/7 helps to activate transcription of E2F responsive 
genes, such as Ad E2, E2F-1 as well as potentially many other cellular genes [Johnson et al, 
1994; Schaley et al, 2005]. 
1.2.2.2 Intermediate Gene Expression 
Intermediate gene expression coincides with the start of viral DNA replication, after the 
initiation of early genes but before the onset of late gene expression. There are two genes 
expressed at intermediate times of infection; protein IVa2 (IVa2) and polypeptide IX (IX).  
IVa2 acts as a transcription factor and is important for activation of late gene expression 
from the major late promoter (MLP). IVa2 can bind a recognition sequence positioned +85 
to +120 bases downstream of the MLP transcription start site [Lutz and Kedinger, 1996; 
Tribouley et al, 1994]. Once bound IVa2 can co-operate with enhancer elements upstream 
of the MLP to activate transcription, discussed in section 1.2.2.3. Activation of IVa2 
transcription first requires removal of the transcriptional repressor IV-RF, which binds to 
elements downstream of the IVa2 promoter [Huang et al, 2003b]. The mechanism by which 
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transcriptional repression is removed is not entirely understood but a build-up of viral DNA 
aids in relieving this block, thus it is speculated IV-RF is titrated out upon viral genome 
amplification [Iftode and Flint, 2004]. An early viral gene product could also be involved in 
relieving IVa2 repression and subsequently activating late gene expression. In these models 
IVa2 acts as part of a „timer‟ for virus replication and gene expression. 
 
Polypeptide IX expression begins at intermediate times of infection and levels of pIX 
increase rapidly at late times of infection. IX is expressed from a separate promoter, 
embedded within the E1B region, and shares its poly(A) site with the E1B transcripts. 
During early phases of infection active transcription of E1B through the IX promoter blocks 
IX expression. Once E1B transcription declines during infection and following DNA 
replication, IX transcription is allowed to proceed [Fessler and Young, 1998; Vales and 
Darnell, Jr., 1989]. Outside its role as a structural protein, IX may have functions in 
transcriptional activation and nuclear reorganisation [reviewed by Parks, 2005; and 
Vellinga et al,  2005]. Transfection assays showed that IX can enhance expression of both 
adenoviral and non-adenoviral genes including: E1A, E4, MLP, HSV thymidine kinase and 
human –globin. To date IX has not been shown to have any direct DNA binding activity. 
In addition, IX has been shown to homo-multimerize and has been suggested to interact 
with other DNA binding elements or transcription factors [Rosa-Calatrava et al, 2001]. 
More recently IX has been shown to co-localise with promyelocytic leukaemia protein 
(PML) and in doing so is thought to have a minor or backup role in regulating the cellular 
antiviral response [Rosa-Calatrava et al, 2003]. However, conflicting evidence using pIX 
deleted viruses and complementing pIX expression either in trans or with stably expressing 
 41 
cell lines, showed pIX had no effect on E1A expression or virus DNA replication [Sargent 
et al, 2004]. 
1.2.2.3 Late Gene Expression 
Late gene expression is controlled by the major late promoter (MLP), which when fully 
active produces a primary transcript approximately 29,000 nucleotides long. This primary 
transcription unit is differentially spliced into multiple mRNAs that are grouped into five 
families termed L1 to L5 [Nevins and Darnell, Jr., 1978] based on the utilization of 
common poly(A) sites (Figure 1-9), which encode 18 proteins. 
 
 
Figure 1-9. Transcription from the major late promoter 
Schematic diagram of the Ad2/5 major late transcription unit, showing the alternatively 
spliced mRNAs and encoded proteins. The 5 families, L1-L5 are labelled along with the 
obligate leaders sequences; 1, 2, 3 and the optional leaders; i, x, y and z [adapted from 
Morris and Leppard, 2009]. 
 
All major late transcripts are spliced to start with the tripartite leader (TPL) sequence. The 
TPL consists of 3 small sequences, termed 1, 2, and 3, which are spliced to the 3‟ acceptor 
sites within the main MLTU body [Logan and Shenk, 1984]. The TPL is important for 
nuclear export, translation and major late mRNA stability [reviewed by Young, 2003]. In 
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addition to sequence 1, 2 and 3, which are present in all MLP transcripts four additional 
leader sequences have been identified; i, x, y and z, which are used less frequently. Despite 
the name, the MLP is active at low levels at early times of infection, producing transcripts 
which preferentially end at the L1 poly(A) site (and do not extend beyond the L3 poly(A) 
site) [Symington et al, 1986]. This results in production of large amounts of L1-52/55K 
mRNA, most of which use the optional i-leader sequence, inserted between leaders 2 and 3 
[Nevins, 1981; Nevins and Wilson, 1981].  
Post Ad DNA replication MLP promoter activity is upregulated by multiple factors which 
act on sequences both upstream and downstream of the transcriptional start site. E1A can 
strongly activate the MLP through binding the TATA motif and through interactions with 
Sp1/MAZ (with their binding sites upstream of the MLP) [Parks and Shenk, 1997]. Protein 
IVa2 has been shown to bind directly with elements downstream of the MLP, termed DE1 
and DE2 (+86 to +96 and +101 to +116, respectively). DE1 and DE2 have been shown to 
bind a homodimer of IVa2, as well as a IVa2 heterodimer with a yet undefined viral 
protein, suggested to be L4-22K or L4-33K [Ali et al, 2007; Farley et al, 2004; Morris and 
Leppard 2009; Ostapchuk et al, 2006; Tribouley et al,  1994]. These proteins bind to factors 
upstream of the initiation codon, such as USF, to activate transcription [Mondesert and 
Kedinger, 1991; Mondesert et al, 1992; Toth et al, 1992]. Late upregulation from the MLP 
also requires cis-acting elements that must be activated in additional to the trans-acting 
factors [Thomas and Mathews, 1980]. 
Beyond encoding for structural proteins the major late transcripts produce several non-
structural proteins with roles within the virus life cycle. L3 produces the adenovirus 
cysteine protease, which is required for cleavage of pVI, pVII, pIII and pTP into their 
mature forms, yielding infectious virus particles [Weber, 1976]. 
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The L1 encoded 52/55kDa (L1-52/55K) proteins are essential for assembly of new virion 
particles. L1-52/55K binds to the viral genome packaging sequence and its deletion result in 
production of empty capsids [Hasson et al, 1992; Perez-Romero et al, 2006].  
Two L4 encoded proteins (L4-33K and L4-22K) have been shown to be required for full 
length MLP activity via post transcriptional mechanisms. L4-33K is a viral splice factor 
which activates splicing to specific late 3‟ mRNA splice sites. It has recently been 
suggested L2-22K acts in a similar manner to L4-33K, however it complements L4-33K by 
activating splicing to alternative 3‟ mRNA [Farley et al,  2004; Morris and Leppard 2009; 
Tormanen et al, 2006]. 
The L4 encoded 100kDa protein (L4-100K) directly blocks cellular mRNA translation by 
disrupting the cap-initiation complex. Furthermore L4-100K binds to the Ad TPL sequence, 
(discussed above), allowing translation of late viral mRNA by a process called ribosome 
shunting [Xi et al, 2005; Yueh and Schneider, 1996]. 
 
All human adenoviruses produce short RNA polymerase III (pol III) transcribed non-coding 
RNA species, termed virus associated or VA RNAs. All human adenoviruses produce two 
distinct VA RNAs, a major species VA RNAI, and a minor species VA RNAII, with the 
exception of species F Ads that only produces VA RNAII. The two VA RNAs in species C 
Ads differ extensively in sequence; however both are highly GC rich and approximately 
160 nucleotides in length. VA RNAs have specific secondary structures, with an apical and 
central domain that form a hairpin-loop like structure that is imperative for their function 
[Mellits et al, 1990; Mellits et al, 1992]. VA RNAs are produced early in infection with 
production rapidly accelerating during late infection. The pol III promoter elements are 
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found downstream of the transcriptional start site, and consist of two regions, an A box and 
a B box [Fowlkes and Shenk, 1980; Guilfoyle and Weinmann, 1981]. 
VA RNAs act to block an interferon (IFN) induced shut-off of cellular translation [Mathews 
and Shenk, 1991]. Upon stimulation by type I IFN, several anti-viral genes are upregulated, 
one of which is dsRNA activated protein kinase R (PKR). In Ad infected cells PKR is 
activated by the formation of dsRNA, produced from convergent transcription of the 
adenovirus genome. Upon activation PKR phosphorylates the  subunit of eukaryotic 
translation initiation factor 2 (eIF-2). Phosphorylation of eIF-2 blocks translational 
initiation thus acting to shut down virally infected cells. VA RNA can bind to PKR in a 
manner similar to that of dsRNA, block PKR activation, yielding un-phosphorylated eIF-2 
and relieving the block on translation (outlined in Figure 1-10). 
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Figure 1-10. PKR inhibition by adenovirus VA RNA 
Regulation of PKR by VA RNA. GDP is bound to the α-subunit of eIF-2 following 
translation initiation, which is exchanged for a molecular of GTP in a reaction catalysed by 
GEF. Activation of PKR by viral dsRNA results in its autophosphorylation. Activated PKR 
phosphorlyates the α-subunit of eIF-2, which then forms a tight complex with GEF, 
preventing the exchange of GDP for GTP, thus blocking translation initiation. VA RNA 
binds to PKR to inhibit activation by dsRNA, thus allowing continued translation [adapted 
from Mathews and Shenk 1991]. 
 
1.2.3 Adenovirus Lytic Life Cycle 
To date little is know about the Ad infectious lifecycle within the natural host. However 
there is detailed understanding of the virus lytic lifecycle in cultured cell lines. 
The Ad cycle begins with the attachment of the virus to cell surface receptors mediated by 
the capsid proteins [reviewed by Arnberg, 2009; and by Nemerow et al, 2009]. Different 
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species of adenovirus use different cell surface receptors and subsequent internalisation 
pathways, however the species C attachment and internalisation pathway has been most 
well characterised. Initial interaction is generally mediated by the Ad fibre protein. Within 
species C Ads the distal C-terminal end of the fibre protein forms a knob domain, which 
contains the initial receptor-binding site. For Ad2 and Ad5 initial attachment is to the 
coxsackievirus and adenoviruses receptor (CAR) via the CAR binding site on the fibre knob 
domain (positioned within the loops between A and B strands, and slightly with the 
adjacent DE and FG loops, shown in Figure 1-11) [Bewley et al, 1999; Roelvink et al, 
1999]. 
CAR has also been demonstrated to be the initial cell attachment receptor for a range of 
species A, E, D and F Ads. Some species B (plus possibly some species D) viruses have 
been shown to use CD46 as the primary receptor [Marttila et al, 2005; Segerman et al, 
2003], but probably not Ad3 and Ad7. Some species B viruses may use CD80 and CD86 as 
receptors or co-receptors [Short et al, 2004], however this interaction has been recently 
disputed. Multiple species D viruses have been shown to enter cells after initial attachment 
to -linked sialic acid [Arnberg et al, 2000a; Arnberg et al, 2000b]. 
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Figure 1-11. Adenovirus fibre and knob domain structure 
A fibre space filling models indicating the sites for receptor attachment modelled from the 
atomic structure of Ad2 (A). A ribbon representation of the fibre knob of Ad35, showing 
the protruding loops with the agreed notations. All fibre knobs have a similar structure, with 
variations in the number and amino acid composition (B) [taken from Russell 2009].  
 
Following initial attachment a second interaction is required for cell internalisation. This 
interaction is between an arg-gly-asp (RGD) binding motif, present on each copy of protein 
III (found on a flexible loop domain) in the penton base, with integrins, a large family of 
hetrodimeric cell surface receptors [Zubieta et al,  2005]. Several integrins have been 
suggested as secondary receptors; however two integrins; αvβ3 and αvβ5 have been directly 
shown to allow virus attachment and are sufficient for virus internalisation [Wickham et al, 
1993]. 
Heparan sulphate proteoglycans (HSPG) have been shown to be receptors for species C 
adenoviruses, potentially via three independent mechanisms. Cell surface expression of 
HSPG has been shown to facilitate CAR independent binding and infection, potentially 
through interaction with a KKTK motif within the fibre shaft [Dechecchi et al, 2001; 
(A)  
 
(B)  
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Dechecchi et al, 2000; Smith et al, 2003]. However it has not been shown that mutation of 
this motif reduces the ability of the virus to directly bind to HSPG. Since then various 
coagulation factors have been shown to facilitate Ad attachment. Initially the Ad5 knob was 
shown to bind factor IX and C4BP (complement component C4 binding protein), and 
through these molecules to HSPG on hepatocyes [Shayakhmetov et al, 2005]. Subsequently 
it was shown coagulation factor X (FX) binds directly to the central depression in the Ad 
hexon protein, and ablation of this binding resulted in dramatically reduced hepatocyte 
transduction in murine models [Kalyuzhniy et al, 2008a; Waddington et al, 2008]. All three 
potential HSPG interactions have to date not been investigated simultaneously and it would 
be interesting to investigate the HSPG-fibre interactions in light of the HSPG-hexon 
evidence. 
Finally, dipalmitoyl phosphatidylcholine, lactoferrin, vascular cell adhesion molecular 1, 
scavenger receptors and MHC-1 α2 have all been implicated as receptors for adenovirus 
[reviewed by Arnberg 2009]. However debate still remains as to the exact in vivo order of 
importance of all the in vitro identified Ad receptors. In vitro attachment of the initial 
receptors normally occurs in concert with integrin binding [Mathias et al, 1994], allowing 
virus internalisation.  
Species C adenoviruses are internalised into clathrin-coated pits via receptor mediated 
endocytosis [reviewed by Greber, 2002], triggered by penton base attachment to αV 
integrins. This process requires rearrangement of the actin cytoskeleton, the large GTPase 
dynamin, PI3K and several other cellular proteins [Varga et al, 1991; Wang et al, 1998; 
Wickham et al,  1993]. Sequential degradation of the viral capsid is initiated at 
internalisation starting with the fibre protein and continues in the endosome where IIIa and 
penton base are lost next. Structural studies have suggested integrin binding may induce a 
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conformational change in penton base, initiating the process of capsid disassembly and 
leading to the intracellular signalling required for internalisation [Lindert et al, 2009]. 
Once in the endosome the acidic conditions allow release of protein VI which facilitates the 
release of the viral particle into the cytosol. In the cytosol the partially disassembled capsid 
traffics to the nucleus via interactions between exposed hexons and the dynein/dynactin 
complex with the cellular microtubules. The partly disassembled capsid locates to a nuclear 
pore complex (NPC) and docks with the NCP filament protein Can/Nup214 [Trotman et al, 
2001]. Import into the nucleus requires a number of cellular components including 
importins, histone H1, hsp70 and CRM1 [Saphire et al, 2000; Strunze et al, 2005; Trotman 
et al,  2001]. Recently protein VII has been suggested to be the major mediator of virus 
DNA import into the nucleus facilitated by interaction with transportin [Hindley et al, 2007; 
Wodrich et al, 2006]. In the nucleus TP associates with the nuclear matrix, a step which 
seems to be required for efficient gene transcription [Fredman and Engler, 1993]. 
Transcription of E1A plus several non-viral factors leads to the release of VII and 
remodelling of virus chromatin, allowing full viral transcription [Chen et al, 2007; Gyurcsik 
et al, 2006; Haruki et al, 2006; Johnson et al, 2004]. 
Gene expression then proceeds starting with the E1A region, followed by the remaining 
early transcription units, which generally block apoptosis and prime the cell for DNA 
replication (functions of early genes are described in section 1.2.2.1). DNA replication 
generally begins 5 to 8 hours post infection (in permissive cells such as HeLa or A529), as 
the E2 gene products accumulate. An overview of viral DNA replication is shown in Figure 
1-12 [as reviewed by Shenk, 2001]. 
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Figure 1-12. Adenovirus DNA replication model 
Overview of the adenovirus DNA replication model. Replication is initiated using pTP as a 
protein primer from one strand of the genome, to produce one dsDNA consisting of one 
daughter and one parental strand. The ITRs of the second parental strand anneal to form a 
„pan-handle‟ structure, which is then used for DNA replication via the same mechanism, 
resulting in the production of a second dsDNA genome. The Ad protease then cleaves pTP 
into the mature TP.  
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The first step is to initiate DNA synthesis from one strand of the linear dsDNA genome. 
This produces one dsDNA duplex, consisting of one parental strand and one daughter 
strand, plus one single strand of parental DNA. The latter parental ssDNA molecule is then 
free to go through the second step of DNA replication. In this process, the ssDNA 
circularises by annealing of the self-complementary ITR sequences. The resulting 
„panhandle‟ structure possesses termini with the same structure as the original dsDNA viral 
genome. DNA synthesis can then take place using the first step machinery, again resulting 
in a dsDNA molecule consisting of one parental strand and one daughter strand, the final 
result being two dsDNA genomes, each one consisting of one parental strand and one 
daughter strand. 
Viral DNA replication is initiated via a protein priming mechanism involving the pTP. The 
ITRs contain the cis-acting viral origins of replications essential for DNA replication. Each 
ITR consists of three functional domains, termed A, B and C. Domain A serves as a binding 
region of a heterodimeric complex of pTP and virus encoded DNA polymerase (pol) 
[Temperley and Hay, 1992]. Domain A is required for DNA replication, but by itself only 
supports minimal DNA replication. Efficient DNA synthesis requires domains B and C 
(located immediately downstream of domain A), which bind cellular factors that greatly 
enhance the efficacy of replication initiation. Domain B binds a dimer of nuclear factor I 
(NFI) and domain C binds nuclear factor III (NFIII),  which together cause a bending in the 
DNA [Mysiak et al, 2004b] and bind to pol and pTP, helping to stabilize the pol-pTP 
complex [Mul and van der Vliet, 1992; Mul et al, 1990]. The heterodimeric pol-pTP 
complex covalently attaches a deoxycytidine monophosphate (dCMP) molecular to pTP 
[Mysiak et al, 2004a] ), which then uses nucleotides 4-6 (GTA) of the template DNA strand 
to form a pTP-CAT primer. This primer then jumps back to the nucleotides 1-3 of the 
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template strand, also GTA, [King and van der Vliet, 1994], where pol disassociates from 
pTP and commences strand elongation. 
Chain elongation also requires the Ad encoded DNA binding protein (DBP) and nuclear 
factor II (NFII). DBP can tightly but non-specifically bind ssDNA molecules using the core 
globular domain and forms multimers using the hinged C-terminal hook domain, which 
hooks into another molecule of DBP. Multimerisation of individual DBPs to form long 
chains along dsDNA causes strand displacement, allowing efficient elongation of the 
daughter strand synthesis [van Breukelen et al, 2000]. 
Late gene expression is stimulated following the start of DNA replication, encoding for 
most of the Ad structural proteins (discussed in section 1.2.2.3), after which virion 
assembly can take place. 
 
Capsid assembly takes place in the nucleus, thus requiring the import of all viral capsid 
proteins from the cytoplasm. L4-100K is required for II trimerisation to form the hexons in 
the cytoplasm, and may act as a scaffold for Ad assembly [Cepko and Sharp, 1982; Morin 
and Boulanger, 1986]. Precursor protein pVI contains two nuclear localisation and two 
nuclear export signals and is responsible for shuttling to and from the nucleus and in doing 
so transports hexons into the nucleus [Honkavuori et al,  2004; Wodrich et al,  2003]. The 
Ad protease is first activated by binding non-specifically to viral DNA [Gupta et al, 2004], 
which allows cleavage of pVI. Upon cleavage, the C-terminal domain of pIV (pVIc) acts as 
a co-factor for the Ad protease to allow full activity and mature VI can act as a capsid 
structural protein. It has been suggested this activated protease-pVIc complex then moves 
along the viral DNA, cleaving the other virion precursor proteins (pIIIa, pVII, pVIII, pIX, 
pTP and pMu) to their mature forms [Russell 2009]. 
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Packaging of viral DNA requires recognition of cis-acting packaging sequences at the left 
end of the genome. The packaging sequence consists of 7 AT rich regions designated A 
repeats (A1-A7) which have the consensus sequence 5‟-TTTG-(N8)-CG-3‟ [Hearing et al, 
1987; Schmid and Hearing, 1997]. The exact mechanism of DNA packaging is unclear. 
Evidence exists which suggests that the viral DNA is packaged into ready-made capsids 
[Tibbetts and Giam, 1979] and that recognition of the packaging sequence is required first, 
before initiation of encapsidation around the viral DNA [Zhang and Imperiale, 2000]. DNA 
encapsidation has however been determined with the bacteriophage 29, which resembles 
Ad in that it is a dsDNA phage that contains a packaging signal located at one end of the 
genome and a covalently linked 5‟ terminal protein. With 29, stable capsid shells are 
produced first into which the phage DNA is inserted. and it is this mechanism which has 
been recently put forward for Ad [reviewed by Ostapchuk and Hearing, 2005]. Whatever 
the molecular mechanism behind DNA encapsidation, several host and viral proteins have 
been identified as essential. 
IVa2 has been shown to directly bind the CG portion of  the A repeats and interact with L1-
52/55K, which also potentially binds the packaging sequence, and both are required for 
successful encapsidation [Gustin and Imperiale, 1998; Hasson et al,  1992] [Gustin et al, 
1996; Perez-Romero et al, 2005]. L1-52/55K appears to be involved in serotype specific Ad 
packaging [Wohl and Hearing, 2008]. Cellular proteins have been reported to bind the 
packaging sequence, including the CCAAT displacement protein (CDP), which forms a 
complex with viral protein IVa2 [Ostapchuk et al, 2005; Tyler et al, 2007]. Furthermore L4-
22K has been shown to be required for virus assembly or DNA packaging, binding the 
TTTG repeats in the packaging sequence, and is thought to assist binding of IVa2 to the 
packaging sequence [Ewing et al, 2007; Ostapchuk et al,  2006]. It is worth considering that 
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if the bacteriophage 29 analogy is correct then an ATP-driven motor is required to move 
the viral DNA into the empty pro-capsid, and recently IVa2 has been shown to bind ATP in 
vitro [Ostapchuk and Hearing, 2008]. 
 
Release of virus particles is a multi-factor process that involves several viral and cellular 
proteins. Two systems have been identified that aid in escape of viral particles. One system 
centres on the E3 adenovirus death protein as discussed in section 1.2.2.1. 
The second system centres on collapsing the cellular cytoskeleton; a process which involves 
the L3 encoded adenovirus protease. The L3 proteinase cleaves the cellular cytokeratin 
K18, rendering it unable to form filaments [Chen et al, 1993]. By both mechanisms the 
intermediate filament network is disrupted, rendering the cell more susceptible to lysis and 
subsequent release of viral progeny. 
During infection a large excess of fibre is produced, in relation to the amount that can be 
incorporated into new virion particles. It has been hypothesised this large excess in fibre is 
to aid in viral escape and spread from the initial site of infection [Walters et al, 2002]. 
Excess fibres are secreted at the basolateral surface, which eventually migrate to cell-cell 
tight junctions were CAR is located. Fibre proteins subsequently bind to CAR and disrupt 
the intercellular CAR-CAR homodimers, which as a result opens up the tight junctions. 
This allows virions which have previously escaped the cell to migrate in between cells, 
towards the apical surface, and thus spread to surrounding cells. 
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1.2.4 Current Adenovirus Cancer Gene Therapy Strategies 
A rapid increase in understanding the molecular mechanisms behind cancer has resulted in 
a large number of studies and clinical trials using Ad for cancer gene therapy. Between 
1993 and 2008 the UK Gene Therapy Advisory Committee (GTAC) approved 126 clinical 
trials for cancer gene therapy alone, almost 20% of which use Ad based vectors [GTAC 
14th Annual Report, 2008]. Multiple strategies have been studied in vitro, some of which 
have been investigated with in vivo murine models, of which a limited number have 
transferred into human clinical trials. 
The most recent in vitro studies use Ad with multiple modifications to both increase tumour 
toxicity and improve vector safety. This next section covers some current cancer gene 
therapy strategies that use adenovirus vectors and reviews the latest vector developments 
and cancer gene therapy trials. 
Adenoviruses have many attributes which make them good gene therapy vectors. Their life 
cycle and biology is well understood, allowing easy strategy design. High titres of virus can 
be readily produced. They can typically infect a broad range of cell types, including both 
actively dividing and non-dividing cells, in comparison to other vectors that have narrow 
tropisms (such as retroviruses for actively dividing cells). Finally integration into the human 
genome is rarely seen, eliminating the chance of insertional mutagenesis that is associated 
with some vectors e.g. retroviruses [Harui et al, 1999]. Disadvantages to adenoviruses 
include their non-integrating nature, which precludes long-term gene expression. The pre-
existing immunity in the general population means adenovirus vectors may be rapidly 
cleared from the body, greatly reducing the therapeutic window. 
Unfortunately ten years ago on the 17
th
 of December 1999, Jesse Gelsinger died in the first 
OTC deficiency gene therapy trial. This patient suffered a severe inflammatory response 
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following administration of 6x10
11
 virus particle/kg of a replication deficient Ad vector via 
the right hepatic artery. It is thought this toxicity was due to an innate or humoral immune 
response primarily to the adenovirus capsid proteins [Raper et al, 2003], but trial protocol 
violations may have played a part in his death. This does however demonstrate how the 
immune response may limit the success of viral vectors. 
1.2.4.1 Replication Deficient Adenovirus Vectors 
The first adenovirus gene therapy vectors used were replication deficient vectors, with the 
entire E1 region and most or the entire E3 region deleted [reviewed by Danthinne and 
Imperiale, 2000]. The E1 deletion removes the E1A and E1B genes while keeping the IX 
gene and renders the virus replication deficient. The E3 region is not essential for 
replication (in vitro) and was therefore dispensed with to increase the transgene capacity. 
With the E1 and E3 regions deleted, first generation Ad vectors can incorporate 
approximately 8kb of insertion. Transgenes are normally inserted as expression cassettes, 
with expression controlled from foreign promoters and poly(A) sequences, generally within 
the E1 deletion and sometimes within the E3 region. Despite deleting the E1 and E3 regions 
first generations showed some level of „autoreplication‟, particularly at very high 
multiplicities of infection, and was associated with transcriptional activity of several viral 
gene including DNA polymerase, DNA binding protein and E4 proteins. Transcriptional 
activity is probably as a result of basal promoter activity and possibly exogenous or cryptic 
promoters which may enhance transcriptional activity [Marienfeld et al, 1999]. Transgene 
expression from first generation vectors is normally shut down 2-3 weeks post infection in 
immuno-competent murine models. Transgene elimination is attributed to immune response 
raised against viral gene expression even in the E1 deleted background [Yang et al, 1996b]. 
Recent evidence has demonstrated leaky protein IX expression from the enhancer elements 
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in upstream transgene promoters, and IX co-expression may be one of the main causes of 
Ad induced immune response in a murine model. By using transgene promoters with 
weaker enhancer elements, transgene expression was considerably extended [Nakai et al, 
2007]. 
Production of first generation replication deficient Ads requires helper cells lines such as 
293 and 911, which expresses the E1 region allowing virus production [Fallaux et al, 1996; 
Graham et al, 1977]. With both cells lines there is the possibility of recombination between 
the E1-deleted viral genome and chromosomally integrated E1A DNA sequences, yielding 
batches of virus contaminated with replication competent virus. To circumvent this 
limitation a new cell line was created, PER.C6, which has a smaller E1 insertion that is 
under control of the human phosphoglycerate kinase promoter. By designing vectors with 
E1 deletions which do not overlap with the E1 sequences in PER.C6 cells, the chance of 
homologous recombination resulting in contaminated batches is reduced [Fallaux et al, 
1998]. First generation Ad vectors are still widely used and are an important tool for cancer 
gene therapy, reflected in the fact two UK trials are still in progress for treatment of glioma 
and intra-abdominal, and one trial recently accepted for treatment of prostate cancer, all 
using an E1/E3 deleted Ad5 vector [GTAC 14th Annual Report 2008] 
In response to the limitations observed with first generation Ad vectors, further genes were 
removed to give second-generation vectors. Second-generation vectors retain the E1 and E3 
deletions and have additional deletions in any of the E2A, E2B, or E4 regions. The aim was 
to completely eliminate viral gene expression, thus reducing the immune response, while 
increasing the transgene capacity up to 14kb. Second generation vectors are however more 
difficult to produce, requiring relevant viral proteins to be supplied in trans [Krougliak and 
Graham, 1995; Nakai et al,  2007; Wang et al, 1995; Zhou et al, 1996]. In the UK two 
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clinical trials are underway using E1 and E4 deleted vectors for the treatment of critical 
limb ischemia and intermittent claudication. However no second generation vectors are 
being used in UK clinical trials for the treatment of cancer [GTAC 14th Annual Report 
2008]. 
By taking the Ad genetic deletions to the extreme, so-called „gutless‟ Ad vectors were 
produced, which only contain the viral ITR, required for DNA replication [reviewed by 
Alba et al, 2005]. Such a large deletion allows insertion of large or multiple transgenes up 
to 35kb. Furthermore, gutless vectors are highly attractive for gene therapy due to a 
reduction in the in vivo immune response in animal models compared to first and second 
generation vectors [Danthinne and Imperiale 2000]. Production of gutless Ad vectors 
requires all the Ad genes to be supplied in trans. This can be achieved by using helper 
viruses which have a system to remove helper virus packaging sequences (such as the Cre-
loxP system), thus removing helper virus contamination. However levels of helper virus 
contamination are still too high for use in clinical trials [Alba et al,  2005]. 
All replication deficient virus vectors need to carry transgenes to elicit a therapeutic effect, 
some of which are discussed below. 
1.2.4.1.1 p53 Tumour Suppressor Replacement 
The p53 protein is an important tumour suppressor that is mutated or lost in approximately 
50% of all human cancers. The initial studies using Ad expressing wildtype p53 (Ad-p53) 
showed inhibition of growth and induction of apoptosis in a range of cancer cell types [Liu 
et al, 1995; Yang et al, 1995]. Several phases I and I/II clinical trials have since 
demonstrated the safety of Ad-p53 both alone and in combination with radiotherapy, 
chemotherapy or surgery [Lang et al, 2003; Pagliaro et al, 2003; Shimada et al, 2006; Wolf 
et al, 2004]. Phase II/III studies are reported to be still ongoing [www.wiley.co.uk, Dec. 09] 
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and one phase III clinical trial has been commenced in the US and Europe by Invitrogen, 
for treatment of squamous cell carcinoma of the head and neck [reported by Invitrogen, 
2007]. Despite this, it is worth noting a previous phase II/III clinical trial using Ad-p53 for 
the treatment of ovarian cancer was closed after the first interim analysis due to an 
inadequate therapeutic benefit, and it was thus suggested the complex nature of cancer 
means that a single gene repair may not be a suitable strategy for the treatment of some 
cancers [reviewed by Zeimet and Marth, 2003].  
In 2004 China approved the use of a replication deficient Ad vector expressing wildtype 
p53 (Gendicine) from a rous sarcoma virus promoter, for the treatment of head and neck in 
conjunction with radiotherapy [reviewed by Peng 2005; and by Xin, 2006]. This 
represented the first commercial available gene therapy treatment for cancer.  
1.2.4.1.2 Enzyme – Prodrug Therapy 
Virus directed enzyme prodrug therapy (VDEPT) or suicide gene therapy uses a viral vector 
to administer a gene encoding an enzyme which can convert a non-toxic prodrug into a 
cytotoxic agent. Furthermore, the cytotoxic effects of the activated prodrug are transferred 
to neighbouring untransduced cells, in a phenomenon called the „bystander‟ effect. 
Because of the bystander effect, VDEPT is less dependent on complete tumour 
transduction, compared to other systems such as tumour suppressor replacement. VDEPT 
should also allow for localised high concentrations of cytotoxic agent within the tumour 
microenvironment, while avoiding high systemic concentrations. This is in comparison to 
conventional chemotherapy in which high systemic concentration of cytotoxic agent can 
cause significant side effects. 
Whereas VDEPT has enjoyed great success in vitro, general in vivo limitations have been 
identified both in murine models and human trials. The requirement for efficient in vivo 
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gene transfer still raises problems even though VDEPT does not in theory require complete 
tumour transduction. Additionally, problems have been identified in achieving local 
concentrations of prodrug upon systemic delivery, to translate into high concentrations of 
cytotoxic agent [Chung-Faye et al, 2001; Jaberipour et al, 2010].  
VDEPT has been used extensively in multiple studies with several different combinations 
of enzyme and prodrug. The three most common enzyme-prodrug systems used in Ad 
delivery are discussed in detail below. 
1.2.4.1.2.1 Herpes Simplex Virus Thymidine Kinase – Ganciclovir 
The herpes simplex virus thymidine kinase (HSVtk) – ganciclovir (GCV) VDEPT system is 
the most widely used system for suicide gene therapy. GCV is a drug commonly used for 
treatment of HSV infection (such as cold sores) and acute CMV infections. HSVtk can 
phosphorylate GCV into GCV-monophosphate, which is subsequently converted to GCV-
diphosphate and tri-phosphate by cellular kinases. GCV-triphosphate (GCV-TP) is a 
nucleotide analogue of dGTP and competes for incorporation into DNA by cellular DNA 
polymerase . Once incorporated GCV-tp acts as a DNA chain terminator, thus inhibiting 
DNA synthesis and resulting in cell death [Cheng et al, 1983a; Cheng et al, 1983b]. 
In vitro and murine studies have revealed that cellular gap junctions, which aid the spread 
of phosphorylated GCV, are involved in the HSVtk-GCV bystander effect [Mesnil and 
Yamasaki, 2000; Princen et al, 1999; Touraine et al, 1998]. Whereas a wide variety of cells 
have shown a good bystander effect, many tumour cell lines show a reduce gap junction 
capacity and thus exhibit a poor bystander effect. This could potentially provide a hurdle for 
treatment of a variety of tumours. Since GCV-TP acts at DNA replication, this system can 
only target cells that are in S-phase. Arguably, this is the system‟s greatest disadvantage, as 
in most tumours only a small fraction may be in S-phase. 
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The HCVtk-GCV system has been extensively investigated in vitro and in animal models 
for the treatment of a variety of cancers. Multiple clinical trials have been reported on using 
this system in replication deficient Ad vectors, summarised in Table 1-2 , with more trials 
reported to be ongoing [www.wiley.co.uk, Dec. 09]. From all the reported trials the authors 
concluded the vector is safe and well tolerated alone and in combination with GCV. Signs 
of clinical efficacy were observed in most trials, however it has been postulated that any 
effect observed may be due to induction of an antitumour immune response [Sterman et al, 
2005]. 
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Target Phase 
Additional 
treatment 
Authors conclusions Reference 
Malignant 
brain cancers 
I  
Vector and GCV were safely 
tolerated in all 13 patients up to the 
maximum virus dose of 2x10
12
 VP. 
[Trask et 
al, 2000] 
Colorectal 
cancer 
I  
In all 16 patients the vector was 
safely administered up to maximum 
dose of 10
13
 VP in combination with 
GCV 
[Sung et 
al, 2001] 
Ovarian 
cancer 
I Topotecan 
From a total of 10 patients the 
median survival was approximately 
1/3 longer following gene therapy 
with topotecan and surgery 
[Hasenbur
g et al, 
2001] 
Malignant 
glioma 
I  
Vector and prodrug doses used in 
this study were safe. Ten of 11 
patients survived >52 weeks post 
diagnosis. 
[Germano 
et al, 
2003] 
Malignant 
glioma 
I  
Vector and prodrug combination 
was safely tolerated in all 14 
patients, and maximum tolerated 
dose was not reached up to 4.6x10
11
 
VP. 
[Smitt et 
al, 2003] 
Prostate 
cancer 
I  
All 11 patients tolerated the therapy 
with no serious adverse events. 
Local cell death was observed in 7 
out of 11 patients 
[Kubo et 
al, 2003] 
Prostate 
cancer 
I/II 
+/- 
radiotherapy 
and 
hormone 
therapy 
All 59 patients tolerated the therapy. 
Combined therapy appeared to 
provide good locoregional control. 
[Teh et al, 
2001; Teh 
et al, 
2004] 
Malignant 
mesothelioma 
I  
In all 21 patients the therapy was 
safe and tolerated. Two patients 
receiving > 1.6x10
13
 VP therapy 
showed long-term responses 
[Sterman 
et al,  
2005; 
Sterman et 
al, 1998] 
Prostate 
cancer 
I/II 
Docetaxel 
and 
estramustine 
All 6 patients tolerated the therapy 
with no serious adverse events. 4 
patients showed a partial response. 
[Shirakaw
a et al, 
2007] 
Head and 
neck cancer 
and other 
malignant 
tumours 
I  
Of 18 patients 10 experienced 
transient fever and 10 local injection 
site reaction. One patient had a 
partial response, 1 had moderate 
response, 5 had stable disease and 
10 had progressive disease 
[Xu et al, 
2009] 
Table 1-2. Clinical trials since 2000 using replication deficient Ad – HSVtk-GCV 
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1.2.4.1.2.2 Cytosine deaminase – 5-Flurocytosine 
The bacterial and yeast enzyme cytosine deaminase (CD) has been used extensively in 
combination with the antifungal agent 5-fluorocytosine (5-FC). CD converts 5-FC into the 
chemotherapeutic agent 5-fluorouracil (5-FU), which is then converted by cellular enzymes 
into 5-F-UTP and 5-F-dUMP. 5-F-dUMP irreversibly inhibits thymidylate synthase 
preventing DNA synthesis, and is thought to be the main mechanism of 5-FC mediated 
toxicity. Additionally, 5-F-UTP can replace UTP in RNA synthesis resulting in the 
inhibition of nuclear mRNA transport. Furthermore, 5-FU molecules are able to diffuse 
through cell membranes without passing through gap junctions to give a powerful bystander 
effect [Lawrence et al, 1998] and 5-FU is also a strong radiosensitiser [Lawrence et al, 
2003]. 
The CD-5-FC system has been used extensively both in vitro and in vivo murine models, 
however this has not transferred into any clinical trials with replication deficient Ad 
vectors. The furthest progress made is for the treatment of prostate cancer, in combination 
with the HSVtk-GCV system in an oncolytic Ad vector, discussed further in section 1.2.4.3. 
1.2.4.1.2.3 Nitroreductase – CB1954 
The nitroreductase (NTR)-CB1954 (5-aziridin-1-yl)-2,4-dinitrobenzamide) enzyme-prodrug 
system uses the E.coli nfsB encoded NTR enzyme in conjunction within the prodrug 
CB1954 (see Figure 1-13). CB1954 was initially used in a 1960s study of Walker rat 
carcinosarcoma that was sensitive to CB1954 killing [Cobb et al, 1969]. Nitroreductase 
reduces CB1954 into a bifunctional alkylating agent by reducing either nitro group to form 
a 2-hydroxylamino or a 4-hydroxylamino derivative, a step which requires either NADH or 
NADPH. Following the initial reduction the 4-hydroxylamino derivative is further 
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converted by cellular thioesters into a bifunctional alkylating agent [Knox et al, 1992], 
which causes interstrand DNA crosslinking, resulting in cell death.  
 
 
Figure 1-13. CB1954 reduction by nitroreductase 
Reduction of CB154 by nitroreductase into the activated cytotoxic agent (see text for 
details). 
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The mode of action of activated CB1954 means it is cytotoxic at any stage of the cell cycle. 
This is a distinct advantage over the HSVtk-GCV and CD-5-FC systems, which require the 
target cells to be in S-phase. Furthermore, the activated CB1954 is able to freely diffuse 
through cell membranes, independent of cellular gap junction, and in doing so elicits a 
powerful bystander effect [Bridgewater et al, 1997]. 
Two clinical trials have been completed using the NTR-CB1954 enzyme prodrug system, 
both using a replication deficient Ad vector [Palmer et al, 2004; Patel et al, 2009]. The 
latest of these was a phase I/II trail for treatment of prostate cancer. The vector, named 
CTL102, has a complete E1 and E3 deletion, and expresses NTR from the CMV immediate 
early promoter, inserted within the E1 deletion. This trial consisted of two arms; the first 
was a dose escalation study of the vector alone in patients with localised prostate cancer 
scheduled for radical prostatectomy. This was to establish vector safety, tolerability and 
NTR expression. The second arm consisted of patients with local failure following primary 
treatment options, who received virus plus prodrug, and was designed to establish safety 
and tolerability. Both arms demonstrated the vector was well tolerated with minimal side 
effects. Immunohistochemistry of resected prostates demonstrated NTR staining at all viral 
doses. 19 patients received virus plus prodrug, with minimal toxicity. Preliminary evidence 
suggested partial efficacy represented by a change in prostate specific antigen (PSA) 
kinetics, with 4/19 showing 0-50% decrease in PSA, and 2/19 showing >50% decrease in 
PSA, 6 months following treatment. Despite this, NTR staining of resected prostates 
showed only localised transgene expression thus demonstrating limited virus distribution 
due to the small number of infection sites and the fact the virus is unable to replicate and 
spread from the initial sites of infection. It is therefore likely enzyme-prodrug systems 
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would benefit from combination with CRAd vectors, which can spread the therapeutic 
transgenes from the initial sites of infection (discussed in section 1.2.4.3). 
1.2.4.2 Oncolytic Adenoviruses 
Conditionally replicating Ad (CRAd) vectors, otherwise known as oncolytic adenoviruses, 
contain gene mutations or deletions, which render them only capable of replicating in 
cancer cells. Over the past two decades multiple modifications have been investigated, 
which can roughly be divided into gene deletions and promoter replacements. 
1.2.4.2.1 Adenovirus Gene Deletions 
Of all CRAd modifications the two most studied are the E1B-55K gene deletion and the 
E1A CR2 24bp deletion. 
An E1B-55K deleted Ad2/5 chimeric virus called dl1520, was initially generated to 
investigate E1B functions [Barker and Berk, 1987]. The virus, later referred to ONYX-015, 
was reported to replicate only in tumour cells, but not in normal cells [Heise et al, 1997]. 
Tumour selectivity was originally thought to be because E1B-55K is not present to bind to 
p53 in normal cells and release a p53 mediate block on the cell cycle. In cancer cells which 
have a broken p53 pathway, this function of E1B-55K is not required and the virus can 
proceed with DNA replication. However tumour selectivity was later shown to be 
independent of p53 status [Goodrum and Ornelles, 1998; Rothmann et al, 1998; Turnell et 
al, 1999]. Further investigations revealed the tumour selectivity was due to inhibition of late 
viral mRNA export in normal cells [O'Shea et al, 2004]. It is now widely accepted E1B-
55K works in concert with E4orf6 to promote late viral mRNA export from the nucleus 
while inhibiting cellular mRNA export (discussed in section 1.2.2.1). In normal cells 
deletion of E1B-55K does not allow export of late viral mRNA thus no late viral proteins 
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are produced. Presumably cancer cells have mutations which allow viral mRNA export, 
despite the E1B-55K deletion.  
ONYX-015 has been tested in multiple phase I and II clinical trials for a variety of cancer 
types, some in conjunction with other therapies. The trials up to 2002 were reviewed by 
Post and by Kirn [Kirn, 2001a; Kirn, 2001b; Post, 2002] and the trials from 2002 are 
summarised in Table 1-3. In 2005 a phase III clinical trial with ONYX-015 was stopped 
due to funding problems [Guo and Xin, 2006] however several phase II trials are still 
ongoing [www.wiley.co.uk, Dec. 09]. 
 
In 2005 China approved a second genetically engineered Ad vector, named H101, with an 
E1B-55K deletion and is similar to ONYX-015. H101 has been approved for head and neck 
cancers, after a phase III clinical trial conducted in China with 160 patients showed 74% of 
patients who received H101 and chemotherapy showed a reduction in tumour size 
compared to 40% receiving chemotherapy alone [reviewed by Guo and Xin 2006]. 
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Target Phase 
Additional 
treatment 
Authors conclusions Reference 
Recurrent/refactory 
epithelial ovarian 
cancer 
Phase I No 
Maximum tolerated 
dose not reached at 
10
11
 PFU and no 
significant toxicities 
observed 
[Vasey et al, 
2002] 
Gastrointestinal 
cancer metastatic 
to the liver 
Phase II 
5-FU and 
leucovorin 
Combination of 
virotherapy and 
chemotherapy showed 
some antitumoural 
activity in some 
chemotherapy-
resistant colorectal 
tumours 
[Reid et al, 
2002] 
Pancreatic cancer 
Phase 
I/II 
Gemcitabine 
After combination 
therapy 2 patients had 
partial regression, 2 
had minor response, 6 
has stable disease and 
11 has progressive 
disease 
[Hecht et al, 
2003] 
Hepatobiliary 
cancer 
Phase II No 
Treatment was safe 
and well tolerated. Of 
20 patients enrolled 
16 were evaluated for 
response. 1 patient 
had a partial response, 
1 has prolonged 
stabilization and 8 had 
a >50% reduction in 
tumour markers. 
[Makower et 
al, 2003] 
Colorectal cancer Phase II No 
Common toxicities 
including flu-like 
symptoms, nausea and 
emesis were observed 
in all 18 patients. All 
18 patients had 
progressive disease.  
[Hamid et al, 
2003] 
Advanced 
malignancy 
Phase I 
pilot 
trial 
Irinotecan 
and 5-FU or 
IL-2 
Virus related toxicity 
was limited to 
transient fever. All 
patients demonstrated 
elevated neutralizing 
antibodies within 4 
weeks of treatment. 
[Nemunaitis et 
al, 2003] 
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Premalignant oral 
dysplasia 
Phase I No 
No toxicities greater 
than grade 2 was 
observed. Histologic 
resolution of dysplasia 
was seen in 7 of 19 
patients. 
[Rudin et al, 
2003] 
Recurrent 
malignant gliomas 
Phase I No 
No maximum 
tolerated dose reached 
at 1x10
10
 PFU.  
[Chiocca et al, 
2004] 
Advanced 
sarcomas 
Phase 
I/II 
MAP 
chemotherapy 
No dose limiting 
toxicity observed. 
Evidence of 
antitumour activity in 
1 out of 6 patients. 
[Galanis et al, 
2005] 
Metastatic 
colorectal cancer 
Phase 
I/II 
No 
No dose limiting 
toxicity observed. Of 
24 patients included 
11 had stable disease 
after 3 months. 
[Reid et al, 
2005] 
Advanced cancers Phase I Enbrel 
No significant adverse 
events were attributed 
to the experimental 
regimen. 
[Nemunaitis et 
al, 2007] 
Table 1-3. Clinical trials with ONYX-015 from 2002 onwards 
 
The E1A CR2 24bp deletion (commonly referred to as E1A CR2 24) removes the region 
of E1A which binds with the highest affinity to the retinoblastoma protein (pRb). Binding 
of E1A to pRb via the CR2 region causes the release of the transcription factor E2F, 
allowing cell cycle progression and virus replication. In normal cells with an intact pRb 
pathway, the mutant E1A cannot bind pRb and release E2F thus virus replication is 
blocked. Within cancer cells with a mutant pRb pathway this function of E1A is redundant 
and the mutant virus is able to replicate and kill the cell. 
Since the initial studies over a decade ago [Fueyo et al, 2000; Howe and Bayley, 1992] the 
E1A CR2 24 CRAd virus has been used extensively for in vitro studies and in vivo murine 
models to treat a variety of cancers [reviewed by Dobbelstein, 2004; and by Everts and van 
der Poel, 2005]. No clinical trials have been completed with an E1A CR2 24 vector, 
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however three clinical trials have been recently approved using 24 vectors which contain 
additional mutations. Two trials use a 24 vector which has been retargeted with either the 
RGD sequence or an Ad5/3 chimeric fibre and are discussed in section 1.2.4.4.1. The third 
trial also uses an RGD retargeted vector, but has insertions to enhance tumour specificity 
and will be discussed in section 1.2.4.4.2. 
In addition to the E1B and E1A deletions, VA RNA deletions have also investigated for 
treatment of pancreatic tumours. VA RNA inactivates PKR to allow continued protein 
translation in virus infected cells. However the Ras pathway, which is active in pancreatic 
tumours, can inactivate PKR and thus dispensing for the need of VA RNA and allowing 
translation to continue [Cascallo et al, 2003]. 
1.2.4.2.2 Promoter Replacements 
The second basic strategy for engineering CRAds involves replacing natural viral promoters 
such as the E1A promoter with tumour or tissue specific promoters. Tumour specific 
promoters respond to factors found over-expressed in cancer cells, but not activated in 
normal cells, such as the E2F-1 promoter, which responds to free E2F generally found in 
most tumours [Jakubczak et al, 2003]. Tissue specific promoters respond to factors found 
only in specific target tissues and are typically upregulated in target cancers, such as the 
prostate specific antigen (PSA) promoter which is found upregulated in prostate cancer 
[Rodriguez et al, 1997]. Many tumour and tissue specific promoters have in investigated in 
vitro, some of which are summarised in Table 1-4, however this is by no means an 
exhaustive list. 
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Promoter 
Replaced 
Inserted 
Promoter 
Selectivity Other Information Reference: 
E1 and E4 
COX-2 and/or 
MK promoter 
Colorectal 
and 
pancreatic 
cancer 
Enhanced viral 
replication specificity 
observed with double 
COX-2/MK promoter 
over either single 
promoter alone 
[Hoffmann 
and 
Wildner, 
2006] 
E1A and 
E4 
pS2 promoter 
containing 
estrogen-
responsive 
elements 
Breast 
cancer 
Estrogen receptor 
positive breast cancer 
cells killed as efficiently 
as wt Ad5 but has 
decreased cytotoxicity 
observed with receptor 
negative cells 
[Hernandez-
Alcoceba et 
al, 2000] 
E1A PSA promoter 
Prostate 
cancer 
E1A expression only 
observed in PSA positive 
prostate cell lines 
[Rodriguez 
et al,  1997] 
E1A 
A33 antigen 
promoter 
Colon 
cancer 
Reduction in tumour 
growth in nude mice with 
colon cancer xenografts 
[Cafferata et 
al, 2009] 
E1A hTERT promoter 
Tumour 
specific 
Inhibition of tumour 
growth in mice 
xenografts with absence 
of hepatotoxicity 
[Huang et 
al, 2003a] 
E1A E2F-1 promoter 
Tumour 
specific 
Replication attenuated in 
non-proliferating normal 
cells 
[Tsukuda et 
al, 2002] 
Table 1-4. CRAd promoter replacements 
 
From the various promoter replacement oncolytic strategies tested in vitro and in animal 
models, to date only two, the hTERT and the PSA promoter, have successfully transferred 
into clinical trial.  
Transcriptional activation of the human telomerase reverse transcriptase (hTERT) promoter 
is a major mechanism for cancer specific activation of telomerase [reviewed by Kyo et al, 
2008]. Telomerase activation is one mechanism used by tumour cells to prevent telomere 
loss, which is necessary to prevent eventual cell senescence. Nemunaitis et al recently 
completed a phase I clinical trail using Telomelysin, an oncolytic Ad vector with the E1A 
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and E1B genes under control of the hTERT promoter, has been tested in patients with 
advanced solid tumours [Nemunaitis et al, 2009]. The trial used a single intratumoural 
injection of the Telomelysin to 16 patients with a variety of solid tumours, which were split 
into three cohorts receiving 1x10
10
, 1x10
11
 or 1x10
12
 viral particles. The authors report that 
the vector was well tolerated at all dose levels with 1 patient having a partial response of the 
injected lesion and 7 patients having stable disease 56 days after treatment, suggesting 
antitumour activity. 
Two PSA responsive oncolytic vectors have been tested in clinical trails; CV706 (also 
know as CN706) and CG7870. CV706 has the E1A promoter region replaced by the 
minimal 5‟ promoter/enhancer elements from the PSA gene, and has been in a phase I 
clinical trial for locally recurrent prostate cancer [Chen et al, 2001; DeWeese et al, 2001]. 
This trial demonstrated CV706 was safe and not associated with any irreversible grade 3 or 
any grade 4 toxicities, and some signs of efficacy were demonstrated by a 50% fall in serum 
PSA levels in 5 of 25 patients. The second vector, CG7870, has the E1A gene under control 
of the rat probasin promoter, the E1B gene under control of the PSA promoter and a full 
length E3 region. This vector has been tested in a phase I and phase I/II clinical trial for the 
treatment of hormone-refractory metastatic prostate cancer [Dilley et al, 2005; Small et al, 
2006]. The most recent of these trials used a single intravenous dose of CG7870, in a dose 
escalation from 1x10
10
 to 6x10
12
 VP. The authors report good tolerance with 3 therapy 
related grade 3 events and no grade 4 events. No complete PSA responses were observed, 
however 5 patients of 23 showed signs of efficacy illustrated by a 25-50% drop in serum 
PSA levels. 
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Initially CRAd vectors contained large deletions within the E3 region. Suzuki et al 
demonstrated that retaining the wt E3 region improved the oncolytic activity of CRAd 
vectors [Suzuki et al, 2002]. It was later shown the oncolytic activity and spread of CRAd 
vectors could be increased by over-expressing the E3 encoded ADP [Doronin et al, 2003]. 
1.2.4.3 Oncolytic Adenoviruses Carrying Transgenes 
The primary drawback with replication deficient Ad vectors is the impracticality of 
achieving complete delivery to every cell in the tumour. Only cells surrounding the 
immediate site of administration are susceptible to treatment, reducing potential efficacy.  
Overall, clinical trials with oncolytic vectors indicate that while CRAd vectors or safe, they 
are unable to significantly alter the course of the disease. Many studies have demonstrated 
that „arming‟ of CRAd vectors with additional cytotoxic functions can improve the lytic 
effect of the virus [reviewed by Cody and Douglas, 2009]. Furthermore, these vectors can 
replicate and disseminate from the initial site of administration, theoretically spreading the 
transgene(s) in the process. However the smaller deletions in CRAd vectors (compared to 
replication defective vectors) limit the size of transgene inserts. 
 
All of the enzyme-prodrug systems described above have been combined with CRAd 
vectors to improve upon the oncolytic effect alone [reviewed by Cody and Douglas 2009]. 
To date the only CRAd/enzyme-prodrug combination put into clinical trial uses an E1B-
55K deleted backbone, carrying an HSVtk-CD fusion gene, in so-called double suicide 
gene therapy. In a series of clinical trials for prostate cancer the safety was assessed alone 
and in combination with radiotherapy. Some signs of efficacy were observed indicated by 
transgene expression, needlecore biopsies and serum PSA levels. Furthermore an increase 
in the PSA doubling time from 17 to 31 months was observed at a 5 year follow-up 
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[Freytag et al, 2002; Freytag et al, 2007a; Freytag et al, 2007b; Freytag et al, 2003]. The 
latest of these studies used a yeast encoded CD (yCD), which is more catalytically active 
then the previously used bacterial CD (bCD), and a mutant HSVtk, HSVtkSR39, which is 
more catalytically active than the wildtype HSKtk. This vector, termed Ad5-yCD/mutTK 
rep-hNIS, also encoded the human sodium iodide symporter as a reporter gene system to 
allow imaging of virus dissemination by PET or SPECT. Again this phase I clinical trial 
was for prostate cancer, and demonstrated the vector safety in all 19 patients (3 grade three 
events and no grade 4 events) and feasibility of nuclear imaging adenovirus mediate gene 
expression and distribution [Barton et al, 2008]. 
1.2.4.4 Improved Adenovirus Systems 
1.2.4.4.1 Retargeting to Tumours 
It was hypothesised that poor virus infection of tumour tissue was one of the primary 
setbacks in Ad based cancer gene therapy. This hypothesis was supported by evidence 
showing the low and variable expression of CAR on cancer cells [Okegawa et al, 2004]. 
CAR is the primary cell surface receptor for species C Ad and is required for efficient Ad5 
infection. In response, several strategies have been investigated using genetic or chemical 
modifications to retarget Ad, in attempts to improve infectivity. 
Various modifications can be employed to genetically retarget Ads, including; pIX gene 
fusions, hexon modification, penton base gene fusions, fibre modifications and whole fibre 
replacements [reviewed by Mathis et al, 2005]. 
The simplest of these strategies is whole fibre replacement to generate so-called 
„pseudotyped‟ or chimeric adenoviruses. This strategy is made possible by the high degree 
of structural similarity between Ad fibres and the identification of Ad serotypes whose 
native tropism is not CAR. Successful Ad fibre replacement was achieved in the mid 
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nineties, by replacement of the Ad5 fibre with that of Ad7 [Gall et al, 1996]. Since then, 
chimeric viruses have been constructed with the fibres from Ad35 (to target lymphoid cell 
lines) and Ad16 (to target cultured synovial cells) [Goossens et al, 2001; Nilsson et al, 
2004], both of which increase target cell transduction. Replacement of the fibre with that of 
Ad37 (a species D virus) produces significantly less viral infection to rat liver in vivo 
[Denby et al, 2004]. Replacement of the entire Ad fibre is perhaps not as desirable as other 
genetic retargeting strategies. The length and flexibility of the fibre shaft appears to play a 
role in Ad cell entry and replacement of longer shafts (such as Ad5) with shorter shafts (as 
found in Ad37) may cause a steric hindrance problem resulting in reduced cell attachment 
[discussed by Nemerow et al,  2009]. 
Krasnykh et al employed a slight variation of this strategy, by replacing just the fibre knob 
domain of Ad5 with that of Ad3 and achieved an increase in transduction of ovarian, renal 
and squamous cell cancer cells [Haviv et al, 2002; Kanerva et al, 2002]. This strategy has 
also been shown possible with the Ad37 fibre knob domain, which uses sialic acid as a 
receptor [Cashman et al, 2004]. 
A more elegant approach to fibre retargeting is the genetic incorporation of targeting 
peptide within the fibre knob domain. Peptide binding motifs can be incorporated into both 
the C-terminal and HI loop of the fibre knob domain. The C-terminal additions were the 
first to be exploited, however this strategy is severely limited, since incorporation of 27 or 
more amino acids inhibits fibre trimerisation [Hong and Engler, 1996]. The HI loop can 
tolerate up to a 83 amino acid insertion, without affecting virion integrity or natural tropism 
[Belousova et al, 2002] and is thus more useful for peptide insertion. 
The most common use of this strategy is insertion of the RGD integrin binding motif within 
the HI loop of the fibre knob domain. The RGD motif is found within the Ad penton base as 
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well as other viral proteins (such as the yellow fever virus envelope protein) and cellular 
proteins (such as fibronectin), and binds V3/5 integrins. By inserting the RGD motif 
within the Ad5 fibre knob the virus can use integrins as the primary cell attachment receptor 
[Dmitriev et al, 1998]. Integrins are generally highly expressed across many cell types and 
therefore represent a good candidate for virus retargeting. Indeed several groups have 
constructed RGD-retargeted Ad5 vectors, and have demonstrated improve transduction of a 
variety of CAR negative cell lines and primary tumour material [Mathis et al,  2005]. 
Retargeting in this way can be performed without affecting the natural CAR tropism. 
Because of the large insertions tolerated in the HI loop, various peptides binding motifs 
have been successfully inserted. A series of investigations have inserted multiple 
immunoglobulin binding domains (also known as Affibodies) into knob-less fibre protein 
and within the fibre HI loop [Henning et al, 2005; Henning et al, 2002; Magnusson et al, 
2007; Myhre et al, 2007]. Recently two immunoglobulin binding domains specific for 
HER2/neu and Taq polymerase, separated by a flexible linker domain, were inserted into 
the HI loop of the same virus. This study demonstrated two separate Affibody molecules 
can be inserted into the same HI-loop while retaining the target specific binding of both 
affinity proteins [Myhre et al, 2009]. 
Other studies have investigated virus retargeting using hexon, penton base and protein IX. 
The RGD motif has been inserted into the fifth hypervariable region of Ad5 hexon and has 
shown enhanced transduction to v integrins [Mathis et al,  2005].  
The C-terminal domain of protein IX has been fused to several peptides to modify the 
tropism of the virus. These include polylysine, the RGD motif and the c-Myc epitope 
[Dmitriev et al, 2002; Vellinga et al, 2004], however direct retargeting to cells has not been 
demonstrated for any of these peptides. The entire IX gene has been fused with a single-
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chain antibody against β-galactosidase, via a spacer sequence. EM demonstrated the 
antibody was present on the outside of the capsid protein and available to its ligand, 
however this method has not been shown to directly retarget virus binding [Vellinga et al, 
2007]. 
A recent series of studies has investigated liver detargeting by ablation of the hexon-FIX 
interaction, which was shown to mediate liver transduction via HSPG in vitro and in vivo 
mice models. Exchanging the hypervariable regions of hexon responsible for FIX binding 
with ones that do not bind FIX, or mutagenesis of the amino acids responsible for FIX 
binding, completely ablated liver transduction in vitro and in vivo murine models [Alba et 
al, 2009; Greig et al, 2009; Kalyuzhniy et al, 2008b]. 
To date no clinical trial has been completed with a retargeted virus. Two phase I trials have 
been recently approved for treatment of recurrent ovarian cancer, both of which use an Ad 
vector with the RGD insertion in the fibre HI loop. The first of these trials uses a replication 
deficient Ad vector expressing both the HSKtk gene for suicide gene therapy, and the 
human somatostatin receptor subtype-2 (hSSTR2) for imaging of virus distribution. This 
vector has been recently tested in a pre-clinical Syrian hamster model to provide 
justification for planned dosing, and insights into any anticipated toxicity [Matthews et al, 
2009] The second of these trials uses an „un-armed‟ oncolytic Ad vector containing the 
E1A CR2 24 deletion. Again a pre-clinical study of this vector has been completed in 
cotton rats to gain insights into clinical dosing and any anticipated toxicity [Page et al, 
2007]. 
A phase I clinical trial has also been approved in the US using an Ad5 vector with a 
chimeric Ad3 fibre for the treatment of recurrent ovarian cancer. However no data has been 
published as yet [www.wiley.co.uk, Dec. 09]. 
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Chemical modifications use synthetic polymers to evade the immune response and for 
tumour targeting. The use of chemical retargeting is outside the scope of this thesis, 
however has been extensively reviewed previously [Kreppel and Kochanek, 2008]. 
1.2.4.4.2 Improving Tumour Specificity 
Increased understanding of cell biochemistry has helped develop more stringent tissue and 
tumour selective CRAd. Replacement of viral promoters with tumour or tissue specific 
promoters has been combined with the E1B-55K or E1A CR2 24 deletion to create an 
extensive variety of CRAd vectors. 
 
In 2002 Johnson et al constructed an E1A CR2 24 vector which had both the E1A and E4 
promoters replaced by the tumour selective E2F-1 promoter [Johnson et al, 2002]. This 
CRAd displaced potent cytotoxic activity against cancer cells but was essentially replication 
deficient in primary culture cells. Later the same vector was armed by replacing the E3B 
region with the NTR gene, to create ONYX-411
NTR
. In combination with the prodrug 
SN28343 this vector was able to eliminate H1299 tumour xenographs in 5 out of 8 (62.5%) 
mice [Singleton et al, 2007]. 
Majem et al constructed two vectors similar to ONYX-411, both of which contained the 
E1A CR2 24 deletion and an RGD motif inserted into the fibre HI-loop [Majem et al, 
2006]; however these vectors retained the wildtype E4 promoter. The first, vICOVIR-1, had 
the natural E1A promoter replaced by the human E2F-1 promoter, preceded by a synthetic 
poly(A) sequence to insulate against transcription from non-selective endogenous viral 
transcription elements. In the second of these vectors, vICOVIR-2, the E2F-1 promoter has 
been additionally insulated using the 0.7kb insulator region from the myotonic dystrophy 
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locus (DM-1). This region contains CTG repeats and CTCF binding regions that together 
function as an insulator, blocking the interaction between promoter-enhancer elements. 
Both vectors expressed less E1A in normal cell lines and introduction of the tumour 
specific promoters did not show any significant loss of antitumour efficacy. Moreover 
introduction of the DM-1 insulator elements resulted in increased selectivity of E1A 
expression [Majem et al,  2006]. During the course of this thesis Alonso et al improved this 
vector by introducing a Kozak consensus sequence direct before the E1A translational start 
site for increased E1A expression. Three studies subsequently demonstrated this vector, 
termed vICOVIR-5, possessed potent anti glioma effect in in vivo mice models, alone and 
in combination with chemotherapy, and low systemic toxicity [Alonso et al, 2007a; Alonso 
et al, 2007b; Cascallo et al, 2007]. Furthermore, this vector has recently been approved for a 
phase I clinical study of gliomer [www.wiley.co.uk, Dec. 09]. Finally in 2009 Rojas et al 
modified the E2F-1 promoter in vICOVIR-5, by inserting an additional two E2F responsive 
regions (each one containing the two E2F binding palindromes), to create the vICOVIR-7 
virus [Rojas et al, 2009]. The presence of these extra E2F binding palindromes caused 
increased tumour selectivity (i.e. reduced expression in normal cells), resulting in a low 
systemic toxicity at high doses in immuno-competent mice. 
Within this series of vectors all the tumour selective modifications made centre on the pRb 
pathway. This could cause a problem, as loss of one control mechanism in normal cells 
would not be compensated for by the second. This is further complicated by presence of 
wildtype E4orf6/7 under control of the wildtype E4 promoter. E4orf6/7 is known to 
dimerise with E2F and activate transcription of E2F response elements, such as those found 
in the Ad5 E2 region and the E2F-1 promoter itself. Thus any leaky expression of E4orf6/7 
could sequester any small amount of free E2F in normal cells and allow transcriptional 
 80 
activation of E1A and E2F itself. More E2F could upregulate E1A transcription, which 
could in turn upregulate E4orf6/7 transcription and further enhance E2F and E1A 
transcription. The resultant positive feedback loop could reduce the normal cell attenuation 
and also cause increased E1A expression at late times of infection. 
 
Increased replication selectivity has been achieved by combining the E1B-55K or E1A CR2 
deletions with various tissue selective promoter replacements. Table 1-5 lists a selection of 
combinations which have been investigated; however this list is by no means exhaustive. 
 
Deletion Promoter Target Conclusion Reference 
E1B-55K Carcinoembryonic 
antigen promoter 
Colon 
cancer 
Elimination of 
colon metastasis in 
mice xenograph 
model 
[Sagawa et al, 
2004] 
E1A CR2 
24 +/- N-
terminal  
Long or short Cox2 
promoter 
Ovarian 
cancer 
>10,000-fold 
growth attenuation 
in normal cells 
[Bauerschmitz 
et al, 2006] 
E1B PPT promoter (PSA 
enhancer, PSMA 
enhancer and 
TARP promoter) 
Prostate 
cancer 
Suppressed growth 
of aggressively 
growing prostate 
tumour in mice 
[Danielsson et 
al, 2008] 
E1A CR2 
24 
E1A replaced with 
poly(A) sequence 
and tyrosinase 
enhancer/promoter 
Malignant 
melanoma 
100-1000 fold 
attenuation in non-
melanocytic tissue 
[Nettelbeck et 
al, 2002] 
Table 1-5. CRAd with tissue specific promoters 
 
Whereas introduction of tissue specific promoters can increase the replication selectivity, it 
of course narrows down the potential therapeutic targets to just one tissue. Additionally 
introduction of tissue specific promoters generally increases the size of the viral genome, 
reducing the space left for introduction of therapeutic transgenes. 
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Use of tissue selective promoters in CRAd vectors has been taken to the extreme by 
replacing almost all the natural Ad promoters with foreign promoters. Fuerer and Iggo 
produced a series of Tcf responsive CRAd vectors for treatment of colon cancer [Fuerer and 
Iggo, 2002]. The Tcf transcription factor is part of the wnt signalling pathway, which is 
pathologically activated in the majority of colon cancers. Mutations, at any one of several 
points in the wnt pathway, result in nuclear localisation of β-catenin where it associates 
with Tcf to activate transcription of wnt responsive genes such as c-myc, cyclin D1 and 
Tcf1. Thus the Tcf controlled viruses should only replicate in colon cancer, where the wnt 
pathway is activated. The panel of viruses created used Tcf responsive elements to control 
early viral gene transcription (including the E1A, E1B, E2 and E4 regions), with or without 
an E1A N-terminal deletion. This deletion removes the region of E1A responsible for 
interacting with p300/CBP, ablating the ability to activate viral transcription in normal 
cells. The CRAd termed vCF62, in which the natural E1A, E1B, E2 and E4 promoters were 
all replaced with Tcf responsive elements, and the N-terminus of E1A deleted, 
demonstrated attenuated growth compared to Ad5 wt in all the cell lines tested. Several 
viral intermediates of vCF62 showed good replication selectivity for a range of colon 
cancer cell lines, and no attenuated growth compared to vCF62. This report not only 
demonstrates how tumour selective promoter can be used successfully, but how extreme 
modifications can result in less useful attenuated vectors. 
The first CRAd vectors contained deletions in the E3 region, which is dispensable for 
growth in tissue culture. However it was demonstrated by Suzuki et al that the presence of 
the E3 region improved lytic activity due to the activity of ADP [Suzuki et al,  2002]. 
Doronin et al over-expressed the ADP protein in a vector with a wt E1 region and all E3 
genes deleted except for E3-12.K [Doronin et al,  2003]. This vector, VRX-007 and later 
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referred to as INGN-007, demonstrated improved oncolytic activity and has recently been 
approved for a phase I clinical trial [www.wiley.co.uk, Dec. 09]. In anticipation of this trial 
pre-clinical studies were completed to investigate toxicity and biodistrubtion in Syrian 
hamsters [Ying et al, 2009]. 
1.2.4.4.3 Improving Enzyme-Prodrug Systems 
Chen et al at The University of Birmingham, School for Cancer Sciences –Gene Therapy 
group (SCS-GT group) developed an E1B-55K deleted CRAd vector expressing NTR, 
termed CRAd-NTR, for combined oncolytic and enzyme-prodrug therapy. NTR expression 
was under control of the CMV immediate early promoter, and had a downstream intron and 
3‟-end processing signals from the human β-globin and complement C2 genes, respectively 
[Chen et al, 2004]. This NTR expression cassette was inserted within the E1B-55K 
deletion. CRAd-NTR out-performed replication deficient vector expressing NTR from a 
similar expression cassette (CTL102), in vitro and in in vivo animal studies [Chen et al,  
2004]. However, the early expression of NTR in combination with CB1954 had a 
detrimental effect on virus replication, reducing the natural oncolytic effect of the virus. In 
response, a second vector was constructed which replaced the pIX coding region with the 
NTR sequence for expression at intermediate times of replication [Roesen, 2006]. As 
expected this virus, vNR6, showed no reduction in virus replication in the presence of the 
prodrug CB1954. Additionally, this virus demonstrated increased in vitro cytotoxicity and 
greater vector spread through monolayer and three dimensional tissue culture models, 
however the level of NTR expression, and hence the degree of sensitisation to CB1954, was 
reduced compared to CRAd-NTR. 
This work illustrates the balance required between viral lytic activity and enzyme-prodrug 
cytotoxicity. If enzyme expression is too high and early, treatment with prodrug can have a 
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detrimental effect of virus growth. However expression needs to be high enough to provide 
a therapeutic effect. 
 
Studies using the NTR-CB1954 enzyme prodrug system in replication deficient vectors in 
vitro and  in vivo demonstrated the extent of cell killing was dependent upon the level of 
expression (or viral dose) and prodrug concentration [Djeha et al, 2001; McNeish et al, 
1998; Weedon et al, 2000]. These data imply that the rate of CB1954 activation is a 
significant limitation to the efficacy of the therapy and indeed CB1954 is a poor substrate 
for the enzyme NTR [Anlezark et al, 1992]. In response to these observations, mutagenesis 
has been used on the NTR gene, nfsB, to create NTR mutant variants, termed „turbo-NTR‟. 
The first study used the crystal structure of NTR to identify 9 potential residues around the 
active site which could directly influence prodrug binding and catalysis. Selected mutations 
in 6 of these residues showed increase sensitivity to CB1954 compared to the wt enzyme 
[Grove et al, 2003]. Guise et al then developed a direct positive selection strategy to 
identify NTR mutants for improved CB1954 catalysis from a library of ~10
6
 possible 
combinations. This strategy identified a triple mutant NTR variant, T41Q/N71S/F124T, 
which conferred a 40- to 80-fold increase in CB1954 sensitivity to ovarian cancer cells 
[Guise et al, 2007]. The single mutations identified by Grove et al were also combined to 
give a panel of 53 double mutant „turbo-NTR‟ variants, of which the best combination, 
T41L/N71S, showed a 14-17 fold increase in sensitisation to CB1954 compared to wt NTR, 
in ovarian cancer cells [Jaberipour et al,  2010]. 
Most studies using the NTR-CB1954 suicide gene therapy system have focused on using 
the minor E.coli NTR encoded by the nsfB gene. The major NTR variant encoded by the 
nfsA gene has also been investigated in combination with the prodrug CB1954. The wt 
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version of nfsA NTR shows a 3.5- to 8-fold greater sensitivity to CB1954 compared to the 
wt nfsB encoded NTR. Furthermore nfsA NTR was shown to have an increased bystander 
effect with CB1954 compared to nfsB NTR, due to selective reduction of the 2-NO2 group 
of CB1954 [Vass et al, 2009]. 
1.3 Prostate Cancer Gene Therapy 
1.3.1 The Prostate and Prostate Cancer 
The prostate is a walnut sized gland situated directly below the bladder, in the pelvic cavity 
between the lower part of the pubic symphysis and the superior fascia of the urogenital 
diaphragm. The prostate is composed of approximately 70% glandular tissue and 30% 
fibromuscular stroma and in normal biology serves as an exocrine gland that produces upto 
12% of semen by volume [Patel, 2006].  
 
Prostate cancer accounts for almost a quarter of all new male cancers diagnosed, making it 
the most common cancer in men in the UK. Over the past 30 years better detection 
techniques have lead to an increase in prostate cancer incidence rates. However this 
increase has not translated into increased mortality, which has remained approximately 
constant since the mid 1970‟s [Patel 2006; Selley et al, 1997; 
www.statistics.gov.uk/statbase/, Dec. 09].  
Incidence rates of prostate cancer are strongly associated with age, with little indicence in 
men under 50 and more than 60% of cases occurring in men over 70 years old. It has been 
estimated upto 30% of men over the age of 50 have histological evidence of prostate 
cancer, which rises to 60-70% of men by the age of 80. However still only 4% 
(approximately 1 in 25) of these men will die from this disease [Selley et al,  1997]. 
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Prostate cancer has the highest prevalence rates in African-American men which is 
significantly higher than that of white Americans, with the lowest rates recorded in Asian 
men and men of South Asian origin [Patel 2006; www.cancer.gov, 09]. In addition to age 
and ethinicity, a family history of prostate cancer in a first degree relative (brother or father) 
also increases the risk of developing prostate cancer by 2 to 3 times [Monroe et al, 1995]. 
Furthermore, men whose families have a history of breast cancer, specifically associated 
with the BRCA2 gene, are also at high risk of prostate cancer. Several dietary factors have 
been assocated with an increased risk of prostate cancer including alpha-linolenic acid, 
cholesterol, dairy products and alcohol [Patel 2006]. It has also been suggested the high 
incidence rates of prostate cancer found in developed countries is associated with the 
western diet, especially the high intake of animal fats. 
1.3.2 Molecular Mechanisms of Prostate Cancer 
Prostate cancer is a highly heterogeneous disease which results from multiple complex 
genetic alterations [reviewed by Reynolds, 2008]. Prostate cancer is a disease of aging and 
is thought to begin with chronic accumulation of prostatic intraepithelial neoplasia (PIN) 
lesions which eventually develop into adenocarcinoma [Lawson, 1997]. Early genetic 
events in the development of prostate cancer are thought to be driven by the loss of tumour 
suppressor proteins such as PTEN, NKX3.1, P27, KLF5 and KLF6. It has been suggested 
these early genetic events, in particular loss of the tumour supressors PTEN and NKX3.1, 
dysregulate cellular proliferation and drive benign to PIN transition [Reynolds 2008]. 
It would seem one of the major factors in the progression from PIN to adenocarcinoma is 
the development of gene fusions between TMPRESS2 and members of the oncogenic ETS 
family of transcription factors [reviewed by Morris et al, 2008]. This fusion joins the 
oncogenic ETS family members to the regulated promoter region of androgen-responsive 
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gene TMPRSS2, resulting in the direct androgen dependent upregulation of the ETS 
oncogenic factors. 
Molecular techniques such as gene array profiling and rt-PCR identified the alpha-methyl 
CoA racemase (AMACAR) gene as being highly upregulated in 100% of prostate cancers 
and has subsequently been used as a marker for prostate cancer morphologies in prostate 
needle biopsies [Magi-Galluzzi et al, 2003; Reynolds 2008]. Histone deacetylases (HDAC) 
are frequently found upregulated in prostate cancer, particularly in hormone-refractory 
diseases. Histone acetylation is a major epigenetic modulation which facilitates 
transcriptional activation and the hypoacetylation of histones is highly associated with DNA 
methylation, which is believed to repress transcription of methylated promoters. 
Hypermethylation of GSTP1, a gene involved in carcinogen detoxification, is one of the 
most frequently observed modifications, in addition to the MDR1 and APC genes [Bastian 
et al, 2005; Lodygin et al, 2005; Yegnasubramanian et al, 2004].  
Androgen receptor gene reactivation is a central transformation event in the transition to 
hormone-refractory prostate cancer. There are several potential mechanisms behind 
androgen receptor reactivation including gene amplification, somatic mutations and 
epigenetic modifications. In addition to androgen receptor, MYC and EIF3S3 have also 
been identified as undergoing frequent gene amplifications in hormone-refractory prostate 
cancers [Nupponen and Visakorpi, 1999].  
Mutations in the p53 tumour suppressor gene are also commonly observed in prostate 
cancer, with an average frequency of 20-30%. Furthermore, p53 mutations are more 
frequently detected in more advanced prostate cancers and have been associated with 
locally advanced hormone-refractory diseases [Gao et al, 1997; Grignon et al, 1997; Quinn 
et al, 2000]. The insulin-like growth factor-binding protein 2 (IGFBP2) has been shown to 
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be overexpressed in 36% of primary prostate tumours and 100% of hormone-refractory 
prostate cancers, while expression is normal in benign prostate hyperplasia samples 
[Reynolds 2008]. When taken together both the p53 and IGFBP2 observations suggest a 
steady accumulation of genetic mutations during the development from benign to advanced 
hormone-refractory disease. 
1.3.3 Current Prostate Cancer Therapy 
Treatment options for early localised prostate cancer comprise of surgery and radiotherapy, 
both of which demonstrate upto a 90% ten-year survival rate [Donovan et al, 1999; Patel 
2006]. Following progression to locally advanced disease patients may receive radiotherapy 
or hormone therapy. Treatment of patients who are at high risk of advanced local recurrence 
with adjuvant radiotherapy following prostatectomy improves five year PSA relapse-free 
survival [Bolla et al, 2005a; Bolla et al, 2005b]. Approximately 30-60% of patients with 
local disease following local therapy go on to show PSA recurrence within 10 years of 
treatment. This rate is substantially higher with locally advanced disease [Patel 2006]. 
Treatment options for locally recurrent prostate cancer centre around surgery and 
radiotherapy, however the selection of treatment depends on many factors and individual 
patient consideration needs to be taken into account. Most patients with locally recurrent 
prostate cancer will fail surgery or radiotherapy with disseminated disease and are managed 
with hormone therapy. Whereas treatment of metastatic disease with hormone therapy gives 
good short-term control there is no curative option and in most cases the cancer beings to 
grow again. As a last resort chemotherapeutic agents such as mitoxantrone or docetaxel 
may be used to try and give a survival benefit; however any benefit has to be weighed 
against the associated toxicity [Tannock et al, 2004]. It is therefore essential novel 
therapies, such as gene therapy, are developed for the treatment of locally recurrent prostate 
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cancers as improved local control would be of major benefit by either postponing or 
avoiding completely the development of metastatic disease and need for systemic hormone 
treatments. 
1.3.4 Gene Thereapy Stratergies for Prostate Cancer 
Gene therapy was first used for prostate cancer in 1994 and since then 103 clinical trials 
have started of which 73 are reported to be ongoing [www.wiley.co.uk, Dec. 09]. A variety 
of viral vectors are undergoing clinical trial for prostate cancer including retrovirus, adeno-
associated virus, pox viruses and vaccinia virus, however more than half of all prostate 
cancer gene therapy trials use adenovirus vectors. Several stratergies have been employed 
using adenovirus delivery and are summaried in Table 1-6.  
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Therapy Gene delivery/modification Number trials 
Tumour suppressor 
replacements 
p53 2 Phase I 
1 Phase II 
p16 1 Phase I 
Immunotherapy IL-2 2 Phase I 
IL-12 2 Phase I 
TRAIL 1 Phase I 
IFN- 1 Phase I 
CD40 + prostate specific membrane antigen 1 Phase I/II 
RTVP-1 1 Phase I 
p501 with p501 protein and adjuvant 1 Phase I 
MUC1 1 Phase I 
PSA vaccine 1 Phase I 
2 Phase II 
Enzyme - prodrug 
therapies 
HSVtk or 
HSVtk with CD 
5 Phase I 
4 Phase I/II 
Purine nucleoside phosphorylase 1 Phase I 
Nitroreductase 1 Phase I 
1 Phase I/II 
Onclytic 
adenovirus 
PSA promoter 4 Phase I 
2 Phase I/I 
2 Phase II 
Osteocalcin promoter 1 Phase I 
Radioisotope 
deliverey 
Sodium iodide cymporter with radioiodine 1 Phase I 
Combined theapies GM-CSF + NT 1 Phase  
Oncolytic vector with combined HVtk and CD 3 Phase I 
2 Phase I/II 
1 Phase II 
1 Phase III 
Oncolytic vectors with sodium iodide smporter 1 Phase I 
Table 1-6. Prostate cancer gene therapy trials reported ongoing 
 
Whereras the use of immunotherapy for treatment of prostate cancer is outside the scope of 
this work the most recently clinical trials using tumour suppressor replacements, enzyme-
prodrug systems, oncolytic adenoviruses and combined therapies have all been previous 
discussed (see sections 1.2.4.1.1 to 1.2.4.4). Of all the adenovirus strategies used oncolytic 
vectors combined with HSVtk and CD has arguably had the most success, demonstrated by 
the fact this is the only phase III clinical trail in progress.  
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1.4 Aims of Thesis 
The aim of this research was to construct improved oncolytic adenovirus vectors armed 
with NTR, for combinational oncolytic virotherapy and NTR/CB1954 enzyme/prodrug 
therapy, for the treatment of prostate cancer. The new oncolytic NTR viruses were based 
around the ICOVIR vectors designed by Dr R. Alemany and were compared to the E1B-
55K deleted vNR vectors (vNR3 and vNR6) 
To begin the ICOVIR-5 and ICOVIR-7 based vectors from Dr R. Alemany's lab were 
chosen for construction of new oncolytic adenovirus vectors expressing the marker 
transgene eGFP. These new oncolytic vectors were to be characterised and compared to the 
E1B-55K deleted vectors vNR3, in terms virus replication, transgene expression, 
cytotoxicity, tumour selectivity, DNA replication, transgene expression and any effect on 
transgene insertion on oncolytic activity.  
Using this data the most tumour selective vector would be chosen of the introduction of the 
therapeutic transgene NTR. ICOVIR based vectors will be constructed which expresses 
either wt NTR, double mutant NTR or triple mutant NTR. These vectors will be 
subsequently characterised and compared to vNR6, in terms of oncolytic cytotoxicity, 
tumour selectivity, NTR/CB1954 mediate cytotoxicity and combined cytotoxicity. From 
this data the vector which showed the greatest tumour selectivity and combined cytotoxicity 
was to be identified as a potential future vector for prostate cancer gene therapy. 
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CHAPTER 2   
 
Materials and Methods 
 92 
2.1 Suppliers of Materials 
Unless otherwise stated all materials were supplied by Sigma-Aldrich (Poole, UK). De-
ionised water (ddH20) was obtained from a Maxima Ultrapure Water (ELGA, High 
Wycombe, UK).  
2.2 Molecular Cloning 
Experiments involving bacteria were performed in a specific work area, within an ACGM 
containment level 2 room. Generally methods for molecular biology were based on 
“Molecular Cloning: A Laboratory Manual” [Sambrook et al, 1989] or “Current Protocols 
in Molecular Biology” [Ausubel et al, 1998], unless otherwise described. All position in the 
adenovirus type 5 genome were in reference to the published Ad5 sequence on GenBank, 
accession number AC_000008 (reference sequence BK000408) 
2.2.1 Restriction Endonuclease Digestion of DNA 
All enzymes were sourced from New England Biolabs (Hitchin, UK) or Roche Welwyn 
Garden City, UK). Reaction components and incubation conditions were all based on 
manufacturer‟s instructions. 
Where digestion with multiple enzymes was required, digestions were either carried out 
simultaneously (provided the reaction conditions were compatible) or DNA was purified 
following the first digestion before being digested with the second enzyme in a separate 
reaction. 
2.2.2 Phenol/Chloroform Extraction 
Phenol/chloroform extraction was performed to purify DNA. Samples were made up to a 
convenient volume (e.g. 200µl) with T10E1 or T10E1N100 as appropriate, to which an equal 
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volume of 1:1 (v/v) phenol/chloroform was added. Samples were securely capped, 
thoroughly mixed by inversion or vortexing before being centrifuged (16,000g for 1 minute 
in a microcentrifuge) to separate the organic and aqueous phases. The DNA containing 
aqueous phase was transferred into a new tube and an equal volume of chloroform added. 
The mixing and centrifuge steps were repeated and the DNA containing aqueous phase 
transferred into a new tube. If residual ethidium bromide (EtBr) was still present multiple 
rounds of extraction were performed. 
2.2.3 Precipitation of DNA 
For DNA precipitation samples were adjusted with T10E1 and 5M NaCl to give a final NaCl 
concentration of 100mM. DNA was precipitated by the addition of 2-2.5 volumes of 100% 
ethanol or 1 volume of isopropanol and incubated for 30-60 minutes at -20
o
C. DNA was 
pelleted by centrifugation (16,000g for 10 minutes in a microcentrifuge), the supernatant 
removed by aspiration and DNA pellets air dried. DNA was resuspended in the required 
volume of T10E1 or ddH2O. 
2.2.4 Agarose Gel Electrophoresis 
0.6% to 2% (w/v) agarose gels were prepared in 1x TAE running buffer (diluted from a 50x 
TAE stock solution) and submerged in 1xTAE buffer in a horizontal gel electrophoresis 
tank. DNA samples were mixed with 5x glycerol loading buffer (50% (v/v) glycerol with 
bromophenol blue in ddH20) and loaded into preformed wells. Commercial DNA ladders 
(100bp – 10kb) were used for measurement of band size. 
Samples were run at 20-100V for 2-16 hours depending on band size and separation 
required. Gels were stained in 1xTAE containing 0.5µg/ml ethidium bromide (diluted from 
a 10 mg/ml stock) and visualised by UV illumination. If required, gels were destained in 
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1xTAE solution. Images were recorded using a Kodak DC290 camera (Kodak, Hemel 
Hempstead, UK) in combination with a Spectroline TVC312A UV transilluminator 
(Spectroline, Westbury, NY, USA). 
2.2.5 Gel Purification of DNA Fragments 
0.6% to 1.5% (w/v) agarose gels were made using SeaKem GTG low melting point agarose 
(Lonza, Wokingham, UK) in 1xTAE solution. DNA samples were mixed with 5x glycerol 
loading buffer and 2µl of SYBR® Gold (Invitrogen, Paisley, UK) before being loaded into 
preformed wells and separated by electrophoresis. Bands were visualised on a blue light 
transilluminator and required bands excised from the gel using a scalpel. 
DNA was extracted using a Qiaquick DNA Gel Extraction Kit (QIAGEN, Crawley, UK) 
following the manufacturer‟s instructions. 
2.2.6 Quantitation of DNA 
DNA concentration was measured by PicoGreen assay [Ahn et al, 1996; Ferrari et al, 1998; 
Murakami and McCaman, 1999]. DNA standards were prepared using bacteriophage 
lambda DNA at 1-1000ng/ml (New England Biolabs, Hitchin, UK) diluted in T10E1. 
Triplicate 100µl aliquots of sample and standard DNA were placed into wells of a 96-well 
plate. PicoGreen
®
 reagent (Invitrogen, Paisley, UK) was diluted 1:200 with T10E1 and 
100µl added to each well, and incubated in the dark for 2 minutes. Fluorescence was 
measured at 485nm excitation / 535nm emission on a Wallac Victor
2
 1430 Multilabel 
counter. DNA concentration was calculated from the standard curve. 
2.2.7 DNA Ligations 
DNA ligation was performed using T4 DNA ligase (Roche, Welwyn Garden City, UK). 
Ligation reactions were set up in a volume of 20µl containing 1µl T4 DNA ligase and 2µl 
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of 10x enzyme buffer (supplied with ligase). A 3:1 molar ratio of insert:vector DNA was 
used for „sticky end‟ ligations. 
When required the 5‟ ends of the plasmid were dephosphorylated before ligation, using calf 
intestinal alkaline phosphatase (CIAP) (New England Biolabs, Hitchin, UK), following 
manufacturer‟s instructions. Dephosphorylation was carried out for 1 hour at 37oC. 
2.2.8 Polymerase Chain Reaction (PCR) 
PCR was used for DNA amplification. When required KOD Hot Start DNA polymerase 
(Novagen, Merck, Nottingham, UK) was used to increase PCR fidelity, otherwise GoTaq
®
 
DNA polymerase (Promega, Southampton, UK) was used. PCR reactions were set up 
following manufacturer‟s instructions. A typical PCR reaction consisted of 10µl 10x 
reaction buffer, 10µl 2mM dNTP mixture, 0.5µM (final concentration) of forward and 
reverse primer, 10-50ng of template DNA, 1 unit of enzyme in a final volume of 100µl. A 
full list of forward and reverse primers can be found in Table 2-1. 
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Primer Description 
Sequence (5’ – 
3’) 
Details or Position in Ad5 
wt genome (5’ - 3’) 
MHp001 
Forward eGFP primer 
with MfeI site 
CGTCAATTGT
ACTAAGCGGT
GATGTTTCTGA
TCAGCCACCAT
GGTGAGCAAG
GGCGAG 
Primer used to introduce an 
MfeI site (bold), splice 
acceptor site (red), Kozak 
sequence (italics) with 
eGFP complementary 
region (underlined) 
MHp002 
Reverse eGFP primer 
with MfeI site 
CAGCAATTGA
AAAATAAAGT
TTATTACTTGT
ACAGCTCGTC
CATGCC 
Primer used to introduce a 
MfeI site (bold) with eGFP 
complementary region 
(underlined) 
MHp003 
pMH003/4 sequencing 
primer and eGFP 
screening 
CGGTACACAG
GAAACAGGAG
A 
32652 - 32672 
MHp004 
pMH003/4 sequencing 
primer and eGFP 
screening 
TCGTGACCAC
CCTGACCTAC 
182 - 201 in eGFP ORF 
MHp005 
pMH003/4 sequencing 
primer 
GAACTCCAGC
AGGACCATGT 
672 - 653 in eGFP ORF 
MHp006 
pMH003/4 sequencing 
primer and eGFP 
screening 
GACAGGAAAC
CGTGTGGAAT 
33056 - 33037 
MHp007 Fibre sequencing primer 
GCTCTGGTATT
GCAGCTTCC 
30930 - 30949 
MHp008 Fibre sequencing primer 
GGAACCATAG
CCTTGTTTGAA 
32165 - 32145 
MHp009 Fibre sequencing primer 
CAAAACCCAA
GGCTCCAGTA 
31777 - 31758 
MHp010 Fibre sequencing primer 
ACAGCACAGG
TGCCATTACA 
32192 - 32211 
MHp017 
ICOVIR-7 promoter 
sequencing primer 
TGTCTGTCCCC
ACCTAGGAC 
Labelled in appendix 2. 
MHp018 
ICOVIR-7 promoter  
sequencing and reverse 
primer used to amplify 
the ICOVIR-7 promoter 
region 
TCGTGAAGGG
TAGGTGGTTC 
693 - 674 
MHp019 
ICOVIR-7 promoter 
sequencing primer and 
forward primer used to 
amplify the ICOVIR-7 
promoter region 
TTTGGGCGTA
ACCGAGTAAG 
245 - 264 
MHp020 
ICOVIR-7 promoter 
sequencing primer 
GGGGACAGCC
TATTTTGCTA 
Labelled in appendix 2. 
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MHp021 
ICOVIR-7 promoter 
sequencing primer 
GCAAATTTCC
CGAGTAAGCA 
Labelled in appendix 2. 
MHp022 
ICOVIR-7 promoter 
sequencing primer 
CCCCACCTATC
GTTGGTTC 
Labelled in appendix 2. 
MHp023 
ICOVIR-7 promoter 
sequencing primer 
GGATCACAGG
ACTGGAGCTG 
Labelled in appendix 2. 
MHp024 
ICOVIR-7 promoter 
sequencing primer 
CGATAGGTAC
CATCCGGACA 
Labelled in appendix 2. 
FibreFwd 
Forward pMH003/4 
screening primer within 
the fibre ORF 
CCCTTACTATC
ACTGCCTCAC
C 
31556 - 31577 
GFPRvs 
Reverse pMH003/4 
screening primer within 
the eGFP ORF 
TTACGTCGCC
GTCCAGCTCG 
70 - 51 in eGFP ORF 
PS1368A 
Forward primer within 
the 24 deletion 
CTGCCACGAG
GCTGGC 
928 - 943 
PS1368B 
Forward primer across 
the 24 deletion 
AGGTGATCGA
TC CACCCAG 
912 - 923 (underlined),  
948 - 954(plain text) 
PS1368C 
Reverse primer in the 
E1A ORF 
CCACACACGC
AATCACAGG 
1572 - 1554 
PS1300A 
Forward NTR primer 
with MfeI site 
CGTCAATTGT
ACTAAGCGGT
GATGTTTCTGA
TCAGCCACCAT
GGATATCATTT
CTGTCGCCT 
Same as MHp001 but 
replacing eGFP 
complementary sequence 
with NTR (underlined). 
PS1300B 
Reverse NTR primer 
with MfeI site 
CAGCAATTGA
AAAATAAAGT
TTATTACACTT
CGGTTAAGGT
GATGT 
Same as MHp002 but 
replacing eGFP 
complementary sequence 
with NTR (underlined). 
Table 2-1. PCR primers used for cloning, screening and sequencing 
 
Reactions were cycled in a Perkin Elmer Gene Amp 2400 thermocycler (PE Applied 
Biosystems, Waltham, MA, USA) following the manufacturer‟s instructions. Thermal 
cycling conditions were: 
Initial denaturation: 94°C for 5 minutes 
30-40 cycles: 94°C for 45 seconds, 55°C for 40 seconds, 72°C for 1-3 minutes (depending 
on target length) 
Final extension: 72°C for 5 minutes. 
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Amplified products were analysed by agarose gel electrophoresis. 
2.2.9 DNA Sequencing 
PCR based sequencing reactions were carried out on purified DNA samples using the ABI 
Prism Big Dye Terminator cycle sequencing ready reaction kit (Applied Biosystems, 
Warrington, UK), according to manufacturer‟s instructions. Sequencing reactions consisted 
of 4µl of 2.5x reaction buffer, 0.5-1µg of template DNA, 5pmoles primer, 4µl terminator 
mix in a final volume of 20µl. Reactions were run in a thermal cycler as follows:  
25 cycles: 96
o
C for 30 seconds, 50
o
C for 15 seconds. 
Then: 60
o
C for 4 minutes. 
The extension products were transferred to a 1.5ml microcentrifuge tube and precipitated by 
addition of 50µl of absolute ethanol and 2µl of 3M sodium acetate. The samples were 
incubated at room temperature for 15 minutes before being centrifuged at 16,000g for 20 
minutes in a microcentrifuge. The pellets were washed with 250µl of 70% ethanol and 
samples centrifuged at 16,000g for 5 minutes in a microcentrifuge. Finally the DNA pellets 
were left to air dry for 15 minutes and stored at -20
o
C. 
Immediately prior to loading into the sequencing 96-well plate, pellets were resuspended in 
12µl of loading dye (5:1 mixture of de-ionised formamide:50mg/ml dextran blue in 25mM 
EDTA pH 8), vortexed and briefly centrifuged. Samples were heated at 90
o
C for 2 minutes 
in a heating block and kept on ice while loading. 7µl of each sample was loaded into 
individual wells of a 96-well plate and analysed on a Prism
®
 377 DNA sequencer (Applied 
Biosystems, Warrington, UK) according to manufacturer‟s instructions. 
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2.2.10 Preparation of Chemically Competent Cells 
Transformation competent E. coli cells were prepared using the calcium chloride method. 
1ml of overnight culture was used to inoculate 100ml of LB medium (bacterial growth 
medium, Table 2-2) and incubated at 37
o
C until the O.D.600 was 0.45-0.55 but for no longer 
than 4 hours. The culture was equally divided into two 50ml tubes and cooled on ice for 15 
to 20 minutes. Cells were pelleted by centrifugation at 4
o
C (500g for 10 minutes in a 
Beckman GS-6R benchtop centrifuge), pellets resuspended in 10ml of ice-cold 0.1M 
calcium chloride and incubated on ice for 30 minutes. Cells were repelleted, resuspended in 
2ml of ice-cold 0.1M calcium chloride, incubated on ice for 2-3 hours, repelleted and 
finally resuspended in 2ml of 0.1M calcium chloride / 15% glycerol. 200µl aliquots were 
transferred into 1.5ml microcentrifuge tubes, frozen in liquid nitrogen and stored at -80
o
C 
until required.  
 
Culture Medium Ingredients 
LB medium 
6g LB broth base (Invitrogen) in 300ml 
ddH20 
SOB medium 8.4g SOB mixture (Difco) in 300ml ddH2O 
LB agar 
6g LB broth base (Invitrogen), 4.5g 
Bactoagar (Difco) in 300ml ddH20 
SOC medium 
SOB medium supplemented with 20mM 
filter sterilised glucose 
Table 2-2. Bacterial growth medium 
 
2.2.11 Bacterial Transformation 
E.coli XL2 cells were used for transformation with plasmid DNA. 50ng of ligated plasmid 
DNA (section 2.2.7) was mixed gently with 100µl of competent cells, previously defrosted 
on ice, and the DNA/cell mixture incubated on ice for 30-45 minutes. The mixture was 
heat-shocked at 42
o
C for 90-120 seconds and immediately placed on ice for a further 2 
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minutes. 900µl of SOC, prewarmed to 37
o
C, was added to the DNA/cell mixture and 
incubated at 37
o
C for 1 hour in a shaking incubator. 100µl and 20µl of the cell suspension 
was spread on to LB agar plates, containing appropriate antibiotic (100µg/ml ampicillin or 
30µg/ml kanamycin). Plates were allowed to dry for 20-30 minutes before incubation at 
37
o
C overnight. 
E.coli BJ5183 cells were used for homologous recombination to introduce novel sequences 
into the Ad genome. The insert sequences were digested away and gel purified from the 
plasmid backbone. The vector was cleaved at the site of recombination, phenol/chloroform 
extracted, ethanol precipitated and re-dissolved in an appropriate volume of T10E1 (a full 
description of insert/vector can be found in CHAPTER 3 ). Cut vector and purified insert 
were mixed at a 1:1 molar ratio and transformed into E.coli BJ5183 cells following the 
above transformation protocol. 100µl and 20µl of each transformation was plated onto LB 
agar plate containing the appropriate antibiotic. Plates were incubated overnight at 32
o
C. 
2.2.12 Small Scale Preparation of Plasmid DNA 
Well-defined colonies were picked into 3ml SOB containing appropriate antibiotic and 
grown for 16 hours. 2ml of the culture was pelleted by centrifugation (5 minutes, 3,100g, in 
SM24 rotor) at 4
o
C, and the pellets resuspended in 100µl of ice-cold solution 1 (50mM 
glucose, 25mM Tris pH8, 10mM EDTA). 50µl of lysozyme solution (10mg/ml lysozyme 
freshly dissolved in solution 1) was added and incubated on ice for 10 minutes. 300µl of 
solution 2 (0.2M NaOH, 1% (w/v) SDS) was added, mixed gently and incubated on ice for 
a further 10 minutes to denature proteins and chromosomal DNA. 225µl of solution 3 (147g 
potassium acetate and 57.5ml glacial acetic acid in 500ml ddH20) was added, carefully 
mixed and incubated for 10 minutes on ice to precipitate protein and single stranded DNA. 
Samples were centrifuged (7,900g, 10 minutes, 4
o
C in a SM24 rotor) and the supernatant 
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decanted into a 1.5ml microcentrifuge tube. Nucleic acids were precipitated by addition of 
675µl of isopropanol and incubated at -20
o
C for 20 minutes. Nucleic acids were pelleted by 
centrifugation (9,500g for 10 minutes in a microcentrifuge), and redissolved in 200µl of 
T100E5N100 containing 10µg/ml RNase A (previously heated for 1 hour at 100
o
C to 
inactivate contaminating DNase). Samples were incubated for 1 hour at 37
o
C, to digest 
RNA. DNA was phenol/chloroform extracted, ethanol precipitated and redissolved in T10E1. 
2.2.13 Large Scale Preparation of Plasmid DNA 
Transformed XL2 clones were picked into 5ml of LB medium (containing appropriate 
antibiotic) and grown for 3-4 hours in a shaking incubator at 37
o
C. These cultures were 
used to inoculate 200ml of LB medium (containing appropriate antibiotic) and grown at 
37
o
C for 16 hours in a shaking incubator. Cultures were centrifuged (3,100g in a Sorvall 
SLA-1500 rotor for 5 minutes at 4
o
C) to pellet the bacteria, and the pellet resuspended in 
4ml of ice-cold solution 1. Bacterial cell walls were digested by addition of 1ml lysozyme 
solution (10mg/ml freshly dissolved in solution 1) and incubation on ice for 10 minutes. 
10ml of solution 2 was added, mixed gently and incubated on ice for 10 minutes before 
addition of 7.5ml of solution 3 and further incubation for 10 minutes on ice. Samples were 
centrifuged (7,900g for 15 minutes at 4
o
C in a Sorvall SLA-1500 rotor), supernatant 
transferred to a fresh 225ml centrifuge tube. 22.5ml of isopropanol was added and samples 
incubated at -20
o
C for 30 minutes, to precipitate nucleic acids. Nucleic acids were pelleted 
by centrifugation (7,900g for 20 minutes at 4
o
C in a Sorvall SMA-1500 rotor) and pellets 
air dried. Pellets were re-dissolved for 16 hours in 2.5ml of T50E10 prior to caesium chloride 
purification. 
To redissolved nucleic acid pellets, 3.29g of caesium chloride and 290µl of 10mg/ml 
ethidium bromide were added and total weight made up to 5.29g with T50E10. The solution 
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was incubated on ice for 10 minutes and RNA pelleted by centrifugation (10,000g for 10 
minutes in a SM24 rotor at 4
o
C). Supernatant containing plasmid DNA was transferred into 
3.9ml Beckman Quick-Seal (Beckman Coulter) tubes, filled with isopycnic caesium 
chloride solution (1g of CsCl in 1ml of T50E10), heat sealed and ultra-centrifuged at 100,000 
rpm (353,288g) for 4 hours, followed by 95,000 rpm (318,842g) for 2 hour and finally 
65,000 rpm for 30 minutes (106,870g) (Beckman Optima TLX bench top ultra-centrifuge 
with a TLN-100 near vertical rotor). The lower plasmid band was carefully removed using a 
21 gauge needle and 2ml syringe and diluted with 3 volumes of ddH2O. Ethidium bromide 
was removed by two rounds of phenol/chloroform extraction, DNA precipitated with 1 
volume of isopropanol and pelleted by centrifugation (7,900g for 10 minutes in a Sorvall 
SM24 rotor at 4
o
C). Plasmid DNA was re-suspended in 500µl of T100E1N100, precipitated 
with 2 volumes of absolute ethanol, pelleted and plasmid DNA pellet dissolved in T10E1. 
2.3 Tissue Culture 
All cells were kept in a Galaxy R 37
o
C humidified incubator with 5% CO2 (RS Biotech, 
Irvine, UK). All tissue culture reagents were sourced from Sigma-Aldrich (Poole, UK) or 
Invitrogen (Paisley, UK). All culture flasks and plates were from Iwaki (Japan). 
2.3.1 Maintenance of Cell Lines 
Details of the cells used in this study are listed in Table 2-3. Cells were routinely cultured 
as monolayers in 25cm
2
, 75cm
2
 or 150cm
2
 tissue culture flasks in DME medium 
supplemented with 10% foetal calf serum (FCS), 2mM glutamine, 100U/ml penicillin and 
100µg/ml streptomycin (referred to as full culture medium). 
Cells were passaged at approximately 80% confluence by removing the medium, washing 
once with phosphate buffered saline (PBS) and incubating with PBS containing 0.05% (v/v) 
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trypsin until the cells detached. Fresh medium was added up to a final volume of 10ml and 
cells seeded into fresh flasks for routine growth. 
 
Cell Line Origin Source 
ATCC 
Number 
Reference 
HEK293 
Human embryonic 
kidney transformed 
with left end of 
Ad5 DNA 
Donated by Dr 
V. Mautner 
CRL-1573 
[Graham et al,  
1977] 
A549 
Human lung 
adenocarcinoma 
Donated by Dr 
V. Mautner 
CCL-185 
[Giard et al, 
1973] 
DU145 
Human brain 
metastases from 
prostate 
adenocarcinoma 
Donated by 
Prof. E. Lalani 
HTB-81 
[Stone et al, 
1978] 
PC3 
Human bone 
metastases from 
prostate 
adenocarcinoma 
Donated by 
Prof. E. Lalani 
CRL-1435 
[Kaighn et al, 
1978] 
22RV1 
Human prostate 
adenocarcinoma 
Purchased 
from ATCC 
CRL-2505 
[Sramkoski et 
al, 1999] 
SKOV3 
Human ovarian 
carcinoma 
Donated by Dr 
R. Hoeben 
HTB-77 
[Fogh et al, 
1977] 
MZ2-
MEL3.0 
Human melanoma 
Donated by Dr 
R. Hoeben 
n/a 
[Herin et al, 
1987] 
MRC5 
Primary human 
foetal lung 
fibroblasts 
Donated by 
Sue Rookes 
CCL-171 
[Jacobs et al, 
1970] 
KS 
Fibroblasts 
Primary human 
skin fibroblasts 
Donated by 
Prof. M. Taylor 
n/a 
Isolated at 
University of 
Birmingham 
A549-RA 
A549 cells from Dr 
R. Alemany 
Donated by Dr 
R. Alemany 
CCL-185 
[Giard et al,  
1973] 
Table 2-3. Cell lines and culture media 
 
2.3.2 Cell Counting 
Cells were counted using FAST-READ 102
®
 disposable counting slides (ISL, Paignton, 
UK) according to manufacturer's instructions. 20µl of cell suspension was pipetted into a 
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single counting chamber and cell number counted from 3 individual large grid squares. 
Total cell concentration = average number of cells in one large grid square x 10
4
. 
2.3.3 Cryogenic Preservation of Cell Lines 
Frozen stocks of cell lines were kept in the vapour phase of liquid nitrogen storage tanks. 
Cells to be stored in nitrogen were trypsinised, full culture medium added and cells pelleted 
by centrifugation (177g for 10 minutes in a Heraus Megafuge 2.0R). The cell pellet was 
resuspended in ice cold FCS supplemented with 10% (v/v) diethyl sulphoxide (DMSO) at 
1ml per 80% confluent 75cm
2
 flask, transferred to a 1ml CryoTube (Nunc, Rosklide, 
Denmark) and slowly frozen to -80
o
C in a Cryo 1C freezing container (NALGENE, 
Hereford UK) filled with isopropanol. 24 hours later cells were transferred for long-term 
storage in liquid nitrogen storage tanks. 
Recovery of frozen cells was performed by rapidly defrosting in a 37
o
C water bath, before 
transferring the cell suspension into 10ml of culture medium prewarmed to 37
o
C. Cells 
were pelleted by centrifugation, supernatant discarded and cell pellet was resuspended in 
pre-warmed culture medium. 
2.4 Adenovirus Methods 
All virus work was performed in class 2 biological safety cabinets in a designated tissue 
culture room at ACGM containment level 2. All work with RGD-retargeted vectors was 
performed in a safety cabinet dedicated to retargeted vectors with dedicated pipettes and 
incubators. 
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2.4.1 Adenovirus Rescue by Calcium Phosphate Co-Precipitation 
Adenovirus rescue was performed by co-transfection of relevant left and right end plasmids 
into HEK293 cells using the calcium phosphate co-precipitation method [Graham and van 
der Eb, 1973]. Left and right end plasmids (see CHAPTER 3 for plasmid structures) were 
digested with the appropriate enzyme to separate Ad sequences from the plasmid backbone, 
phenol/chloroform extracted and ethanol precipitated. DNA was pelleted (9,500g for 10 
minutes in a microcentrifuge) and dissolved in an appropriate volume of sterile 10mM Tris-
HCl pH 7.5. HEK293 cells were plated in 60mm tissue culture dishes for transfection. 
When approximately 75% confluent (approximately 1.5x10
6
 cells/dish), a 1:1 molar ratio of 
left and right end adenovirus fragments were used at a total of 5-20µg per dish. The 
appropriate volumes of left and right end fragments were mixed in a 5ml tube and made up 
to 175µl of 10mM Tris-HCl pH 7.5. 25µl of 2M CaCl2 was added to the DNA solution and 
gentle mixed. The DNA/CaCl2 solution was added dropwise to 200µl of 2xHEBS (50 mM 
HEPES pH 7.05, 0.25M NaCl and 1.5mM Na3PO4, adjusted to pH 7.05 with NaOH), while 
gently mixing, and incubated for 20-30 minutes at room temperature, during which time a 
fine white precipitate formed. Chloroquin was added directly to the culture medium to a 
final concentration of 100µM, just before the DNA/CaCl2/HEBS suspension was added 
dropwise. Cells were incubated with the DNA for 4-5 hours, before the medium was 
removed and replaced with fresh culture medium. Cells were incubated for up to 14 days 
post transfection at 37
o
C 5% CO2 in a humidified incubator until signs of significant 
cytopathic effect (CPE), when they were harvested as primary virus seed stocks. 
2.4.2 Harvesting of Adenovirus Seed Stocks 
Upon significant CPE, cells were harvested into the culture medium, pelleted by 
centrifugation (840g, 10 minutes, 4
o
C in a Heraeus Megafuge 2.0R) and resuspended in full 
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culture medium (normally 0.5ml per 150cm
2
 per flask of infected cells) Virus was released 
from the cells by 3 cycles of freezing in liquid nitrogen and thawing at 37
o
C. Cell debris 
was pelleted by centrifugation (840g, 10 minutes, 4
o
C in a Heraeus Megafuge 2.0R) and 
supernatant containing virus stored at -80
o
C until required. 
2.4.3 Infecting Tissue Culture Cells with Adenovirus Seed Stock 
Unless otherwise stated virus seed stock was prepared in A549 cells (for replication 
competent viruses) or HEK293 cells (for replication deficient viruses). 80% confluent 
monolayers were infected with adenovirus seed stock (typically at a 1:1,000 dilution) in a 
minimal volume of full culture medium (4ml for a 150cm
2
 flask). Cells were incubated with 
the virus for 90 minutes at 37
o
C before the virus containing medium was removed and 
replaced with infection medium (DME + HEPES supplemented with 2% FCS, 2mM 
glutamine, 100U/ml penicillin and 100µg/ml streptomycin). 
Flasks were maintained at 37
o
C 5%CO2 in a humidified incubator until extensive CPE was 
observed, when virus was harvested as in section 2.4.2. 
2.4.4 Plaque Purification of Adenovirus 
All viruses constructed were subjected to double plaque purification. DU145 cells were 
grown to 80% confluency on 60mm tissue culture treated dishes. Medium was removed to 
leave 400µl per dish, to which 100µl of unpurified virus seed stock was added, that had 
previously been serially diluted in infection medium (typically 10
-2
 to 10
-6
). Dishes were 
incubated for 90 minutes at 37
o
C, 5% CO2 before the medium was removed and 
monolayers covered with 4ml of overlay mixture (0.7% w/v Noble agar (Invitrogen, 
Paisley, UK) in DME + HEPES, 2% v/v FCS, 100U/ml penicillin, 100µg/ml streptomycin, 
491µM MgCl2, 898µM CaCl2, 6mM NaHCO3). An additional 3ml of overlay mixture was 
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added every 3-4 days. When distinct plaques were observed (typically 7-14 days), 6 well 
isolated plaques were picked into 500µl of infection medium (termed primary plaques A-F). 
Picked plaques were freeze/thawed three times and three (A, B, C) used in a second round 
of plaque purification (primary plaques were stored at -80
o
C). From each primary plaque 6 
secondary plaques were picked into 500µl of infection medium (A1-6, B1-6 and C1-6), 
freeze/thawed 3 times and stored at -80
o
C. 
2.4.5 Caesium Chloride Purification of Adenovirus 
Virus seed stocks were used to prepare caesium chloride banded virus stocks. To virus seed 
stocks water saturated n-butanol was added (to 1% v/v) and incubated on ice for 1 hour. 
Cell debris was pelleted by centrifugation (840g for 10 minutes at 4
o
C in a Heraeus 
Megafuge 2.0R) and the supernatant layered onto glycerol/CsCl gradients (2ml lower layer 
of =1.45 CsCl (in 10mM Tris, pH7.9), a 3ml middle layer of =1.32 CsCl (in 10mM Tris, 
pH7.9), a 2ml top layer of 40% glycerol (in 10mM Tris, pH7.9)). Gradients were 
centrifuged using a SW40Ti rotor (Beckman Coulter, High Wycombe, UK) at 25,000 rpm 
(160,000g) for 90 minutes at 4
o
C. The lower opalescent band corresponding to intact virus 
particles was removed using a 21 gauge needle and 5ml syringe. Virus particles were 
dialysed in a Slide-A-Lyzer dialysis cassette with a 10,000 molecular weight cut off 
(Thermo Scientific, Waltham, MA, USA) against 400ml of PBSg (PBS, 10% (v/v) glycerol, 
491µM MgCl2 and 898µM CaCl2) at 4
o
C overnight, changing the dialysis buffer 3 times. 
Dialysed, banded virus was aliquoted and stored at -80
o
C. 
2.4.6 Plaque Assay for Quantitation of Infectious Viral Particles 
DU145 (for replication competent viruses) or HEK293 (for replication deficient viruses) 
cells were grown until 80% confluency (approximately 1.5x10
6
 cells/dish) on 60mm tissue 
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culture treated dishes. Plaque assays were set up as for plaque purification, described in 
section 2.4.4. Cells were fed by the addition of 3ml of overlay mixture every 3-4 days. 
Plaques were identified by macroscopic inspection of monolayers and counted 14 days post 
infection when appearance of plaques was stable. The mean value from triplicate plates was 
used to calculate the concentration of infectious virus particles in the undiluted virus stock, 
expressed as plaque forming units (PFU/ml). 
2.4.7 Quantitation of Virus Particle Number by PicoGreen Assay 
Virus particle concentration was calculated by PicoGreen assay [Murakami and McCaman 
1999]. 10µl of banded virus was mixed with 10µl of 0.1% (w/v) SDS before heat-
inactivation at 56
o
C for 30 minutes. DNA concentration was quantified by PicoGreen assay 
using a standard curve of bacteriophage lambda DNA, as described in section 2.2.6. Virus 
particle number was calculated on the basis 1µg of DNA = 2.54x10
10
 virus particles. 
2.4.8 Infecting Monolayers with Banded Virus Stocks 
Banded virus stocks were routinely used for infection of monolayer cultures in 96-well and 
24-well tissue culture plates. For infections in 24-well plates: cells were plated at 1x10
5
 or 
3x10
4
 cells/well for tumour cell lines and fibroblasts, respectively. Cells were allowed to 
adhere for 16 hours before infection with the appropriate dilution of banded virus, (to give 
the required multiplicity of infection (MOI)), diluted in 250µl of infection medium per well. 
Cells were incubated with virus for 90 minutes at 37
o
C, before the medium was removed, 
cells washed once, and replaced by 2ml of fresh infection medium per well. For infections 
in 96-well plates: cells were plated at 3x10
4
 or 1x10
4
 cells/well for tumour cell lines and 
fibroblasts, respectively. Cells were allowed to adhere for 16 hours before infection with the 
appropriate dilution of banded virus, (to give the required MOI), diluted in 100µl of 
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infection medium per well. Cells were incubated with virus for 90 minutes at 37
o
C, before 
the medium was removed, cells washed once, and replaced by 200µl of fresh infection 
medium per well. 
Infected cells were incubated at 37
o
C 5% CO2 in a humidified incubator until required.  
2.5 Measurement of Cell Viability 
2.5.1 Acid Phosphatase Cell Viability Assay 
The intracellular acid phosphatase (AP) assay was used routinely to measure cell viability 
in monolayer cultures [Yang et al, 1996a]. The intracellular acid phosphatase in viable cells 
hydrolyzes -nitrophenyl phosphate to -nitrophenol, which can be measured by absorption 
at 405nm. For cells grown as monolayers in 96-well plates, the cell culture medium was 
aspirated using a Vacusafe Comfort (INTEGRA Bioscience, Zizers, Switzerland), wells 
washed once with 200µl of PBS and to each well 100µl of AP assay solution (5mM -
nitrophenyl phosphate in 0.1M sodium acetate pH5, 0.1% (v/v) Triton X-100) added. 
Cells in suspension were pelleted (500g for 10 minutes in a Heraeus Megafuge 2.0R), 
washed once with 200µl of PBS and resuspended in 100µl of assay solution. 
Cells were incubated with assay solution for 30 minutes at 37
o
C. The reaction was stopped 
by addition of 10µl 1M NaOH and absorbance read immediately at 405nm using a Wallac 
Victor
2
 1420 Multilabel counter 
2.5.2 MTS Cell Viability Assay 
When stated cell survival was measured by Cell Titer 96
®
 AQueous One Solution Cell 
Proliferation Assay (Promega, Southampton, UK), following manufacturer‟s instructions. 
For monolayer cultures in 96-well plates the culture medium was aspirated using a 
Vacusafe Comfort (INTERGRA Biosciences, Zizers, Switzerland) and cells washed once 
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with PBS. 100µl of full culture medium and 20µl of Aqueous One Solution was added 
before cells were incubated for 30 minutes (unless otherwise stated) at 37
o
C. 
For suspension cultures the cells were first pelleted by centrifugation (500g for 10 minutes 
in a Heraeus Megafuge 2.0R), the supernatant gently aspirated and the cells resuspended in 
100µl of fresh culture medium per well. To each well 20µl of Aqueous Once Solution was 
added and cell incubated for 30 minutes (unless otherwise stated) at 37
o
C. 
Following incubation the wells were read immediately for absorbance at 490nm using a 
Wallac Victor
2
 1420 Multilabel counter. 
2.6 Extraction of DNA and RNA 
2.6.1 Extraction of DNA from Virus Seed stocks 
The required volume of viral seed stock was thawed and transferred to a clean tube. 5M 
NaCl was added to a final concentration of 1M, mixed and incubated on ice for 16 hours. 
Samples were centrifuged (16,000g for 30 minutes at 4
o
C in a microcentrifuge) to pellet the 
chromatin and the supernatant transferred to a new tube. DNA was extracted using the 
QIAamp DNA mini kit (QIAGEN, Crawley, UK), following the manufacturer‟s instruction. 
2.6.2 Extraction of DNA from CsCl Purified Virus 
Extraction of pure viral DNA was performed on CsCl purified banded virus stocks using 
the QIAamp DNA mini kit (QIAGEN, Crawley, UK), following the manufacturer‟s 
instructions. 
2.6.3 Extraction of Total DNA 
DNA was extracted from infected monolayers for analysis of virus DNA replication, using 
the QIAamp DNA mini kit (QIAGEN, Crawley, UK). The medium was first removed from 
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the cells, before 200µl of lysis buffer AL was added to each well of a 24 well plate, 
incubated at room temperature for 5 minutes and the lysate transferred into a 1.5ml 
microcentrifuge tube. Each sample was mixed with 200µl of infection medium and stored at 
-20
o
C prior to DNA extraction. Once all samples had been collected DNA was extracted 
using the QIAamp DNA mini kit, following manufacturer‟s protocol. Total DNA was 
eluted in 200µl of elution buffer AE and stored at -20
o
C ready for Q-PCR. 
2.6.4 Extraction of Total RNA 
RNA was extracted from virus infected monolayers using the RNeasy mini kit (QIAGEN, 
Crawley, UK) following manufacturer‟s instructions. To begin, the medium was removed 
from monolayers and cells lysed by the addition of 200µl of buffer RTL to each well of a 
24-well plate. Plates were incubated at room temperature for 2 minutes and transferred to a 
sterile, RNase-, DNase-free 1.5ml microcentrifuge tube. Samples were stored at -20
o
C prior 
to RNA extraction.  
Once all samples were harvested, they were thawed rapidly at 37
o
C and RNA extracted 
using the RNeasy mini kit, following manufacturer‟s instructions. Contaminating DNA was 
digested using RNase-free DNase set (QIAGEN, Crawley UK) following the off-column 
DNase protocol. A second RNeasy mini kit column was used to clean up the RNA 
following the RNA Cleanup protocol. RNA was eluted in 50µl of RNase-free water. 
2.7 DNA and RNA Detection 
2.7.1 Quantitative-PCR (Q-PCR) 
Q-PCR was performed to quantify adenovirus and cellular DNA copies in virus infected 
cells. Total DNA was extracted from cells as described in section 2.6.3. For detection of 
virus genomes the „BARTS‟ primers and probe set (donated by Dr D. Onion) was used, 
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which lie within the adenovirus hexon gene. For cell DNA control β-2M primers and probe 
set were used. Information on primers and probes, including final reaction concentration, 
can be found in Table 2-4 below. 
 
Primers 
and Probes 
Description 
Final 
Concentration 
Sequence 
Position in Ad5 
Genome or 
Reference 
BARTS 
forward 
primer 
Forward hexon 
primer for 
detection of Ad 
genomes 
300nM 
CCACCCTTCT
TTATGTTTTG
TTTGA 
21579-21602 
 
BARTS 
reverse 
primer 
Reverse hexon 
primer for 
detection of Ad 
genomes 
300nM 
GCAGGTACA
CGGTCTCGA
TGA 
21665-21645 
BARTS 
probe 
FAM labelled 
hexon probe 
200nM 
TCTTTGACGT
GGTCCGTGT
GCACC 
21606-21629 
β-2M 
forward 
primer 
Forward β-2M 
primer for 
detection of cell 
copies 
225nM 
GGAATTGAT
TTGGGAGAG
CAT 
[Murray et al, 
2003] 
β-2M 
reverse 
primer 
Reverse β-2M 
primer for 
detection of cell 
copies 
300nM 
CAGGTCCTG
GCTCTACAA
TTTACTAA 
[Murray et al,  
2003] 
β-2M probe 
VIC labelled β-
2M probe 
50nM 
AGTGTGACT
GGGCAGATC
ATCCAGCCT
C 
[Murray et al,  
2003] 
Table 2-4. Primers and probes for Q-PCR 
 
Reactions were set up in UV irradiated class I PCR hoods to prevent DNA contamination, 
with 10µl of TaqMan Universal Master Mix (Applied Biosystems, Warrington, UK), 
appropriate dilution of primers and probes, 5µl of sample DNA in a final volume of 20µl. 
All samples were set up in triplicate along with „no template‟ control wells and a 10-fold 
serial dilution of standard DNA. Standard DNA was DNA extracted from a known number 
of Ad5 wt virus particles mixed with a known number of DU145 cells. Reactions were set 
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up in MicroAmp Fast optical 96-well reaction plates (Applied Biosystems, Warrington, 
UK), covered tightly with EU Opti-Seal optical films (Geneflow, Fradley, UK) before 
centrifugation at 360g for 5 minutes in a Heraeus Megafuge 2.0R. Reactions were run in an 
AB7500FAST machine, using the absolute quantification protocol, (Applied Biosystems, 
Warrington, UK) with the following cycling conditions: 
Initial cycle: 50
o
C for 2 minutes, 95
o
C for 10 minutes 
40 cycles: 94
o
C for 15 seconds, 60
o
C for 1 minute. 
Data were analyzed with Applied Biosystems 7500 System Software (Applied Biosystem, 
Warrington, UK) using the standard curve to quantify copy number. Q-PCR reactions were 
carried out using BARTS and β-2M primers/probe for each sample, and virus genome copy 
number normalized to cellular genome number. 
2.7.2 Production of cDNA by Reverse Transcription 
Total RNA extracted and treated with DNase was used to make cDNA for quantification by 
Q-PCR. cDNA was made using the High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Warrington, UK,), following manufacturer‟s instructions. Briefly, 
total RNA was quantified using a NanoDrop ND-100 spectrophotometer for absorbance at 
260nm (Labtech International, Ringmer, UK) with RNase-free water as blank measurement. 
50ng of RNA was used for reverse transcription in 20µl reactions with 2µl of 10x RT 
buffer, 0.8µl of 25x dNTP mix, 2µl 10x RT random primers, 1µl of MultiScribe reverse 
transcriptase, 1µl of DNase inhibitor. Reactions were prepared on ice and cycled in a Perkin 
Elmer Gene Amp 2400 thermocycler (PE Applied Biosystems, Warrington, UK) as follows: 
25
o
C for 10 minutes,  
37
o
C for 120 minutes,  
85
o
C for 5 seconds  
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and finally hold at 4
o
C. 
cDNA samples were stored at -20
o
C ready for Q-PCR. 
2.7.3 Relative Quantification 
E1A RNA expression was measured using the CT method for relative quantification. 
Standard Q-PCR reactions were set up as described in section 2.7.1 using 5µl of cDNA (as 
described above) and E1A primers/probe set shown in Table 2-5. 
 
Primer and 
Probe 
Description 
Final 
Concentration 
Sequence  
(5’ – 3’) 
Reference 
E1A 13S.SEQ-
541F 
Forward 
E1A primer 
900nM 
ATGTTTGTCTAC
AGTCCTGTGTCT
GAA 
Donated by 
Dr A. Turnell 
E1A 13S.SEQ-
639R 
Reverse 
E1A primer 
900nM 
GATAGCAGGCG
CCATTTTAGG 
Donated by 
Dr A. Turnell 
E1A 13S.SEQ-
586T 
FAM 
labelled 
E1A probe 
100nM 
CCAGAACCGGA
GCCTGCAAGAC
CTAC 
Donated by 
Dr A. Turnell 
Table 2-5. E1A primers and probe 
 
Separate reactions were set up for 18S rRNA as endogenous control using the TaqMan 
Gene Expression Assay Eukaryotic 18S rRNA 20x (Applied Biosystems, Warrington, UK), 
with 5µl of cDNA, 1µl of TaqMan Gene Expression Assay, 4µl of water and 10µl of 
TaqMan Universal Master Mix. 
Both sets of reactions were run on the AB 7500FAST machine (Applied Biosystems, 
Warrington, UK) using the relative quantification plate protocol. Cycling conditions were 
as described previously (section 2.7.1). 
Data was analysed with Applied Biosystems 7500 System Software (Applied Biosystem, 
Warrington, UK) using the relative quantification study protocol with E1A as the target and 
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18S rRNA as endogenous control. Samples were normalised to E1A expression in DU145 
cells infected with 10 PFU/cell of Ad5 wt at 4 hours post infection. 
2.8 Detection of Proteins by Western Blotting 
2.8.1 Preparation of Protein Samples 
The culture medium from virus infected monolayer was removed and wells washed once 
with PBS, 8M urea (typically 200µl per well of a 24-well tissue culture plate) was added to 
the well and incubated for 2 minutes at room temperature. Following incubation the entire 
protein suspension was carefully transferred into a 1.5ml microcentrifuge tube. The samples 
were stored at -20
o
C until required, ready for protein quantification and SDS-PAGE. 
2.8.2 Protein Quantitation by Bradford Assay 
Protein concentration was quantified by Bradford assay. Protein standards were 0.1 to 
1mg/ml bovine serum albumin in PBS. 5µl of sample and standard protein was pipetted into 
triplicate wells of a 96-well plate, already containing 95µl of T10E1N100. Bradford reagent 
(BioRad, Hemel Hempstead, UK) was diluted 1:4 with ddH20 and filtered through a 
0.45µm pore size Acrodisc (Pall, Portsmouth, UK). 100µl was added to each well of the 96-
well plate and incubated at room temperature for 1 minute. Plates were read for absorbance 
at 595nm on a Wallac Victor
2
 1430 Multilabel counter. Protein concentration was 
determined from the standard curve. 
2.8.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated by SDS-PAGE using a 12% resolving gel and 4% stacking gel. All 
gels were run using the Mini-PROTEAN® Tetra Cell apparatus (BioRad, Hemel 
Hempstead, UK), following the manufacturer‟s instructions. 1.5mm separators were used 
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with 8ml of resolving gel (4ml 30% acrylamide/bis (BioRad), 2.5ml 1.5M Tris-HCl pH 8.8, 
100µl 10% SDS, 50µl 10% APS, 10µl TEMED and 3.35ml of ddH2O) and 4ml of stacking 
gel (1.33ml 30% acrylamide/bis (BioRad), 2.5ml 0.5M Tris-HCl pH 6.8, 100µl 10% w/v 
SDS, 50µl 10% w/v APS and 10µl TEMED). Polymerised gels were transferred into the 
running apparatus, place in an electrophoresis tank with sufficient SDS-PAGE running 
buffer (25mM Tris, 200 mM glycine and 1% SDS). 
2.5µg of protein sample in 15µl of 8M urea was mixed with 5µl of 4x (U)SB (8% SDS, 
40% glycerol, 320mM Tris pH 6.8, 400mM DTT, Bromo-phenol blue), incubated at 95
o
C 
for 5 minutes and loaded into preformed wells. PageRule prestained protein ladder plus 
(Fermentas, York, UK) was loaded in adjacent lanes for determination of molecular weight. 
Electrophoresis was carried out for 90 to 120 minutes at 100V to achieve the required 
degree of separation. 
2.8.4 Western Blotting 
Following electrophoresis the resolving gel was incubated for 5 minutes in transfer buffer 
(39mM glycine, 48mM Tris pH 8.3, 20% (v/v) methanol), with four pieces of Whatman 
3MM blotting paper and two synthetic sponges. 
Immuno-Blot PVDF membrane (BioRad, Hemel Hempstead, UK) was soaked for 5 
minutes in methanol then for 5 minutes in transfer buffer, before being assembled with the 
gel in the transfer stacks. Proteins were transferred onto the membrane at 100V for 90 
minutes using a semi-dry blotting tank. Following electrophoresis the membrane was 
briefly washed in PBSt (PBS with 0.1% v/v tween-20) before being blocked in PBSt with 
5% skimmed milk (w/v) for one hour at room temperature. 
Membranes were probed with primary antibodies diluted to the appropriate concentration in 
PBSt with 2% skimmed milk (w/v) for 16 hours at 4
o
C. The membranes were washed with 
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4 changes of PBSt, changing the buffer every 10-15 minutes. Species-specific IgG 
secondary antibodies, pre-conjugated with peroxidase, were incubated with the membrane 
at the required dilution in PBSt with 2% skimmed milk (w/v), for 1 hour at room 
temperature. Details of the antibodies used for western blotting can be found in Table 2-6. 
 
Antibody 
Target(s) and 
Size(s) 
Information Dilution Source 
anti-NTR NTR, 24kDa Sheep Polyclonal 1:50,000 
Donated by Dr 
P. Searle 
R2/99 
Adenovirus late 
proteins 
Rabbit polyclonal 1:1,000 
Donated by Dr 
V. Mautner 
M73 E1A E1A, 26-32kDa Mouse monoclonal 1:100 
Donated by Dr 
E. Blair 
Anti-β-tubulin 
β-tubulin, 
55kDa 
Mouse monoclonal 1:20,000 
Sigma-Aldrich, 
Poole, UK 
Anti-mouse n/a 
Goat polyclonal, 
peroxidase conjugate 
1:20,000 
Sigma-Aldrich, 
Poole, UK 
Anti-rabbit n/a 
Goat polyclonal, 
peroxidase conjugate 
1:20,000 
Sigma-Aldrich, 
Poole, UK 
Anti-sheep n/a 
Donkey polyclonal, 
peroxidase conjugate 
1:20,000 
Sigma-Aldrich, 
Poole, UK 
Table 2-6. Antibodies used in western blotting 
 
Membranes were washed as before and peroxidase activity detected using an Amersham 
ECL™ Advance Western Blotting Detection Kit (GE Healthcare, Chalfont St Giles, UK), 
following the manufacturer‟s instructions. 1ml of component A was mixed with 1ml of 
component B, the membrane soaked in this for 2 minutes, and transferred to an Amersham 
Hypercassette (GE Healthcare, Chalfont St Giles, UK). Signal was detected using 
Amersham Hyperfilm MP autoradiography film (GE Healthcare, Chalfont St Giles, UK) 
with varying exposure times (dependent on signal strength), and developed using a Kodak 
X-O-graph developer (Kodak, Hemel Hempstead, UK). 
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2.9 Imaging Techniques 
2.9.1 Flow Cytometry 
Flow cytometry was used to directly measure eGFP expression, and surface antigen 
expression using antibodies. 
2.9.1.1 GFP Sample Preparation and Antibody Staining 
GFP expression from eGFP expressing viruses was analysed by flow cytometry. For 
analysis of eGFP expression, the medium was removed from the virus infected cells, cells 
washed once with PBS and detached by trypsinisation. The cell suspension was transferred 
into a FACS tube containing 3ml of FACS buffer. The cells were pelleted by centrifugation 
(840g for 5 minutes in a Heraeus Megafuge 2.0R), resuspended in 300-500µl of FACS fix, 
and stored at 4
o
C prior to analysis. 
 
For antibody surface staining, cells were detached into the medium by scraping and the cell 
suspension transferred to a FACS tube. Cells were washed with FACS buffer, resuspended 
in 50µl of FACS buffer containing the appropriate dilution of primary antibody, incubated 
for 1 hour at 4
o
C then washed with 4ml of FACS buffer. If the primary antibody was 
directly conjugated to a fluorophore, cells were resuspended in 300-500µl of FACS buffer 
ready for analysis. If a secondary antibody was required the cell pellet was resuspended in 
50µl FACS buffer containing the appropriate dilution of labelled secondary antibody. Cells 
were incubated for a further 1 hour at 4
o
C before being washed with 4ml of FACS buffer 
and resuspended in 300-500µl of FACS buffer ready for analysis. Details of the antibodies 
used for flow cytometry can be found in Table 2-7. 
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Antibody Target Information Dilution Source 
RmCB CAR 
unconjugated, 
mouse monoclonal 
neat 
CRUK (ATCC # 
CRL-237) 
anti-human 
V3 
Human integrin 
V3 
PE-conjugated, 
mouse monoclonal 
1:5000 
R and D Systems, 
Abingdon, UK 
anti-human 
V5 
Human integrin 
V5 
PE-conjugated, 
mouse monoclonal 
1:5000 
R and D Systems, 
Abingdon, UK 
Anti-mouse n/a FITC-conjugated 1:2000 
Sigma-Aldrich, 
Poole, UK 
Table 2-7. Antibodies used for flow cytometry 
 
2.9.1.2 Analysis of Cells by Flow Cytometry 
Cells were analysed using either a 4 colour Beckman Coulter XL flow cytometer (Beckman 
Coulter, High Wycombe, UK) with Coulter System II software for data acquisition, or a 15 
colour BD LSRII flow cytometer (Becton Dickinson, Oxford, UK) with DIVA software 
(Becton Dickinson, Oxford, UK). Data was analysed using FlowJo7.5.3 (Tree Star Inc., 
Ashland, OR, USA). 
Unstained or mock infected cells were the first samples to be analysed, followed by 
negative and isotype controls and finally test samples. The desired cell population was 
gated using forward scatter and side scatter properties, gating out debris and the majority of 
dead cells. Voltages were appropriately set for photo multiplier tubes (PMT) in all channels 
using the negative controls. If multicolour staining was being performed appropriate colour 
controls were run and compensation performed to eliminate cross talk into all other colours 
being analysed. Voltages, gates and compensation controls were kept constant for all 
samples analysed. At least 10
4
 cell events were analysed per sample from replicate samples. 
Data was analysed for percentage positive cells and fold increase in mean fluorescence. 
Percentage positive refers to the percentage of gated cells fluorescing above the appropriate 
negative control, measured using a gate set to include 2% of the negative control cells. 
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Mean fluorescence was taken as an arithmetic mean expressed in arbitrary units of the 
positive population. Fold increase in mean fluorescence was calculated by dividing the 
fluorescence of the positive population by the fluorescence of the negative control sample. 
2.9.2 Microscopy 
A Zeiss Axiovert 25 (Carl Zeiss, Welwyn Garden City, UK) inverted microscope was used 
for phase-contrast and eGFP fluorescence microscopy of monolayer cultures. Objectives 
used were 5x, 10x, 20x and 40x with 21x, 42x, 84x and 168x overall magnification, 
respectively. Images were taken using a SPOT camera with SPOT Advanced software 
(Diagnostic Instruments, Michigan, USA). The exposure time and gain was kept constant 
for all fluorescent images, throughout one experiment. 
2.10 Graph Plotting and Statistical Analysis 
All graph plotting and statistical analysis was performed using GraphPad Prism version 5 
software (GraphPad software Inc, La Jolla, CA, USA). Unless otherwise stated, sigmoid 
dose response curves were plotted to data normalised using empty wells (0% viability) and 
mock infected wells (100% viability). All EC50 values with 95% confidence intervals (C.I) 
were calculated by GraphPad software to 3 significant figures.  
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CHAPTER 3   
 
vMH Vector Construction 
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3.1 Introduction 
Arguably the two most successful strategies using Ad vectors for the treatment of cancer 
utilise oncolytic CRAd vectors or enzyme/prodrug suicide gene therapy. Previous studies 
by The University of Birmingham, SCS-GT group combined these two strategies by arming 
two E1B-55K deleted oncolytic CRAd vectors with the therapeutic transgene NTR for 
NTR/CB1954 enzyme/prodrug therapy [Chen et al,  2004; Roesen 2006]. Of these, vNR6 
(pIX ORF replaced with NTR) demonstrated higher oncolytic cytotoxicity than CRAd-NTR 
(NTR under CMV promoter control), particularly at low MOI (discussed in section 
1.2.4.4.3). However experiments with vNR6 and an equivalent vector expressing eGFP in 
place of NTR (vNR3), demonstrated some cytotoxicity and transgene expression in primary 
human fibroblasts. 
Recently Dr R. Alemany‟s group at the Institut Català d'Oncologia constructed an E1A CR2 
24 vector, vICOVIR-5, which had the E1A promoter replaced by the E2F-1 promoter 
insulated by an upstream poly(A) site and DM-1 insulator element [Alonso et al,  2007a; 
Alonso et al,  2007b; Cascallo et al,  2007; Majem et al,  2006]. This ICOVIR-5 promoter 
was designed to increase replication specificity by restricting E1A expression to tumour 
cells with high levels of free E2F. The ICOVIR-5 promoter was further developed by 
inserting two additional E2F binding regions within the E2F-1 promoter to create 
vICOVIR7 [Rojas et al,  2009]. Within this new ICOVIR-7 promoter both E2F binding 
regions were positioned upstream of the existing E2F-1 binding elements. The ICOVIR-7 
promoter was designed to increase tumour specificity by further restricting E1A expression 
to cells with the highest E2F levels. Schematics of the ICOVIR-5 and ICOVIR-7 promoters 
can be found in Figure 3-1. 
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Figure 3-1. Schematic of the ICOVIR-5 and ICOVIR-7 promoters 
The wt E1A promoter from position 342 to 559 was deleted and replaced by the ICOVIR-5 
or ICOVIR-7 promoter. The ICOVIR-5 promoter consists of a poly(A) site, followed by the 
DM-1 insulator element, the E2F promoter and a Kozak sequence directly before the E1A 
translational start site. The ICOVIR-7 promoter has two additional E2F binding regions 
inserted upstream of the existing E2F binding region. 
ITR = inverted terminal repeat, poly(A) = poly(A) sequence, DM-1 = DM-1 insulator 
element, E2F-1p = E2F-1 promoter sequence, K = Kozak sequence, ATG = E1A ATG site. 
Grey boxes indicate the E2F binding regions. Numbers above the sequence refer to the 
position in the Ad5 wt genome, numbers below the sequence refer to position within the 
ICOVIR-5 or ICOVIR-7 promoter (diagrams not to scale). 
 
Both of these vectors would provide appropriate oncolytic Ad backbones for the 
introduction of the therapeutic transgene NTR: at the beginning of this study there was no 
published data on either vector, therefore, to identify which might be the best candidate for 
the introduction of NTR, both vectors were first modified to express the marker transgene 
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eGFP (enhanced green fluorescent protein) from the MLP. Marker transgene was used to 
assess the background oncolytic activity of the vector while taking into account any effect 
transgene insertion might have, and to assess the level and timing of transgene expression 
before insertion of NTR. The MLP was chosen to achieve high transgene expression and 
elicit a good therapeutic effect, but late in Ad infection to have a minimal negative effect on 
Ad progeny production. 
Alongside, similar constructs were made with the wildtype (wt) E1A promoter and E1A 
CR2 24 deletion, to investigate the effect of E1A promoter replacement. 
3.2 Aim of Chapter 
The aim of this chapter was to construct new adenovirus vectors expressing eGFP, based on 
the E2F-1 responsive vectors from Dr R. Alemany‟s laboratory. The vectors generated in 
this chapter were characterised in subsequent chapters to identify the optimal vector, in 
terms of tumour selectivity, cytotoxicity and transgene expression, for insertion of the 
therapeutic transgene NTR. 
3.3 Overview of Vector Design 
Figure 3-2 shows a schematic of the eGFP expressing vector vNR3 [Roesen 2006], 
alongside the 5 new vMH vectors. The vNR vector contains an E1B-55K gene deletion 
rendering it conditionally replicating. In comparison, all vMH vectors contain the E1A CR2 
24 deletion which takes advantage of the mutated E2F/pRB pathway (discussed in section 
1.2.4.2.1). The first of these vectors, vMH2, contains the wt E1A promoter. Vectors vMH4 
and vMH5 have the E1A promoter replaced by the ICOVIR-5 promoter (described above) 
for increased tumour specificity. vMH5 contains the RGD-4C sequence introduced into the 
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fibre knob HI-loop. This insert confers the ability to use αVβ3/5 integrins as the primary cell 
surface receptor in order to enhance virus uptake in CAR negative cells. 
Vectors vMH6 and vMH7 incorporate two additional E2F binding regions within the E2F-1 
promoter region of the ICOVIR-5 promoter. This larger ICOVIR-7 promoter (described 
above) is designed to further restrict E1A expression to tumour cells which have high levels 
of free E2F, thus increasing tumour specificity. vMH7 also contains the RGD-4C sequence 
introduced into the fibre knob HI-loop. 
All vMH vectors express the eGFP transgene from a splice acceptor site, inserted directly 
downstream of the fibre gene, for expression from the Ad MLP. Furthermore, a Kozak 
sequence has been inserted directly upstream of the eGFP translational start site for 
enhanced translation. In vNR3 the pIX ORF has been directly substituted with the eGFP 
ORF, retaining the pIX promoter, ATG site and E1B/pIX poly(A) signal, for expression at 
intermediate times of infection. 
All vMH vectors retained the wt E3 region whereas vNR3 had a partial E3 deletion between 
the Xbal restriction sites at position 28593 and 30470 of the Ad5 genome. 
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Figure 3-2. Schematic of vMH viruses 
Schematic layout of vNR3 and the vMH vectors. vNR3 has an E1B-55K from 2507-
3328bp, an E3 deletion from 28593 - 30470 and the pIX ORF is replaced by the eGFP 
ORF. All vMH vectors contain the E1A CR2 24 deletion (922-947). vMH4 and vMH5 
have the wt E1A promoter replaced by the ICOVIR-5 promoter. vMH6 and vMH7 have the 
wt E1A promoter replaced by the ICOVIR-7 promoter. Both vMH5 and vMH7 have the 
RGD-4C motif inserted into the fibre knob HI loop. All vMH vectors have a wt E3 region 
and express the eGFP transgene from a splice acceptor site, inserted directly downstream of 
the fibre gene. 
p(A) = poly(A) sequence, DM-1 = DM-1 insulator element, E2Fp = E2F-1 promoter, K = 
Kozak sequence, ATG = E1A translation initiation site, RGD = RGD-4C motif (diagrams 
not to scale) 
 
3.4 Virus Cloning Strategy 
All viruses were constructed using plasmids previously made in Dr P. Searle‟s lab or by our 
collaborator, Dr R. Alemany‟s group at the Institut Català d'Oncologia in Barcelona (see 
Table 3-1). A detailed „road map‟ of virus construction can be found in Figure 3-3.  
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Plasmid Source Reference 
pPS1055 Dr P. Searle Shown in Figure 3-3 (A) 
pPS1344G8 Dr P. Searle Shown in Figure 3-3 (A) 
pPS1335M Dr P. Searle Shown in Figure 3-3 (B) 
pNKfibreRGD Dr R. Alemany 
[Majem et al,  2006], 
Shown in Figure 3-3 (A) 
pICOVIR-5 (also known as 
pShuttleDME2FKE124) 
Dr R. Alemany 
[Cascallo et al,  2007], 
Shown in Figure 3-3 (B) 
pICOVIR-7 ( also known as 
pShDME2FKE1ad24E2F2) 
Dr R. Alemany 
[Rojas et al,  2009], 
Shown in Figure 3-3(B) 
Table 3-1. Starting plasmids used in the study 
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  (A) 
pMH001
(8161 bp)
AmpR
rITR
E4
Fibre
MfeI
SwaI
pMH003
(8932 bp)
AmpR
rITR
Fibre
eGFP
PacI
MfeI
MfeI
SwaI
pMH004
(9079 bp)KanR
eGFP
Fibre
MfeI
MfeIKpnI
NotI
pNKfiberRGD
(8308 bp)
KanR
Fibre
MfeI
KpnI
NotI
eGFP
MfeI MfeI
pMH008 eGFP
(38106 bp)
rITR
Fibre
eGFP
ClaI
MfeI
MfeI
SwaI
pMH009 eGFP
(38133 bp)
rITR
eGFP
Fibre
ClaI
MfeI
MfeI
SwaI
pPS1344G8
(37091 bp)
rITR
pIX
pIVa2
Fibre
ClaI
BstBI
SwaI
pPS1055
(8177 bp)
AmpR
rITR
E4
Fibre
MfeI
SwaI
MfeI
SwaI
RGD
RGD
PCR of eGFP with flanking MfeI site 
RGD
Removel of 
MfeI
eGFP ligated into pMH003/4 
using MfeI
pMH004 
recombined 
with 
pPS1334G8 
pMH003 
recombined 
with 
pPS1334G8 
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  (B) 
pPS1335M.gcc
(14644 bp)
A m p R
A d 5  ( 7 0 0 1 - 8 0 0 0 )
l - I T R
E 1 A
p I V a 2
E 1 B
SwaI
922-947 deletion
SalI
SalI
pICOVIR5.gcc
(10709 bp)
D M - 1
E 2 F
l - I T R
E 1 A
K a n R
A d 5  ( 2 0 0 0 - 5 7 8 1 )
PacI
922-947 deletion
EcoRI
pICOVIR-7.gcc
(10835 bp)
D M - 1
l - I T R
E 1 A
3 x E 2 F
A d 5  ( 2 0 0 0 - 5 7 8 1 )
K a n R
922-947 deletion
EcoRI
PacI
Digested with PacI and 
EcoRI for homologous 
recombination with pMH008 
or pMH009
Digested with SwaI and SalI 
for homologous 
recombination with pMH008 
and pMH009
 
Figure 3-3. vMH Virus construction ‘road map’ 
„Road map‟ of vMH virus contraction. See text for details of the cloning pathway.  
Nucleotide markers are for Ad5 wt. Blue = Ad sequence, black = plasmid backbone, green 
= eGFP, red = wt fibre and purple = RGD-retargeted fibre. 
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Initially plasmid pPS1055, containing the right end of Ad5 from position 30475, was fully 
digested with SwaI, gel purified and religated to remove the MfeI site between the two 
SwaI sites. The resultant plasmid, pMH001, retains a unique MfeI site, 38bp downstream of 
the fibre ORF, suitable for downstream cloning. 
Plasmid pNKfibreRGD contains the Ad5 sequence from position 29511 to 33598 of the 
Ad5 wt genome. This plasmid includes the 32bp RGD-4C motif introduced into the fibre 
ORF replacing nucleotides 32680-32684 (of the Ad5 wt genome) and also retains the 
unique MfeI site 38bp downstream of the fibre ORF. 
The entire eGFP ORF was amplified and purified from vector pxLNCX-GFP [Vass, 2007], 
using primers MHp001 and MHp002 to introduce flanking MfeI sites (described in Table 
2-1). Primer MHp001 introduces a splice acceptor site, for subsequent splicing from the 
MLP, located between the MfeI site and complementary eGFP sequence with a Kozak 
sequence directly before the eGFP translation initiation codon. The purified eGFP PCR 
fragment was cloned into pMH001 and into pNKfibreRGD using MfeI to give pMH003 and 
pMH004, respectively. Following cloning the entire insert and 100bp of flanking region 
were sequenced by PCR using primers MHp003, p004, p005 and p006 to verify the insert 
sequence was correct (data not shown). 
Plasmids pMH008 eGFP and pMH009 eGFP were created via homologous recombination 
in E.coli BJ5183, between pPS1344G8 and pMH003 or pMH004, respectively. Plasmid 
pPS1344G8 contains the Ad5 sequence from position 3525 near the start of pIX up to the 
right end and has a unique BstBI site introduced 42bp downstream of the fibre ORF. For 
recombination pPS1344G8 was linearised by digestion at the unique BstBI site. Plasmid 
pMH003 was digested with SwaI and PacI, pMH004 was digested with NotI and KpnI, and 
the Ad sequence fragment gel purified. Recombination was performed using chemically 
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competent E.coli BJ5183 cells grown at 32
o
C with a total of 50ng of DNA (see section 
2.2.11). Single recombinant colonies were picked, DNA extracted and screened by 
digestion with HindIII and SacII. The HindIII digestion identifies a successful insert/vector 
recombination and SacII differentiates between wildtype and RGD-retargeted fibre. 
The resultant plasmids pMH008 eGFP and pMH009 eGFP contain the Ad5 sequence from 
position 3525 near the start of pIX up to the right end, with the eGFP ORF downstream of 
fibre. Plasmid pMH008 eGFP contains a wildtype fibre, whereas pMH009 eGFP contains 
the RGD-4C retargeted fibre. 
 
Virus rescue was performed using plasmids pMH008 eGFP and pMH009 eGFP in 
combination with left end plasmids; pPS1335M, pICOVIR-5 and pICOVIR-7 (shown in 
Figure 3-3 (B)). 
Plasmid pPS1335M has the left end of the Ad5 genome up to the Xbal site at position 
10589 and the E1A CR2 24 at position 922-947 of the Ad5 genome [this deletion has been 
previously reported by Heise et al, 2000].  
Plasmids pICOVIR-5 and pICOVIR-7 were constructed by our collaborators and have been 
described recently [Cascallo et al,  2007; Majem et al,  2006; Rojas et al,  2009]. Both 
pICOVIR-5 and pICOVIR-7 contain the Ad5 sequence from the left end to position 5781 of 
the Ad5 genome beyond the pIX gene. pICOVIR-5 has the SV40 late poly(A) signal from 
pGL3-plasmid, (Promega, Southampton, UK) followed by the DM-1 insulator element from 
nucleotides 13006 to 13474 of the DM-1 locus, containing the CTCF-binding sites and 
CTG repeats required for insulation. Located downstream of this is the E2F-1 promoter 
sequence (taken from the -218 to +51 region of the E2F-1 gene); this contains the E2F-1 
binding region, which includes four E2F binding sites organised into two imperfect 
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palindromes. Finally a GCCACC Kozak consensus sequence was inserted directly before 
the E1A ATG site. 
To obtain pICOVIR-7, site directed mutagenesis was used to introduce a unique BsiWI site 
into pICOVIR-5, 222bp upstream of the E1A ATG site. Into this unique site, 
complementary oligonucleotides containing the E2F binding region (consisting of the two 
imperfect palindromes) were used to introduce two additional E2F binding regions, thus 
increasing the total number of E2F binding regions to three (and the number of actual E2F 
binding sites to 12). 
3.5 Virus Recovery and Verification 
Virus recovery was performed by homologous recombination in HEK293 cells with 
appropriate combinations of left end plasmids; pPS1335M, pICOVIR-5 and pICOVIR-7 
with the right end plasmids pMH008 eGFP and pMH009 eGFP, to make 5 novel vectors. 
To remove plasmid backbones both right end plasmids were first digested with ClaI and 
SwaI. pPS1335M was digested with SwaI and SalI while pICOVIR-5 and pICOVIR-7 were 
digested with EcoRI and PacI. HEK293 cells (used for the high transfection efficiency) 
were co-transfected with appropriate left and right ends using the calcium phosphate 
transfection protocol (described in section 2.4.1) with a 1:1 molar ratio of left: right ends, to 
rescue viruses as outlined in Table 3-2 (see also Figure 3-3) 
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 Right End 
  pMH008 pMH009 
L
ef
t 
E
n
d
 
pPS1335M vMH2 Not rescued 
pICOVIR-5 vMH4 vMH5 
pICOVIR-7 vMH6 vMH7 
Table 3-2. Virus recovery combinations 
See Figure 3-3 for plasmid constructs 
 
When significant CPE and eGFP expression was observed, indicating virus production, 
cells were harvested and 1
o
 seed stocks generated (see section 2.4.2 for generation of seed 
stocks). All subsequent virus passages were performed in A549 cells. 1
o
 virus seed stocks 
were passaged once (at a 1/10 dilution) into 25cm
2
 flasks to generate 2
o
 seed stocks, which 
were then used for double plaque purification (as described in section 2.4.4). Nine plaques 
were picked, after screening by fluorescent microscopy to confirm eGFP expression, and 
used to infect 25cm
2
 flasks (using half of the plaque for infection) to obtain a p1 seed stock. 
DNA was extracted from half of each p1 seed stock and screened by PCR for the presence 
of contaminating wt E1A sequences using primers PS1368A, PS1368B and PS1368C (see 
Table 2-1). 
Primers PS1368A and B are designed to distinguish between contaminating wt E1A 
sequences and the E1A CR2 24 deletion. Primer PS1368A is located within the E1A CR2 
24 deletion and should only detect wt E1A and not the CR2 24 deletion. Primer 
PS1368B is complementary to the sequences flanking the CR2 24 deletion and thus 
should only detect CR2 24 E1A and not wt E1A. Both were used with reverse primer 
PS1368C located 636bp downstream. 
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Figure 3-4. PCR screening vMH vectors for E1A CR2 24 deletion 
DNA was extracted from the plaque purified p1 seed stocks and screened for contaminating 
wt E1A sequences. Reactions were set up with forward primer PS1368A (A) within the 
CR2 deletion or PS1368 (B) spanning the CR2 deletion, with reverse primer PS1368C. 
Reactions were setup using GoTaq polymerase in a final volume of 50l and run for 40 
cycles in a thermal cycler (as described in section 2.2.8 ). 10l of each reaction were 
analysed by agarose gel electrophoresis. 
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Figure 3-4 shows the results of the E1A screening. All plaques screened were free of 
contaminating wt E1A sequences shown by the lack of band with primer PS1368A. As 
would be expected, no band was observed in the PCR grade water control and a clear band 
of correct size can be seen in the Ad5 wt positive control. However in three of the screens 
(vMH4, vMH6 and vMH7) a band can be observed with the pICOVIR-7 control samples. 
Since this plasmid contains the E1A CR2 24 deletion this contamination is probably due 
to water contamination since the plasmid prep used was not sterile. If this experiment was 
to be repeated a sterile prep of pICOVIR-7 dissolved in PCR grade water should be used to 
avoid the Ad contamination. 
With primer PS1368B clear bands of the expected size were seen with all the picked 
plaques and pICOVIR-7 control. Again no band was observed with the PCR grade water as 
would be expected. A band was also observed with Ad5 wt control, probably due to 
PS1368B mispriming. 
Following E1A screening the DNA samples were screened by PCR for the presence of 
eGFP insert and for contaminating transgene-deleted virus, using primer MHp003, 
MHp004 and MHp006 (described in Table 2-1). Primer MHp003 is located upstream of the 
transgene insertion site and detects both virus with insert and insert-deleted virus. Primer 
MHp004 is located within the eGFP insertion and thus only detects virus with the eGFP 
insertion. Both primers were used with MHp006 designed downstream of the insertion site. 
This primer produces an 1175bp band with MHp003 in the presence of transgene, a 404bp 
band with MHp003 and Ad5 wt, and a 784bp band with primer MHp004 and full length 
transgene. 
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Figure 3-5. PCR screening vMH vectors for eGFP insertion 
DNA was extracted from the plaque purified p1 seed stocks and screened for the presence 
of the eGFP transgene. Reactions were set up with forward primer MHp003 (A) located 
upstream of the insertion or MHp004 (B) located within the eGFP insertion, with reverse 
primer MHp006. Reaction were setup using GoTaq polymerase in a final volume of 50µl 
and run for 40 cycles in a thermal cycler (as described in section 2.2.8 ). 10l of each 
reaction were analysed by agarose gel electrophoresis. 
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Figure 3-5 shows the results of eGFP insert screening. As predicted, no band was observed 
for PCR grade water with primer MHp003 or MHp004. Primer MHp003 produced a band 
of approximately 1200bp with all plaques, demonstrating the presence of eGFP insert. 
However one plaque, vMH2 plaque B3, also produced a band of approximately 500bp, 
demonstrating contamination with a virus which had undergone rearrangement to delete 
part of the insertion. 
No band was observed for Ad5 wt with MHp004, and as expected a clear band of 
approximately 800bp could be seen with all plaques screened. 
 
For each virus three p1 seed stocks (A1, B1 and C3), which were free of contaminating 
viruses, were chosen and each passaged into three 150cm
2
 flasks, to generate p2 seed 
stocks. For each virus the p2 seed stock which showed the most CPE was chosen and 
passaged into 20x150cm
2
 flasks. When good CPE was observe the flasks were harvested 
and virus purified by CsCl centrifugation to give a p3 banded virus stock. 
DNA was extracted from each p3 banded stock and restriction enzyme profile confirmed 
with HindIII, BglII, and KpnI (detailed in appendix 1). Restriction profiles for all vectors 
were as predicted, confirming they had not undergone any major re-arrangements. 
Following restriction enzyme profiling, the p3 banded stocks were quantitated by 
PicoGreen assay for virus particles and plaques counted on DU145 cells for infectious 
particles (as described in 2.4.6). The results of virus particles count, plaque count and the 
particle to infectivity (P:I) ratios are shown in Table 3-3, along with vector size and 
percentage size relative to the Ad5 wt genome. Table 3-3 also shows the data for banded 
Ad5 wt, vNR3 and Ad-GFP (replication deficient E1, E3 Ad vector expressing eGFP 
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from the CMV immediate early promoter) used in this thesis, all of which were generated 
from p2 or p3 seed stocks (kind gifts from Dr V. Mautner).  
All banded viruses possessed a P:I ratio in the acceptable range of 10-110. With increasing 
genome size there is a clear increase in P:I ratio. Spearman rank analysis showed a 
statistically significant correlation between virus genome size and P:I ratio (spearman rank 
= 0.9429 and P value = 0.0167). All vectors have similar virus particle counts and the 
increase in P:I ratio comes from a decrease in infectious virus particle count, with vMH6 
and vMH7 having the lowest values. Because of the low infectious virus count with vMH6 
and vMH7, a second batch of p3 banded virus was made using the appropriate seed stocks. 
The second batches of these viruses showed similar properties to the first batches, with high 
P:I ratios and low infectious virus counts. 
 
Virus 
Particle 
count 
(VP/ml) 
Plaque 
count 
(PFU/ml) 
P:I 
ratio 
Size 
(bp) 
Percentage 
of Ad5 wt 
vMH2 2.12x10
12
 4.00x10
10
 28.0 36682 102.07 
vMH4 3.13x10
11
 1.00x10
10
 31.6 37673 104.83 
vMH5 3.41x10
11
 6.67x10
9
 51.2 37700 104.90 
vMH6 
Batch 1 1.58x10
11
 1.40x10
9
 112.6 
37799 105.18 
Batch 2 1.22x10
11
 1.20x10
9
 101.0 
vMH7 
Batch 1 2.07x10
11
 2.00x10
9
 104.0 
37826 105.25 
Batch 2 9.68x10
10
 1.00x10
9
 97.0 
vNR3 4.65x10
11
 2.20x10
10
 21.0 33596 93.48 
Ad5 wt 3.26x10
12
 3.00x10
11
 11.0 35938 100.00 
Ad-GFP 9.30x10
11
 9.30x10
10
 10.0 33871 94.25 
Table 3-3. Virus particle count, plaque count and P:I ratios. 
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3.6 Discussion 
3.6.1 Virus Construction and Screening 
Standard molecular cloning techniques were used to construct 5 CRAd vectors for oncolytic 
virotherapy. Virus p1 seed stocks were screened by PCR for the presence of contaminating 
virus which could have acquired the wt E1A region from recombination with DNA 
sequences in HEK293 cells or could have deleted the eGFP transgene. All p1 seed stocks 
screened showed no E1A or eGFP recombination with one exception where an eGFP 
rearrangement had taken place. 
The restriction profile of each banded p3 stock was also confirmed by digestion with 
HindIII, BglII and KpnI. 
 
No problems were encountered while culturing any vMH vectors and good eGFP 
expression was observed throughout. However, in culturing vMH vectors differences were 
observed in the time taken to achieve good CPE, plaque size and rate of plaque appearance. 
vMH2 reached complete CPE in 3-4 days and also formed the largest plaques. Both vMH6 
and vMH7 were slower growing, taking 5-6 days to reach good CPE and also having 
smaller plaques. 
3.6.2 Virus Titres and Particle to Infectivity Ratios 
All vMH vectors had reasonable virus particle counts comparable to the E1B-55K deleted 
virus vNR3, but not as high as Ad5 wt. All vMH vectors have P:I ratios of 10 to 100, which 
are acceptable for in vitro studies. However it is notable that with increase in genome size 
there is a decrease in infectious virus particles, which gives an increase in the P:I ratio. Bett 
et al identified the adenovirus packaging limit as approximately 105% of the wildtype Ad5 
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genome [Bett et al, 1993]: by passage 9, virus constructs at 106.2, 106.1 and 105.4% of the 
Ad5 genome underwent rearrangements to decrease vector size. In comparison vectors of 
104.6 and 103.1% were stable up to 20 passages. Taken together these results show Ad has 
a relatively tight constraint on the packaging limit and whereas vectors below 105% are 
stable a packaging limit exists between 104.6 and approximately 105.4%. Unfortunately, 
there have been no more recent reports investigating the upper Ad packaging limit which 
might have narrowed down this range. Both vMH6 and vMH7 have genomes over 105% of 
the Ad5 wt genome (105.18 and 105.25%, respectively) and it is worth noting this may 
have an effect on packaging efficiency and P:I ratio. 
Whereas the low infectious virus titre and higher P:I ratios do not pose a direct problem for 
this study, there are some possible implications for any future clinical work with these 
vectors. All batches of adenovirus for clinical use have to be made to GMP (good 
manufacturing practice) standards, which includes production and quality control 
specifications. Part of the UK GMP guidelines state “clinical grade adenovirus requires a 
P:I ratio less than 100”. Both batches of vMH6 and vMH7 have P:I ratios close to or higher 
than 100 and therefore could potentially pose a fundamental problem in the manufacture of 
clinical virus. It may also be worth noting that whereas no regulations are set out as to 
minimum virus titre, the low virus particle yield from vMH6 and vMH7 may have 
significant cost implication for the production of clinical grade virus stocks. 
3.7 Summary 
I have cloned and constructed 5 new adenovirus vectors expressing eGFP for prostate 
oncolytic virotherapy. These vectors have been screening by PCR and profiled by 
restricting enzyme digestion. These vectors will be characterised in subsequent chapters to 
select the optimal vector for introduction of the therapeutic transgene NTR.  
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CHAPTER 4   
 
Characterisation of vMH Viruses 
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4.1 Introduction 
The 5 new vMH vectors (vMH2, 4, 5, 6 and 7) incorporate E1A modifications for improved 
tumour specificity, RGD-retargeted fibre for increased tumour transduction and all are 
designed to express eGFP at late times of infection. These vectors were characterised 
alongside the E1B-55K vector vNR3, to identify the optimal vector in terms of tumour 
selectivity, cytotoxicity and transgene expression, for the introduction of the therapeutic 
transgene NTR. Initial experiments were conducted to investigate the tumour specificity of 
these vectors, by measuring the cytotoxicity in prostate tumour cell lines and non-
transformed human fibroblasts. Further characterisation was performed to see the effects of 
each modification on virus replication, gene expression and spread. Finally, the vMH 
vectors were compared with similar vectors which lacked any transgene, to investigate the 
effects of transgene insertion. 
 
Chen et al demonstrated over-expression of NTR from the CMV immediate early promoter 
had a detrimental effect virus recovery when combined with high concentration of the 
prodrug CB1954 [Chen et al,  2004]. Dr Roesen expressed NTR at intermediate times of 
replication from the pIX virus promoter [Roesen 2006]. This alleviated the CB1954 
associated toxicity on virus replication and spread; however NTR expression from the pIX 
promoter was significantly lower than from the CMV promoter, resulting in a lower 
therapeutic potential. All vMH vectors were designed to express transgene from the Ad 
MLP to achieve late and high transgene expression. It was therefore anticipated that 
subsequent replacement of the eGFP transgene with NTR should not affect virus 
replication, but would give high NTR expression late in virus infection (post DNA 
replication), resulting in a high therapeutic potential. 
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4.2 Aims of Chapter 
The aim for this chapter was to characterise 5 eGFP expressing vMH vectors in term of 
virus replication, gene expression, spread and tumour specificity. These vectors were 
compared with vNR3 (the E1B-55K virus constructed by Dr Roesen), which expressed 
eGFP from the pIX promoter. 
4.3 Results 
4.3.1 CAR and Integrin Expression 
To begin, the CAR and αVβ3/5 integrin status of the cell lines; A549, DU145, 22RV1, PC3, 
MRC5, KS fibroblasts, SKOV3 and MZ2-MEL3.0 was assessed by flow cytometry. Cells 
were plated at three concentrations to see if confluence affected cell surface expression. 
The percentage of cells CAR or integrin positive cells was calculated relative to the 
appropriate isotype control; see Figure 4-1. 
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(C) 22RV1
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(F) KS fibroblasts
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Figure 4-1. Surface CAR and integrin expression of the cells used in this study 
A549 (A), DU145 (B), 22RV1 (C), PC3 (D), MRC5 (E), KS fibroblast (F), SKOV3 (G) 
and MZ2-MEL3.0 (H) cells were seeded in 24-well plates at 3x10
4
, 7x10
4
 and 1x10
5
 cells 
per well in 2ml of medium per well. Cells were allowed to adhere for 48 hours before being 
harvested and stained with anti-CAR, anti-αVβ3 or anti-αVβ5 for 1 hour at 4
o
C (as described 
in section 2.9.1), and analysed by flow cytometry. Graphs show the percent positive relative 
to the isotype control. 
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A549 and DU145 cells expressed similar levels of CAR and integrins; both showing high 
CAR expression (>80% positive), high αVβ5 expression (>98% positive) and no detectable 
αVβ3 expression. 22RV1 cells also expressed a high level of αVβ5 (>95% positive) and good 
CAR expression (66-75% positive), but also had moderate αVβ3 expression (approximately 
50% positive). PC3 cells showed little αVβ3 expression (<10% positive), a moderate level of 
CAR expression (approximately 50% positive) and also a high level of αVβ5. A high level 
of αVβ5 expression (>98% positive) was observed with MRC5 fibroblasts, with moderate 
levels of CAR and αVβ3 (both approximately 50% positive). In contrast, KS fibroblasts 
showed no CAR expression and moderate levels of αVβ3 and αVβ5 expression, both 
approximately 50-60% positive. Both SKOV3 and MZ2-MEL3.0 showed little CAR 
expression (>5% positive), some αVβ3 expression (25-40% positive) and good levels of 
αVβ5 expression (approximately 75% positive). For all cell lines, no major change in CAR 
or integrin expression was observed with varying cell density. The levels of mean 
fluorescent intensity corroborated these observations (data not shown). 
4.3.2 Cytotoxicity of vMH Vectors 
All vMH vectors were designed to replicate conditionally within tumour cells and to spare 
normal cells. Previous studies have demonstrated that E1A CR2 24 vectors show good 
cytotoxicity to cancer cells, but high levels of cytotoxicity are also observed with non-
transformed primary cells which have not been growth arrested [Bazan-Peregrino et al, 
2008]. The further modifications within vMH4, 5, 6 and 7 are designed to enhance the 
tumour cell selectivity by restricting E1A expression to cells with high E2F levels. 
Furthermore vMH5 and vMH7 contain a retargeted fibre which should aid in transduction 
of cells expressing low amounts of CAR. 
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To investigate the comparative selectivity of these vectors, cytotoxicity was measured in 
three prostate cancer cells lines; DU145, 22RV1 and PC3, and two non-transformed human 
fibroblasts lines; MRC5 and KS fibroblasts.  
Cells in 96-well plates were infected in triplicate with 10-fold serial dilutions of vMH 
vectors, Ad5 wt, Ad-GFP and vNR3 from 1x10
-2
 to 3x10
3
 PFU/cell (as described in section 
2.4.8). Cell survival was measured 5 days post infection by acid phosphatase (AP) assay 
(described in section 2.5.1), dose response curves fitted (Figure 4-2) and EC50 values 
calculated (Table 4-1), as described in section 2.10.  
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Figure 4-2. Dose response curves for vMH cytotoxicity 
DU145 (A), 22RV1 (B), PC3 (C) were seeded in 96-well plates at 3x10
4
 cells per well, 
while MRC5 (D) and KS (E) fibroblasts were seeded in 96-well plates at 1x10
4
 cells per 
well. Triplicate wells were infected with a serial dilution of Ad5 wt, Ad-GFP, vNR3 and 
vMH vectors as described in section 2.4.8. Cell survival was measured 5 days post infection 
by AP assay and normalised to mock infected cells (100% survival) and empty wells (0% 
cell survival). Plots show mean cell survival, ± S.D. (where no error bars are visible S.D. 
was <5%), where n=3 for each data point and fitted sigmoid dose response curves Dose 
response curves were used to calculate EC50 values. GraphPad software was used to 
calculate error bars, dose response curves and EC50 values. A schematic of each CRAd can 
be found in Figure 3-2. 
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Virus DU145 22RV1 PC3 MRC5 KS fibro 
Ad5 
wt 
8.61 
(7.85 - 9.43) 
0.613 
(0.479 - 0.784) 
31.4 
(22.1 - 44.7) 
720 
(571 - 909) 
661 
(260 – 1680) 
vNR3 
67.9 
(60.2 - 76.7) 
2.44 
(2.15 - 2.76) 
32.5 
(28.2 - 37.4) 
191 
(138 - 264) 
453 
(282 - 729) 
vMH2 
1.95 
(1.64 - 2.32) 
0.622 
(0.568 - 0.681) 
2.83 
(1.67 - 4.79) 
78.1 
(66.7 - 91.5) 
319 
(165 - 616) 
vMH4 
25.3 
(22.8 - 28.1) 
2.52 
(1.82 - 3.51) 
48.8 
(42.2 - 56.4) 
791 
(386 - 1620) 
>1000 
vMH5 
30.6 
(26.8 - 34.9) 
1.86 
(1.22 - 2.82) 
15.8 
(13.1 - 19.1) 
392 
(314 - 489) 
>1000 
vMH6 
251 
(243 – 260) 
15.0 
(9.93 - 22.7) 
91.9 
(76.8 - 110) 
>3000 >1000 
vMH7 
311 
(251 – 384) 
13.5 
(12.0 - 15.2) 
65.9 
(51.2 - 84.7) 
>3000 >1000 
Table 4-1. EC50 values with 95% C.I. (PFU/cell) for vMH cytotoxicity 
 
vMH2 (wt E1A promoter, CR2 24) demonstrated cytotoxicity equal to or up to 10-fold 
greater than Ad5 wt, in all prostate cancer cells lines and non-transformed fibroblasts. 
vMH4 (ICOVIR-5 promoter, CR2 24) demonstrated a 3- to 5-fold reduction in 
cytotoxicity relative to Ad5 wt in prostate cancer cells, with cytotoxicity equal to Ad5 wt in 
MRC5 cells and very little cytotoxicity in KS fibroblasts, with an EC50 value greater than 
1000 PFU/cell. In comparison, the equivalent RGD-retargeted vector vMH5, demonstrated 
a range of cytotoxicities in prostate cancer cell lines, with a 2-fold increase in cytotoxicity 
over Ad5 wt in PC3 cells, but a 3-fold decrease in cytotoxicity in DU145 and 22RV1 cells. 
Little cytotoxicity was observed with vMH5 in KS fibroblasts; however a 2-fold increase in 
cytotoxicity over Ad5 wt was seen in MRC5 fibroblasts. No significant difference was 
observed in the cytotoxicity of vMH6 (ICOVIR-7 promoter, CR2 24) and the equivalent 
RGD-retargeted vector vMH7, both of which showed a 3- to 30-fold decrease in 
cytotoxicity relative to Ad5 wt in prostate cancer cell lines, and very little cytotoxicity in 
MRC5 or KS fibroblasts, with over 50% cell survival at the highest MOI. 
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Very little difference in cytotoxicity was observed between matched wt fibre and RGD-
retargeted fibre vectors (i.e. vMH4 vs vMH5 and vMH6 vs vMH7). In both 22RV1 and 
PC3 cells the RGD-retargeted vectors showed a small reduction in the EC50 values 
compared to the wt equivalent vector. vMH5 also showed a slight increase in cytotoxicity 
over vMH4 in MRC5 cells, however no difference was observed in these cells between 
vMH6 and vMH7. In contrast the opposite was observed in DU145 cells, with the RGD-
retargeted fibre vectors demonstrating a slightly higher EC50 value than the wt equivalents. 
However it must be noted that, with one exception, the 95% confidence intervals of EC50 
values between wt and RGD-retargeted vectors were overlapping. The one exception was 
vMH5, which showed a 3-fold increase in cytotoxicity over vMH4 in PC3 cells. 
Flow cytometry for CAR expression demonstrated CAR expression on all the prostate 
cancer cell lines used here, and on MRC5 cells. However, PC3 and MRC5 cells expressed 
lower levels of CAR compared DU145 and 22RV1 cells (see Figure 4-1), therefore if any 
cytotoxic advantage were to be observed with the RGD-retargeted fibre it would possibly 
be expected in these cells. Since CAR expression was high in 22RV1 and DU145 cells, the 
CAR receptor is unlikely to be saturated by the MOI used in this study (3x10
4
 PFU/cell), 
therefore it was not unexpected that the RGD-retargeted vectors did not show an oncolytic 
advantage in these cells. 
 
To give an indication of the tumour cell selectivity, the therapeutic index (TI) was 
calculated for each virus, by dividing the non-transformed cell EC50 values by the target 
tumour cell EC50 values; the higher the index the more selective the vector (see Figure 
4-3). As no EC50 value was observed with vMH4-7 in KS fibroblasts, MRC5 cells were 
used as the non-transformed cell references. Since even in MRC5 fibroblasts, no EC50 
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value was obtained for vMH6 and vMH7 the indices of these viruses were calculated using 
the top dose used (3000 PFU/cell), and is therefore is an underestimation of the actual 
tumour selectivity. 
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Figure 4-3. Therapeutic indices for vMH vectors 
The therapeutic index for each virus was calculated in DU145, 22RV1 and PC3 cells by 
dividing the MRC5 EC50 value by the target prostate cell line EC50 value.  
No definitive EC50 value was ascertained for vMH6 and vMH7 in MRC5 cells therefore 
the value of 3000 PFU/cell was used; however the actual therapeutic index for these vectors 
is higher than shown (indicated by #).  
 
A range of therapeutic indices was observed for the vectors, with no single virus having the 
highest therapeutic index throughout all cell lines, this is probably a result of the varying 
p53 status, pRb status and CAR expression, discussed further in section 4.4.1. Furthermore, 
Ad5 wt showed the highest therapeutic index in both DU145 and 22RV1 cells, also 
discussed in section 4.4.1. However, all ICOVIR-5 (vMH4 and vMH5) and ICOVIR-7 
(vMH6 and vMH7) based vectors were more selective than the CR2 24 vector with the wt 
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E1A promoter (vMH2) and the E1B-55K virus (vNR3). In both DU145 and 22RV1 cells 
vMH4 showed the highest therapeutic index of all CRAd vectors, followed by vMH5 and 
vMH6. In PC3 cells vMH6 and vMH7 showed the highest therapeutic index, followed by 
vMH6 and then vMH5. However, it must be noted the actual ranking of vMH6 and vMH7 
is not known, and the „true‟ TI of both vMH6 and vMH7 could be greater than Ad5 wt in 
DU145 and 22RV1 cells.  
4.3.3 eGFP Transgene Expression with vMH Vectors 
All vMH vectors were designed to express the eGFP transgene from the Ad MPL, to 
achieve high but late transgene expression. In comparison, vNR3 expresses eGFP from the 
intermediate pIX viral promoter. To investigate eGFP transgene expression level and 
timing, eGFP expression was measured by flow cytometry. 24-well plates of DU145 and 
22RV1 were infected with 100 VP/cell of Ad-GFP or vMH vectors and MRC5 cells were 
infected at 1000 VP/cell. For practical reasons 2 individual experiments were carried out 
with two groups of viruses; vMH2, vMH7 and vNR3 or vMH4, vMH5 and vMH6 with Ad-
GFP included in both experiments as an internal reference. At timepoints between 0 and 60 
hours post infection duplicate infected wells were analysed by flow cytometry (as described 
in section 2.9.1). 
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Figure 4-4. eGFP percentage positive with vMH vectors 
DU145 cells (A and B) and 22RV1 cells (C and D) in 24-well plates were infected with Ad-
GFP, vNR3, vMH2 and vMH7 (A, C and E) or Ad-GFP, vMH4, vMH5 and vMH6 (B, D 
and F) at 100 VP/cell for DU145 and 22RV1 cells or 1000 VP/cell for MRC5 cells (as 
described in 2.4.8). Duplicate wells were harvested at timepoints from 4 to 60 hours post 
infection, washed, fixed and eGFP expression analysed by flow cytometry. Graphs show 
the mean percentage eGFP positive (n=2), ± S.D. (where no error bars are visible S.D. was 
<5%). 
 
 154 
Figure 4-4 shows the percentage eGFP positive cells for all three cell lines. Ad-GFP clearly 
expressed detectable levels of GFP at 8 hours post infection in all cell lines tested. vNR3 
expressed detectable levels of eGFP in both prostate cell lines from 8 hours post infection, 
which rose steadily until plateauing at approximately 36 hours. In contrast, eGFP 
expression with the vMH viruses, with the exception of vMH7, was not observed until 24 
hours post infection, as would be expected for late gene expression. With vMH7 no eGFP 
expression was detected until 36 hours post infection, approximately 8 hours after all other 
vMH vectors. The maximum number of cells transduced with each vMH vector reflected 
the variation in P:I ratio (e.g. vMH7 achieved a maximum transduction 4-fold lower than 
vMH2, but vMH7 had a 4-fold higher P:I ratio).  
Within the normal cell line MRC5, the vMH vectors and vNR3 did not express detectable 
levels of eGFP until 24-36 hours post infection. Furthermore, the maximum number of 
positive cells remained under 20% up to 60 hours post infection, despite using 10-fold more 
virus than with prostate carcinoma cell lines. In comparison, Ad-GFP transduced 75% of 
cells by 60 hours post infection, demonstrating selective transgene expression with vMH 
vectors and vNR3.  
 
The fold increase in mean fluorescence intensity (MFI) relative to mock infected cells was 
calculated for the eGFP positive population, shown in Figure 4-5. vNR3 had detectable 
levels of eGFP from 24 hours post infection, after which the intensity increased steadily 
reaching maximal expression at 36 hours post infection. With all vMH vectors except 
vMH7, eGFP expression began at 16-24 hours post infection, after which the level of 
expression rose rapidly, reaching maximum intensity at 36 hours post infection. vMH7 
clearly demonstrated an 8-10 hour delay in eGFP compared to the other vMH vectors, with 
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eGFP expression not detectable until 24-36 hours post infection. Despite this delay the 
intensity of eGFP expression with vMH7 reached a level similar to that of all other vMH 
vectors. The maximum level eGFP expression with all vMH vectors was 10-fold and 3-fold 
higher than vNR3, in DU145 and 22RV1 cells, respectively.  
At the final timepoint (60 hours post infection) CPE could clearly be observed with vNR3 
and vMH2. In comparison little CPE was observed with all the E2F-1 controlled vMH 
vectors at 60 hours post infection. 
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Figure 4-5. eGFP MFI with vMH vectors 
The same experiment as in Figure 4-4; showing calculated fold increase in MFI over mock 
infection was calculated. Graphs show the mean of the duplicate infection (n=2), ± S.D. 
(where no error bars are visible S.D. was <5%). 
4.3.4 DNA Replication with vMH Vectors 
Full length MLP transcription first requires the initiation of DNA replication. With vMH2, 
4, 5 and 6 eGFP expression began 24 hours post infection and accelerated rapidly over the 
next 12 hours. One vector, vMH7, had an 8-10 hour delay in the onset of eGFP expression. 
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To investigate whether this was a consequence of delayed virus DNA replication, Q-PCR 
was used to measure the timecourse of virus DNA replication for the MH vectors. DU145 
cells in 24-well plates were infected with 100 VP/cell of Ad5 wt, vNR3 or vMH vectors (as 
described in section 2.4.8). Two individual experiments were carried out with two groups 
of viruses; vMH2, vMH7 and vNR3 or vMH4, vMH5 and vMH6. Ad5 wt was included in 
both experiments as an internal control. At timepoints between 0 to 60 hours post infection 
duplicate wells. Q-PCR was carried out for virus DNA and cellular DNA as described in 
section 2.7.1. 
 
 158 
 
(A)
0 10 20 30 40 50 60 70
10 -3
10 -2
10 -1
100
101
102
103
104
105
Ad5 wt
vMH2
vMH7
vNR3
Time P.I. (hours)
V
ir
u
s
 C
o
p
ie
s
 p
e
r 
C
e
ll
(B)
0 10 20 30 40 50 60 70
10 -3
10 -2
10 -1
100
101
102
103
104
105
vMH4
vMH5
vMH6
Ad5 wt
Time P.I. (hours)
V
ir
u
s
 C
o
p
ie
s
 p
e
r 
C
e
ll
 
Figure 4-6. DNA replication of vMH vectors 
DU145 cells were seeded at 1x10
5
 cells per well in 24-well plates before being infected 
with 100 VP/cell of vMH2, vMH7, vNR3 and Ad5 wt (A), or vMH4, vMH5, vMH6 and 
Ad5 wt (B) as described in section 2.4.8. Duplicate wells were harvested at timepoints from 
4 to 60 hours post infection, DNA extracted, and Q-PCR performed for viral genomes and 
cellular DNA. Virus genome copies were normalised to cellular DNA copies. Graphs show 
the mean of duplicate wells (n=1), ± S.D. (where no error bars are visible S.D. was <5%). 
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Figure 4-6 shows the timecourse of viral DNA replication profile normalised to copies of 
cellular DNA. Ad5 wt virus DNA replication began 8-16 hours post infection and started to 
plateau 24-36 hours post infection. All vMH vectors, except vMH7, had DNA replication 
profiles very similar to Ad5 wt. As would be expected, the end of virus DNA replication 
coincides with the onset of eGFP expression, at approximately 24 hours post infection. 
vMH7 virus DNA replication did not begin until 20-24 hours post infection, approximately 
8-10 hours later than all other vMH vectors. It therefore seems the 8-10 hour delay 
observed with vMH7 eGFP expression reflects an 8-10 hour delay in the onset of virus 
DNA replication. vMH7 also showed a 100-fold decrease in virus genomes/cell before the 
onset of DNA replication, which was due to a decrease in virus copy number, not an 
increase in cellular DNA.  
4.3.5 E1A Expression 
All E2F responsive vectors have a 10-100 fold reduction in oncolytic activity compared to 
vMH2, which has the wt E1A promoter. Replacing the E1A promoter could result in lower 
or delayed E1A expression, which in turn could result in reduced oncolytic activity. It was 
therefore decided to investigate the E1A expression from vMH vectors by western blot. 24-
well plates of DU145 cells were infected with 10 PFU/cell of Ad5 wt or vMH vectors, as 
described in section 2.4.8. At timepoints between 4 and 60 hours post infection, total 
protein was harvested and prepared for western blot, as described in section 2.8. For each 
vMH vector separate western blots were performed, alongside Ad5 wt to act as an internal 
control. Blots were probed for E1A and β-tubulin (loading control) using unconjugated 
primary antibodies, with anti-mouse HRP conjugate secondary antibody and an ECL 
detection kit. Westerns were subsequently reprobed for late protein production using rabbit 
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serum to whole heat inactivated virus, with anti-rabbit HRP secondary antibody and ECL 
detection. All antibodies for western blotting are listed in Table 2-6.  
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Figure 4-7. Western blots for E1A expression with vMH vectors 
DU145 cells were seeded at 1x10
5
 cells per well in 24-well plates were infected with 10 
PFU/cell of Ad5 wt or vMH vectors as described in section 2.4.8. Total protein was 
harvested from wells at 4 to 60 hours post infection and 2.5g of each sample separated by 
SDS-PAGE and western blotted. Separate blots were performed for each vMH vector, each 
ran alongside Ad5 wt as an internal control. Blots were probed for E1A, Ad core and β-
tubulin expression (loading control). An additional western was performed directly 
comparing vMH6 and vMH7 to verify the differential E1A expression observed. 
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Figure 4-7 shows compiled western blots for all vMH viruses alongside Ad5 wt. Ad5 wt 
E1A expression was just detectable 8 hours post infection and clearly detectable at 16 hours 
post infection. In comparison, with vMH2 E1A expression can clearly be observed at 8 
hours post infection and ultimately rises to produce more E1A than Ad5 wt.  
Both ICOVIR-5 based vectors vMH4 and vMH5, and the ICOVIR-7 based vector vMH6, 
show similar E1A expression profiles, with no E1A detectable until 16 hours post infection. 
However, all three vectors produced E1A levels equivalent to Ad5 wt by 24 hours post 
infection. In comparison, vMH7 did not produce a detectable level of E1A until 24 hours 
post infection, significantly later than observed with the other vMH vectors.  
Core protein (protein V, part of the MLTU) was first detected with Ad5 wt at 24 hours post 
infection. With vMH2, 4, 5 and 6 it was first detectable at 24 hours post infection, and 
showed a similar level of expression to Ad5 wt. vMH7 also produced detectable core 
protein by 24 hours post infection, however it was markedly reduced compared to Ad5 wt. 
The reduced E1A expression observed with vMH4, 5 and 6 compared to Ad5 wt is 
consistent with the reduced oncolytic activity observed with these vectors. Furthermore, the 
onset of protein V expression observed with vMH2, 4, 5 and 6 coincided with the start of 
eGFP expression with these vectors.  
The ICOVIR-7 based vectors vMH6 and vMH7 have the E1A promoter replaced by the 
same ICOVIR-7 promoter and were therefore expected to produce very similar levels of 
E1A. The data in Figure 4-7(D) and (E) would suggest vMH7 produces lower amounts of 
E1A compared to vMH6. To confirm these results the experiment was repeated, directly 
comparing vMH6 and vMH7, as shown in Figure 4-7(F).  
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To further investigate whether the delayed and lower E1A expression observed was a result 
of reduced promoter activity, E1A RNA levels were investigated using rtQ-PCR. 24-well 
plates of DU145 cells were infected with 10 PFU/cell of Ad5 wt or vMH vectors. At 4, 8 
and 16 hours post infection wells were harvested, total RNA extracted, and used to 
synthesise complete cDNA with random primers (as described in section 2.6.4 and 2.7.2, 
respectively). Q-PCR was performed on samples for the E1A RNA target and for 18S 
rRNA endogenous control, using the CT method as described in section 2.7.3, 
referenced to Ad5 wt 4 hours post infection.  
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Figure 4-8. rtQ-PCR for E1A expression with vMH vectors 
DU145 cells were seeded at 1x10
5
 cells per well in 24-well plates before being infected 
with 10 PFU/cell of Ad5 wt, vNR3 or vMH vectors as described in section 2.4.8. Samples 
were harvested at 4 (A), 8 (B) and 16 (C) hours post infection and total RNA extracted. 
50ng of total RNA was used to synthesis cDNA using random primers. Q-PCR was 
performed in on cDNA for E1A RNA (target sample) and 18S rRNA (endogenous control) 
using the CT method for relative quantification. Bar graphs show E1A expression 
relative to Ad5 wt 4 hour post infection, ± S.E.M. from triplicate Q-PCR reactions 
experiment (n=1).  
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Figure 4-8 shows that at 4 hours post infection vMH2 produced approximately 10-fold 
more E1A RNA than Ad5 wt, vMH4 expressed 3-fold more E1A RNA compared to Ad5 
wt, and vMH5 and vMH6 expressed the same level as Ad5 wt. In contrast, vMH7 E1A 
RNA expression was approximately 4-fold lower than Ad5 wt.  
At 8 hours post infection vMH5 and vMH6 E1A RNA expression were equivalent to 
vMH4, however vMH7 E1A RNA expression was still markedly lower. Finally at 16 hours 
post infection E1A RNA expression was high for all vMH viruses, with vMH6 showing the 
highest expression level. 
4.3.6 DNA Replication and Transgene Expression in HEK293 Cells 
Although vMH6 and vMH7 have E1A under control of the same E2F-1 promoter, vMH7 
produces less E1A RNA and protein, which could explain the delay in virus DNA 
replication of approximately 8-10 hours, and the resultant delay in eGFP expression. 
HEK293 cells express a high level of Ad5 E1A (greater then A549 cells with 10 PFU/cell 
of Ad5 wt at 24 hour post infection, Dr D. Onion, personal communication) and they 
should overcome any variation in E1A expression between vMH6 and vMH7. Therefore if 
the lower E1A expression observed with vMH7 is directly responsible for the delay in 
DNA replication and eGFP expression, the delay should not be observed in HEK293 cells. 
Therefore, vMH6 and vMH7 DNA replication was measured in HEK293 cells by Q-PCR. 
24-well plates of HEK293 cells were infected with 100 VP/cell of vMH6, vMH7 or Ad5 wt 
(as described in section 2.4.8). At timepoints between 4 and 48 hours post infection 
duplicate wells were harvested and analysed as in section 4.3.4. 
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Figure 4-9. DNA replication of vMH vectors in HEK293 cells 
HEK293 cells were seeded at 1x10
5
 cells per well in 24-well plates and duplicate wells 
were infected with Ad5 wt, vMH6 or vMH7 at 100 VP/cell as described in section 2.4.8. 
Duplicate wells were harvested at timepoints from 4 to 60 hours post infection, DNA 
extracted, and Q-PCR performed for viral genomes and cellular DNA. Virus genome copies 
were normalised to cellular DNA copies. Graph shows the mean of duplicate wells (n=1), ± 
S.D. (where no error bars are visible S.D. was <5%). 
 
Figure 4-9 shows the virus DNA replication profile, normalised to cell DNA copies. The 
profiles of vMH6, vMH7 and Ad5 wt were all very similar, with essentially no difference 
between vMH6 and vMH7. vMH6 and vMH7 showed a 1x10
4
-fold increase in genome 
copy number. In comparison Ad5 wt showed a 2.5x10
4
-fold increase in genome copy 
number: this small difference may have been due to the 10-fold lower P:I ratio of Ad5 wt or 
the smaller genome size, or a possibly a minor detrimental effect of the eGFP insert.  
 
To investigate eGFP expression HEK293 cells in 24-well plates were infected with 100 
VP/cell of vMH2, vMH6, vMH7 or Ad-GFP, as described in section 2.4.8. At timepoints 
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between 0 and 48 hours post infection duplicate wells were harvested, fixed and analysed 
by flow cytometry for percentage eGFP positive cells (Figure 4-10 (A)). For the eGFP 
positive population the fold increase in MFI over uninfected cells was calculated (Figure 
4-10 (B)). 
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Figure 4-10. vMH eGFP expression in HEK293 cells 
HEK293 cells were seeded at 1x10
5
 cells per well in 24-well plates before being infected 
with 100 VP/cell of Ad-GFP, vMH2, vMH6 or vMH7 as described in 2.4.8. Duplicate 
wells were harvested at timepoints from 4 to 60 hours post infection, washed, fixed and 
eGFP expression analysed by flow cytometry. The mean percentage eGFP positive from 
duplicate wells was calculated (A) and of the fold increase in MFI of the eGFP positive 
population calculated over mock infected (B). Graphs show average from duplicate wells 
(n=2), ± S.D. (where no error bars are visible S.D. was <5%).  
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For Ad-GFP, expression was first detected 4 hours post infection and showed a maximal 
transduction of 75% by 12 hours post infection. With vMH2, vMH6 and vMH7 no eGFP 
expression was detected until 16 hours post infection. All vMH vectors showed maximal 
transduction by approximately 36 hours post infection; with the maximum number of cells 
transduced reflecting the variation in P:I ratio (i.e. in comparison to vMH6 and vMH7, 
vMH2 had a 4-fold higher maximal transduction and a 4-fold lower P:I ratio). vMH7 also 
had a slightly slower rate of increase in percentage positive compared to vMH6, which 
itself was slightly slower than vMH2. However all vMH vectors reached a similar level of 
fluorescent intensity, peaking at 36 hours post infection. 
4.3.7 Cytotoxicity of vMH Vectors in HEK293 Cells 
Results in section 4.3.5 demonstrated that replacement of the E1A promoter with the 
insulated E2F-1 promoter from ICOVIR-5 or ICOVIR-7 results in lower E1A RNA and 
protein expression. Reduced E1A expression could in turn lead to the reduced lytic activity 
observed with these vectors in prostate cancer cell lines. However replacement of the 
natural E1A promoter also results in an increase in viral genome size: vMH2 is 102.07% of 
the Ad5 wt genome, vMH4 with the ICOVIR-5 promoter is 104.83% and vMH6, with the 
ICOVIR-7 promoter is 105.18%. This could also have a detrimental effect on virus 
packaging, resulting in reduced infectious virus yields and subsequently reduced lytic 
activity. It was therefore decided to investigate virus induced cytotoxicity in HEK293 cells. 
HEK293 cells express a high level of E1A, compensating for the range of E1A expression 
observed with vMH vectors, allowing assessment of vector genome size on cytotoxicity. 
96-well plates of HEK293 cells were infected with a serial dilution of Ad5 wt, vNR3 or 
vMH vectors from 1x10
-4
 to 1x10
2
 PFU/cell (as described in section 2.4.8). Cell survival 
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was measured 5 days post infection by AP assay, data normalised, dose response curves 
fitted (Figure 4-11) and EC50 values calculated (Table 4-2).  
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Figure 4-11. Dose response curves for vMH cytotoxicity in HEK293 cells 
HEK293 were seeded in 96-well plates at 3x10
4
 cells per well. Triplicate wells were 
infected with a serial dilution of Ad5 wt, vNR3 or vMH vectors as described in section 
2.4.8. Cell survival was measured 5 days post infection by AP assay and normalised to 
mock infected cells (100% survival) and empty wells (0% cell survival). Plots show mean 
cell survival from triplicate wells (n=1), ± S.D. (where no error bars are visible S.D. was 
<5%), and fitted sigmoid dose response curves. Dose response curves were used to 
calculate EC50 values. 
 
Virus HEK293 EC50 (95% C.I.) PFU/cell 
Ad5 wt 0.00404 (0.00713 - 0.0110) 
vNR3 0.0343 (0.0254 – 0.0462) 
vMH2 0.0193 (0.0130 – 0.0289) 
vMH4 0.0433 (0.0271 – 0.0692) 
vMH5 0.0917 (0.0531 – 0.159) 
vMH6 0.0354 (0.0225 – 0.0556) 
vMH7 0.0449 (0.0227 – 0.0737) 
Table 4-2. EC50 values with 95% C.I. (PFU/cell) in HEK293 cells 
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No significant difference was observed in the cytotoxicity for all vMH vectors in HEK293 
cells, all of which had similar EC50 values with overlapping 95% confidence intervals. 
However, it is worth noting that vMH2, which has the smallest genome of all vMH vectors, 
did show the lowest EC50 value. Ad5 wt was significantly more cytotoxic than all vMH 
vectors, with 3- to 10-fold lower EC50 values. This would suggest the additional genome 
size resulting from replacement of the wt E1A promoter with the ICOVIR-5 or ICOVIR-7 
promoter may cause a minor reduction in cytotoxicity. However, in comparison to Ad5 wt, 
all vMH vectors demonstrated lower EC50 values, potentially indicating the introduction of 
transgene may have had a detrimental effect on cytotoxicity. However, the difference was 
only small, and it was not clear whether this is specifically due to the position at which the 
transgene was inserted, or due to the increase in genome size conferred by transgene 
insertion. 
4.3.8 Sequencing the ICOVIR-7 Promoter in vMH6 and vMH7 
vMH6 and vMH7 were created by homologous recombination in HEK293 with the same 
left end plasmid, pICOVIR-7, and pMH008 or pMH009, respectively (as described in 
section 3.5). Both viruses were shown to be free of contaminating wt E1A sequences by 
PCR, and had no evidence of the wt E1A promoter by restriction enzyme profiling. 
However vMH7 produced significantly lower levels of E1A RNA compared to vMH6. It 
was possible a mutation had occurred in the ICOVIR-7 promoter sequence in either vMH6 
or vMH7, which would result in differential RNA expression. It was therefore decided to 
sequence the E1A promoters from vMH6 and vMH7 banded virus stocks, plus the 
pICOVIR-7 plasmid stock used for virus recovery.  
The entire E1A promoter region was amplified by PCR using KOD Taq (for increased 
fidelity) with primers MHp018 and MHp019 (see Table 2-1 for description of primers). The 
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amplified 1.5kb promoter region was gel purified and sequenced as described in section 
2.2.9, with primers MHp017-024. 
vMH6 and vMH7 possess an ICOVIR-7 promoter with identical sequence (see appendix 2.) 
and also identical to the sequence found in pICOVIR-7. Sequencing results do however 
show that both viruses and the original plasmid contain base differences at 5 positions in 
comparison to the expected plasmid sequence (provided by Dr R. Alemany) (differences 
are annotated in appendix 2). These changes were at the cloning junctions between the 
promoter components, and it was therefore likely they were accidentally introduced during 
the original cloning of pICOVIR-7 by our collaborators. It is possible but unlikely that 
these mutations would have an effect on promoter activity. Furthermore, there was no 
difference in the ICOVIR-7 promoter region of vMH6 and vMH7 and this deviation from 
the expected sequence did not explain the differential E1A RNA expression observed 
between the two vectors. 
4.3.9 Lytic Timecourse in DU145 
Figure 4-2 indicated that there was no significant difference in the cytotoxicity between 
vMH6 and vMH7 at 5 days post infection. However, this data was a single timepoint (5 
days post infection), and it is possible vMH6 and vMH7 have different timecourses of cell 
lysis. To investigate this possibility, timecourse experiments were undertaken to measure 
the cell survival, up to 7 days post infection. DU145 cells in 96-well plates were infected 
with vMH2, vMH6, vMH7 and Ad5 wt at 30 and 100 PFU/cell, as described in section 
2.4.8. On days 1-7 post infection cell survival was measured from triplicate wells by AP 
assay. The data was normalised, and used to plot survival timecourses, shown in Figure 
4-12. 
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Figure 4-12. Lytic timecourse for vMH vectors 
DU145 cells were seeded in 96-well plates at 3x10
4
 cells per well before being infected 
with 30 (A) and 100 (B) PFU/cell of Ad5 wt, vMH2, vMH6 or vMH7 as described in 
section 2.4.8. Cell survival was measured daily up to 7 days post infection by AP assay and 
the data normalised on each day to mock infected cells (100% survival) and empty wells 
(0% survival). Plots show mean cell survival from triplicate wells (n=1), ± S.D. (where no 
error bars are visible S.D. was <5%), with fitted cell survival curves. 
 
At both MOI, vMH2 showed the most rapid and complete cytotoxicity, reaching 50% cell 
death approximately one day earlier than Ad5 wt at 30 PFU/cell, and 12 hours earlier than 
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Ad5 wt at 100 PFU/cell. Both vMH6 and vMH7 showed little cytotoxicity at 30 PFU/cell, 
reaching approximately 25% cell death by 6 days post infection. At 100 PFU/cell both 
vMH6 and vMH7 showed 50% cell death by 7 days post infection, however there was a 
very slight difference in the rate of cell death, with vMH7 taking approximately one day 
longer to reach 25% cell death. This suggests vMH6 may have a slightly greater rate of cell 
lysis compared to vMH7, however the difference at these MOIs was only minor. There was 
no difference in the P:I ratios of vMH6 and vMH7, both of which were approximately 100.  
4.3.10 Effect of Transgene Insertion 
4.3.10.1 Comparison of vMH6 and vMH7 with vICOVIR-7  
The vMH vectors incorporate the eGFP transgene downstream of fibre, for expression from 
the adenovirus MLP. Whereas this was not predicted to have a direct detrimental effect on 
virus cytotoxicity, it does increase the virus genome size, which could result in reduced 
packaging efficiency, lower infectious virus yields and reduced cytotoxicity. While this 
work was in progress Dr R. Alemany constructed vICOVIR-7, an ICOVIR-7 based 
oncolytic Ad vector (i.e. E1A promoter replaced with the ICOVIR-7 promoter and the E1A 
CR2 24 deletion) with an RGD-retargeted fibre, but lacking a transgene insertion. This 
gave the opportunity to compare vMH6 and vMH7 with vICOVIR-7, which should have 
the same oncolytic „backbone‟ but lacking the eGFP insertion.  
4.3.10.1.1 Cytotoxicity of vICOVIR-7 vs vMH6 and vMH7 
Approximately 100µl of CsCl banded vICOVIR-7 was kindly donated by Dr R. Alemany 
(2.4x10
11
 VP/ml, 1.1x10
10
 PFU/ml, P:I ratio = 21.8). This was initially used to investigate 
oncolytic activity in two cell lines; DU145 and A549-RA. DU145 cells were used for 
comparison with previous results with vMH vectors and A549-RA cells are A549 cells 
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from Dr. R. Alemany and were used for comparison with Dr R. Alemany‟s observations. 
96-well plates of DU145 and A549-RA cells were infected with serial dilutions of vMH6, 
vMH7, vICOVIR-7, Ad5 wt or Ad-GFP from 1x10
-1
 to 1x10
3
 PFU/cell (as described in 
section 2.4.8). Cell survival was measured 5 days post infection by AP assay, dose response 
curves plotted (Figure 4-13) and EC50 values calculated (Table 4-3). 
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Figure 4-13. Dose response curves for vMH6 and vMH7 vs vICOVIR-7 cytotoxicity 
DU145 (A) and A549-RA (B) cells seeded in 96-well plates at 3x10
4
 cells per well were 
infected with a serial dilution of Ad5 wt, Ad-GFP, vMH2, vMH6, vMH7 or vICOVIR-7 as 
described in section 2.4.8. Cell survival was measured 5 days post infection by AP assay 
and the data normalised to mock infected cells (100% survival) and empty wells (0% 
survival). Plots show mean cell survival from triplicate wells (n=1), ± S.D. (where no error 
bars are visible S.D. was <5%), with fitted sigmoid dose response curves. Dose response 
curves were used to calculated EC50 values. 
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Virus DU145 EC50 (95% C.I.) PFU/cell A549-RA EC50 (95% C.I.) PFU/cell 
Ad5 wt 28.6 (11.2 - 73.1) 16.0 (12.21 - 20.94) 
vMH6 132 (42.5 - 412) 369 (256 - 534) 
vMH7 253 (82.5 - 779) 507 (253 - 1010) 
vICOVIR-7 7.78 (1.79 - 33.9) 2.23 (1.87 - 2.83) 
Table 4-3. EC50 values with 95% C.I. for vMH6 and vMH7 vs vICOVIR-7 
 
vICOVIR-7 was the most cytotoxic vector in both cell lines, with a 4- to 5-fold increase in 
lytic activity of Ad5 wt. vMH6 and vMH7 demonstrated a 10-fold reduction in cytotoxicity 
over Ad5 wt in DU145 cells (as was previously observed in section 4.3.2), and a 20- to 30-
fold reduction in cytotoxicity in A549-RA cells. However, vICOVIR-7 is approximately 
20- to 30-fold more lytic than vMH6 and vMH7 in DU145 cells, and over 100-fold more 
cytotoxic in A549-RA cells. No difference in the pattern of cytotoxicity between all the 
vectors was observed in DU145 cell and A549-RA cells, demonstrating the reduction in 
cytotoxicity observed with vMH6 and vMH7 was not prostate cancer cell specific. 
4.3.10.1.2 Restriction Profiling and PCR Screening of vICOVIR-7 
The banded vICOVIR-7 virus was passaged once into 20x150cm
2
 flasks of A549 cells and 
CsCl banded to be used for restriction profiling. DNA was extracted from 200µl of the new 
banded vICOVIR-7 virus stock, termed vICOVIR-7MHB1, and 200µl of Ad5 wt for direct 
comparison (as described in 2.6.2) and digested with HindIII, BglII and KpnI, which 
distinguishes between the wt E1A promoter and the ICOVIR-7 promoter. The restriction 
enzyme profile of each virus is shown in Figure 4-14 (A), and the predicted restriction 
enzyme profile is shown in Figure 4-14 (B). 
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Figure 4-14. Restriction enzyme profile of Ad5 wt and vICOVIR-7 
DNA was extracted from 200l of banded Ad5 wt and vICOVIR-7MHB1 as described in 
section 2.6.2 and digested with HindIII, BglII and KpnI using excess enzyme for 16 hours. 
Digested samples were analysed by gel electrophoresis (A) and compared to the predicted 
restriction enzyme profile (B). Red arrows mark the bands diagnostic of Ad5 wt left end 
and the blue arrows mark the bands diagnostic of vICOVIR-7 left end.  
 
For vICOVIR-7MHB1 we predict; loss of the Ad5 wt HindIII 2.8kb band and appearance 
of 750bp and 3.1kb bands; increase of the Ad5 wt BglII 3.3kb band to 4.4kb; loss of the 
Ad5 wt KpnI 2kb band and appearance of 1.3kb and 1.8kb bands. Figure 4-14 shows that 
the passaged and banded vICOVIR-7MHB1 virus had a restriction enzyme profile almost 
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indistinguishable from Ad5 wt. However there was slight differences between the HindIII 
digest at approximately 3kb, with vICOVIR-7MHB1 possibly showing slightly larger 
bands than Ad5 wt. Additional large bands (>5kb) could be observed with the KpnI 
digested vICOVIR-7MHB1, possibly due to an incomplete digestion, despite use of excess 
enzyme at optimal conditions for 36 hours.  
 
The restriction pattern in Figure 4-14 suggested vICOVIR-7MHB1 was predominately a 
virus which was almost indistinguishable from Ad5 wt. To investigate this further the 
banded vICOVIR-7MHB1 and the original vICOVIR-7 stock were subject to PCR analysis 
using primers designed within the E1A CR2 24 deletion (primer PS1368A), spanning the 
E1A CR2 24 deletion (primer PS1368B), within the DM-1 insulator element found only 
in the ICOVIR-7 promoter (primer MHp022) or just downstream of the left ITR (MHp019). 
The same reverse primer located just downstream of the E1A ORF (primer PS1368C) was 
used with each forward primer. These PCR reactions allow discrimination between the E1A 
CR2 24 deletion and wt E1A, and between the ICOVIR-7 promoter and the wt E1A 
promoter. A schematic of primer layout can be found in Figure 4-15 below, along with a 
table of predicted band sizes in Table 4-4.  
Banded vMH7 and pICOVIR-7 were also analysed as control samples. PCR was carried out 
as described in section 2.2.8, with 10
8
 VP/reaction for 35 cycles and products analysed by 
gel electrophoresis, shown in Figure 4-16.  
 
 180 
 
Figure 4-15. Schematic of PCR primers covering E1A and its promoter region 
Schematic layout of the PCR primers used to screen for the E1A CR2 24 deletion and the 
ICOVIR-7 promoter. See text for description of the primers. Details of the primers can be 
found in Table 2-1. 
 
Table 4-4. Predicted PCR bands with E1A screening primes 
 
 
Figure 4-16. E1A PCR screening of vICOVIR-7 
DNA was extracted from banded vMH7, vICOVIR-7MHB1, vICOVIR-7 and Ad5 wt and 
screened for contaminating wt E1A sequences, along with pICOVIR-7 and water for 
Forward 
Primer 
Reverse 
Primer 
Band with vICOVIR-7 Band with Ad5 wt 
PS1368A PS1368C No Band 636bp 
PS1368B PS1368C 636bp 636bp (misprime) 
MHp19 PS1368C 2.4kb 1.3kb 
MHp22 PS1368C 2kb No Band 
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controls. Four reactions were setup using forward primers PS1369A, vPS1368B, MHp19 
and MHp22 all with reverse primer PS1368C. A schematic of primer locations can be 
found in Figure 4-15 and predicted bands in Table 4-4.  Reactions were setup using GoTaq 
polymerase in a final volume of 50l and run for 40 cycles in a thermal cycler (as described 
in section 2.2.8 ). 10l of each reaction were analysed by agarose gel electrophoresis. 
 
 
With primer PS1368A we only predict to see a band with wt E1A, as this primer is located 
within the CR2 24 deletion. As expected no band was observed with vMH7. Clear bands 
consistent with the 636bp expected from wt E1A can be observed in both vICOVIR-7 and 
vICOVIR-7MHB1 indicating both of these virus stocks are contaminated with wt E1A 
sequences. No band was expected with the pICOVIR-7 template, however at least 4 faint 
bands between 300 and 4000bp were observed. These bands could not be matched with any 
predicted bands, and are possibility due to mispriming and because the template used was 
supercoiled, resulting in aberrant PCR products A clear band of correct size was observed 
with Ad5 wt positive control. 
Primer PS1368B spans the E1A CR2 24 deletion and therefore is predicted to detect E1A 
CR2 24 but not wt E1A. As predicted, clear bands can be observed with vMH7, 
vICOVIR-7, vICOVIR-7MHB1 and the pICOVIR-7 positive control, demonstrating these 
virus stocks contain the E1A CR2 24 deletion. A band was also observed with Ad5 wt and 
PS1368B. Although this primer was intended not to prime from the wt E1A sequence, 
previous observations have also shown that this can detect wt E1A, due to the short region 
of homology with the wt E1A sequence either side of the 24 deletion (see section 3.5). 
This band was not observed in subsequent experiments using PS1368B with Ad5 wt for 
touchdown PCR, further suggesting this band product is due to mispriming. 
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Primer MHp19 is located downstream of the left ITR and detects both the wt E1A promoter 
and the ICOVIR-7 promoter to produce bands of 1.3kb and 2.4kb, respectively. As 
expected, bands of approximately 2.4kb were observed with vMH7 and the pICOVIR-7 
positive control, demonstrating that vMH7 contains the ICOVIR-7 promoter. vICOVIR-7 
and vICOVIR-7MHB1 had a predominant band of approximately 1.3kb, demonstrating that 
both of these virus stocks are heavily contaminated with a virus lacking the full ICOVIR-7 
promoter sequence. However, this band appeared slightly smaller than the Ad5 wt band, 
suggesting this promoter region is not identical to the wt E1A promoter region. The minor 
band at approximately 500bp with vMH7 and pICOVIR-7 cannot be attributed to any 
predicted product. 
Primer MHp22 is located within the DM-1 insulator element and therefore should only 
detect the ICOVIR-7 promoter to produce a 2kb band. A band of 2kb was observed with 
vMH7, demonstrating the presence of the ICOVIR-7 promoter sequence. Bands of identical 
size were also observed with vICOVIR-7 and vICOVIR-7MHB1, suggesting both of these 
stocks also contains a virus with the ICOVIR-7 promoter sequence. As expected a clear 2kb 
band was observed with the pICOVIR-7 positive control, and no band was observed with 
Ad5 wt negative control. 
Together these results indicate that both vICOVIR-7 and vICOVIR-7MHB1 predominately 
contained genomes which do not have the E1A CR2 24 deletion, and also predominately 
contained a promoter region much shorter than the ICOVIR-7 promoter. However, the 
ICOVIR-7 promoter was still detected within these stocks. This data, in addition to the 
restriction enzyme profile, suggested that both the vICOVIR-7MHB1 and the original 
vICOVIR-7 stock from Dr R. Alemany were heavily contaminated with a virus similar to 
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Ad5 wt, but still contain some ICOVIR-7 promoter-containing virus. However, from this 
data it was not possible to identify the source or identity of the contaminating virus.  
The vICOVIR-7 vectors from Dr R. Alemany incorporate the RGD-4C insertion into the 
fibre HI loop, which introduces an extra SacII restriction site. Introduction of this site 
cleaves a 6.6kb SacII band from the Ad5 wt sequence into two 3.3kb bands. Furthermore, 
replacement of the wt E1A promoter with the ICOVIR-7 promoter increases a 3.2kb SacII 
band up to approximately 4.5kb. vICOVIR-7MHB1 was therefore digested with SacII to 
investigate both the presence of the wt E1A region, and the presence of the RGD-4C fibre. 
For an ICOVIR-7 left end and a wt fibre we predict a 4.5kb band and a 6.6kb band, for 
ICOVIR-7 left end and RGD-retargeted fibre we predict a 4.5kb band and a 3.3kb doublet, 
for a wt left end and a wt fibre we predict a 3.2kb band and a 6.6kb band and finally for a 
wt left end and RGD-retargeted fibre we predict a triplet at approximately 3.3kb.  
As shown in Figure 4-17, the last of these potential band combinations was observed. 
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Figure 4-17. SacII restriction enzyme profile of vICOVIR-7MHB1 
DNA was extracted from 100l of banded Ad5 wt and vICOVIR-7MHB1 as described in 
section 2.6.2 and digested with SacII for 16 hours. Digested samples were analysed by gel 
electrophoresis. 
 
Together with the previous evidence, this suggests vICOVIR-7 and vICOVIR-7MHB1 are 
highly contaminated with an adenovirus with a wildtype left end and an RGD-retargeted 
fibre. No virus of this composition had previously been handled in our laboratory. 
4.3.10.2 Cytotoxicity of vPS1393 vs vMH Vectors 
Towards the end of this work The University of Birmingham SCS-GT group constructed 
vPS1393, an oncolytic Ad vector with the ICOVIR-7 promoter (poly(A) site, DM-1 
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insulator and triple E2F promoter), E1A CR2 24 deletion but with a wt fibre protein, and 
no transgene. Thus vPS1393 was similar to vMH6, but without the eGFP transgene 
insertion. This vector was used to further investigate the effect of eGFP transgene insertion 
on virus induced cytotoxicity.  
The virus vPS1393 has been rescued in A549 cells, double plaque purified on DU145 cells, 
screened by PCR and confirmed free of contaminating wt E1A sequences (Dr P. Searle, 
personal communication). Following confirmation of the E1A status and restriction profile, 
I passaged a p2 seed stock once in 20x150cm
2
 flasks of A549 cells to produce a p3 seed 
stock, which was used to make a vPS1393 banded virus stock. Virus particle concentration 
was determined by PicoGreen assay and infectious virus counted by plaque assay on 
DU145 cells (5.92x10
11
 VP/ml, 2.15x10
10
 PFU/ml, P:I ratio= 27.5, Size= 103.04% of Ad5).  
 
Experiments were undertaken to examine the lytic activity of vPS1393 compared to vMH 
vectors in cancer cell lines. 96-well plates of DU145 and 22RV1 cells were infected with 
serial dilutions of vMH vectors, Ad5 wt, vPS1393 or Ad-GFP from 1x10
-1
 to 1x10
3
 
PFU/cell. Cell survival was measured 5 days post infection by AP assay, dose response 
curves plotted and EC50 values calculated. Figure 4-18 shows the dose response curves for 
Ad5 wt, vMH6, vMH7 and vPS1393, and the EC50 values for all viruses can be found in 
Table 4-5. 
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Figure 4-18. Dose response curves for vPS1393 cytotoxicity 
DU145 (A) and 22RV1 (B) cells were seeded in 96-well plates at 3x10
4
 cells per well 
before triplicate wells were infected with a serial dilution  of Ad5 wt, vMH vectors, or 
vPS1393 as described in section 2.4.8. Cell survival was measured 5 days post infection by 
AP assay and the data normalised to mock infected cells (100% survival) and empty wells 
(0% survival). Plots show mean cell survival from triplicate wells (n=1), ± S.D. (where no 
error bars are visible S.D. was <5%), with fitted sigmoid dose response curves. Dose 
response curves were used to calculated EC50 values. 
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Virus DU145 EC50 (95% C.I.) PFU/cell 22RV1 EC50 (95% C.I.) PFU/cell 
Ad5 wt 62.9 (55.0 - 71.9) 4.42 (3.68 - 5.30) 
vMH2 15.7 (14.2 - 17.3) 1.42 (1.28 - 1.57) 
vMH4 62.8 (53.5 - 73.6) 23.1 (20.1 - 26.6) 
vMH5 34.8 (28.2 - 42.9) 30.8 (25.6 - 37.1) 
vMH6 250 (190 - 320) 109 (86.4 - 138) 
vMH7 331 (231 - 475) 60.2 (42.2 – 90.0) 
vPS1393 356 (274 - 463) 31.5 (26.7 - 37.3) 
Table 4-5. EC50 values with 95% C.I. (PFU/cell) for vMH vectors and vPS1393 
 
There was no notable difference in the cytotoxicity of vMH6, vMH7 and vPS1393 in 
DU145 cells, all of which showed a 5- to 8-fold higher EC50 compared to Ad5 wt and have 
overlapping 95% confidence intervals. In 22RV1 cells both vMH6 and vMH7 showed 
similar cytotoxicities, with EC50 values 15- to 20-fold higher than Ad5 wt. In comparison, 
vPS1393 had a 5- to 10-fold lower cytotoxicity compared to Ad5 wt and showed a 2- to 3-
fold increase in cytotoxicity compared to vMH6 and vMH7.  
To further analyse the effect of eGFP introduction, the lytic activity of these vectors was 
assessed in HEK293 cells, where any variation in E1A expression between vectors will be 
eliminated, allowing a more direct comparison of the effect of transgene insertion. HEK293 
cells in 96-well plates were infected with a serial dilution for vMH vectors, Ad5wt and 
vPS1393 from 1x10
-5
 to 1x10
1
 PFU/cell (this range of MOI was used based on previous 
observations in Figure 4-11). Cell survival was measured 5 days post infection, data 
normalised, dose response curves plotted (Figure 4-19) and EC50 values calculated (Table 
4-6).  
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Figure 4-19. Dose response curves for vPS1393 cytotoxicity in HEK293 cells 
HEK293 cells were seeded in 96-well plates at 3x10
4
 cells per well before triplicate wells 
were infected with a serial dilution  of Ad5 wt, vMH vectors, or vPS1393 as described in 
section 2.4.8. Cell survival was measured 5 days post infection by AP assay and the data 
normalised to mock infected cells (100% survival) and empty wells (0% survival). Plots 
show mean cell survival from triplicate wells (n=1), ± S.D. (where no error bars are visible 
S.D. was <5%), with fitted sigmoid dose response curves. Dose response curves were used 
to calculate EC50 values. 
 
Virus HEK293 EC50 (95% C.I.) PFU/cell 
Ad5 wt 0.00470 (0.00262 - 0.00842) 
vMH2 0.0143 (0.00954 - 0.0216) 
vMH4 0.0399 (0.0240 - 0.0667) 
vMH5 0.0484 (0.0290 - 0.0808) 
vMH6 0.0584 (0.0341 - 0.0998) 
vMH7 0.0555 (0.0358 - 0.0859) 
vPS1393 0.0175 (0.0118 - 0.0259) 
Table 4-6. EC50 values with 95% C.I. (PFU/cell) for cytotoxicity in HEK293 
 
No significant difference was observed in the cytotoxicity of vMH4, 5, 6 and 7, which had 
similar EC50 values with overlapping 95% confidence intervals. vMH2 was slightly more 
cytotoxic than the other vMH vectors, with a 2- to 4- fold lower EC50 values compared to 
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the other vMH vectors. vPS1393 showed cytotoxicity equivalent to that of vMH2, and was 
approximately 3-fold more cytotoxic than the equivalent eGFP expressing vector vMH6. 
Ad5 wt was significantly more cytotoxic than all vMH vectors or vPS1393, with 3- to 13-
fold lower EC50 values. This data suggests insertion of the ICOVIR-5 or ICOVIR-7 
promoter or insertion of eGFP transgene results in a minor reduction of vector cytotoxicity. 
4.3.11 Transduction of Carcinoma Cell Lines 
In 1998 Dmitriev et al characterised the use of an RGD-retargeted adenovirus vector which 
was able to use αVβ3/5 integrin as the primary cell surface receptor, and showed increased 
uptake into CAR negative cells [Dmitriev et al,  1998]. Since then the RGD-retargeted fibre 
has been extensively and successfully used to increase transduction into CAR negative and 
low CAR cells. Two vMH vectors, vMH5 and vMH7, contain the RGD-retargeted fibre and 
were expected to display increased viral uptake compared to their wt fibre equivalents, 
vMH4 and vMH6, respectively. It was therefore necessary to demonstrate the RGD-
retargeted fibres in vMH5 and vMH7 were functional and could increase viral uptake in 
cell lines expressing low levels of CAR. 
Virus mediated transduction was assayed by eGFP expression in two CAR negative cell 
lines; SKOV3 and MZ2-MEL3.0, plus DU145 cells which expresses high levels of CAR 
(see section 4.3.1 for CAR and integrin staining). Cells in 24-well plates were infected with 
Ad-GFP, vMH4, vMH5, vMH6 and vMH7 at 10, 30 and 100 PFU/cell (as described in 
section 2.4.8). 48 hours post infection (when eGFP expression was maximal, as shown in 
Figure 4-4), wells were harvested and analysed for eGFP expression by flow cytometry. 
The experiment was repeated twice and the mean percent eGFP positive calculated, shown 
in Figure 4-20.  
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Figure 4-20. Transduction of CAR negative cells by vMH vectors 
DU145 (A and B), MZ2-MEL3.0 (C and D) and SKOV3 (E and F) cells were seeded into 
24-well plates at 1x10
5
 cells per well and infected with 10, 30 or 100 PFU/cell of vMH4 or 
vMH5 (A, C and E) and vMH6 or vMH7 (B, D and F), as described in section 2.4.8. 48 
hours post infection cells were harvested, fixed and analysed by flow cytometry. The 
experiment was repeated twice, results collated and percent eGFP positive population 
calculated. Graphs show the mean of the two experiments (n=2) ± S.D. (where no error bars 
are seen the S.D. was < 1%). 
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In DU145 cells the same level of transduction was achieved at all 3 MOI, with 
approximately 80% of the cells eGFP positive at 10 PFU/cell and >95% of cells positive at 
30 and 100 PFU/cell.  
In both MZ2-MEL3.0 and SKOV3 cells, vMH5 showed increased transduction at all MOI 
compared to the wt fibre equivalent vector vMH4 (except MZ2-MEl3.0 cells at 100 
PFU/cell, where no significant difference was observed). In both cell lines and at all 3 MOI 
vMH7 showed higher transduction efficiencies compared to the equivalent wt fibre vector, 
vMH6. 
4.3.12 Virus Dissemination in Monolayers 
In plaque assaying vMH vectors some phenotypic differences were observed, with vMH2 
showing the largest plaques, which appeared more rapidly than all other vMH vectors. To 
investigate this further, infectious centre assays were undertaken using DU145 cells to 
directly compare vMH vectors in terms of rate of plaque appearance and plaque size. 
DU145 cells were scraped into suspension and infected with 3 or 30 PFU/cell of vMH 
vectors for 90 minutes at 37
o
C. Infected cells were washed once with trypsin (to remove 
any virus which had not internalised) and once with infection medium. 120 infected DU145 
cells was mixed with 3x10
6
 uninfected DU145 cells in a final volume of 12ml of infection 
medium, which was spread equally across three 60mm plates, to achieve 40 infected cells 
and 1x10
6
 uninfected cells per plate. Cells were allowed to adhere for 8 hours before the 
medium was carefully removed and replaced with 4ml of agar overlay mixture (as in 
section 2.4.4). Every 3 days an extra 4ml of agar overlay mixture was added, and plaque 
appearance was monitored from 2 days post infection. 
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Figure 4-21. Infectious centre assays for vMH vectors in DU145 cells 
10
5
 DU145 cells were infected in suspension with 3 (A) or 30 (B) PFU/cell of vMH vectors 
for 90 minutes at 37
o
C before being washed once with trypsin and once with full culture 
medium. Infected DU145 cells were mixed at a ratio of 40:10
6
 with uninfected DU145 cells 
and plated out in triplicate onto 60mm dishes in 4 ml of culture medium. Cells were 
allowed to adhere for 8 hours before the medium was removed and replaced with overlay 
mixture. Plaques were counted from 2 to 14 days post infection. Plots show the mean of 
triplicate plates (n=1), ± S.D. 
 
Figure 4-21 shows the average number of plaques per plate from 2 to 14 days post 
infection. At both MOI, plaque appearance with vMH2 is significantly faster than other 
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vMH vectors. Little difference in the rate of plaque appearance was observed between 
vMH4, 5, 6 and 7; however both ICOVIR-7 based vectors may be very slightly slower 
compared to ICOVIR-5 based vectors. No difference was observed in the rate of plaque 
appearance between the RGD-retargeted vectors, vMH5 and vMH7, and their equivalent wt 
fibre vectors, vMH4 and vMH6, respectively. These observations were also reflected by 
assessing the plaque size at 10 days post infection via eGFP expression, imaged by 
fluorescence microscopy. Examples are shown in Figure 4-22, below. 
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Figure 4-22. Fluorescence microscopy images of representative vMH vector plaques 
Representative plaques at 10 days post infection from the infectious centre assay shown in 
Figure 4-21. Plaques were imaged by UV microscopy at 21x magnification.  
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The experiment was repeated using infected MRC5 cells mixed with uninfected DU145 
cells to further study the selective nature of vMH vectors. Any productive infection within 
the MRC5 cells would result in release of progeny infectious virus, which would 
subsequently infected surrounding DU145s, resulting in plaque formation. Furthermore, 
plaque size gives an indication of the number of infectious virus progeny released, as 
release of more infectious virus would result in more rapid formation of larger plaques. 
MRC5 cells were scraped into suspension and infected with 30 or 300 PFU/cell of vMH 
vectors for 90 minutes at 37
o
C. Infected cells were washed once with trypsin then once with 
infection medium. Infected MRC5 cells were mixed with uninfected DU145 cells and 
treated as above to achieve triplicate plaques at 40 MRC5 cells per plate. Again plaque 
appearance was monitored from 2 to 14 days post infection. 
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Figure 4-23. Infectious centre assays for vMH vectors in MRC5 cells 
10
5
 MRC5 cells were infected in suspension with 30 (A) or 300 (B) PFU/cell of vMH 
vectors for 90 minutes at 37
o
C before being washed once with trypsin and once with full 
culture medium. Infected MRC5 cells were mixed at a ratio of 40:10
6
 with uninfected 
DU145 cells and plated out in triplicate onto 60mm dishes in 4 ml of culture medium. Cells 
were allowed to adhere for 8 hours before the medium was removed and replaced with 
overlay mixture. Plaques were counted from 2 to 14 days post infection. Plots show the 
mean of triplicate plates (n=1), ± S.D. 
 
At both MOIs, vMH2 showed the fastest rate of plaque appearance with plaques first 
detected at 5 days post infection. With the remaining vMH vectors at 30 PFU/cell plaques 
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were first observed at 7 days post infection; with vMH4 and vMH5 showing more rapid 
plaque appearance, followed by vMH7 and finally vMH6. At 30 PFU/cell neither vMH6 
nor vMH7 reached 40 plaques per plate by 14 days post infection. At 300 PFU/cell there 
was no noticeable difference in the rate of plaque appearance between vMH4, 5 6 and 7; all 
of which rapidly formed plaques from 5 days post infection. This data would suggest the 
ICOVIR-7 based vectors were the most attenuated vectors in MRC5 fibroblasts, showing 
the least number of plaques at 30 PFU/cell. However this attenuation can be overcome with 
a 10-fold greater MOI.  
4.4 Discussion 
This chapter characterised the new vMH vectors and compared them to the E1B-55K 
vector vNR3. All vMH vectors and vNR3 express eGFP allowing assessment of transgene 
expression in preparation for introduction of the therapeutic transgene NTR. Experiments 
conducted in this chapter allow assessment of the vector lytic activities and tumour cell 
selectivity by calculating the therapeutic index. Western blot and rtQ-PCR demonstrated 
differential E1A protein and RNA expression with each vMH vector. Cytotoxicity 
experiments in HEK293 cells allow for the assessment of lytic activity while removing 
some of the effect of varying E1A expression. Finally, comparisons to vPS1393 allow for 
the assessment of any effect on cytotoxicity of introduction of the transgene eGFP. Each 
one of these points will be discussed in detail below. 
4.4.1 Lytic Activity and Therapeutic Index 
The lytic activity of vMH vectors was assessed in three prostate cancer cell lines and two 
non-transformed human fibroblasts. Table 4-7 ranks the cytotoxicity, therapeutic indices 
and E1A expression with vMH vectors and vNR3. In all cell lines vMH2 showed the most 
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cytotoxicity, equal to or greater than Ad5 wt. This was followed by the ICOVIR-5 based 
vectors, vMH4 and vMH5, and finally both ICOVIR-7 based vectors, vMH6 and vMH7, 
which showed the least cytotoxicity in all cells. Both RGD-retargeted vectors (vMH5 and 
vMH7) showed similar levels of cytotoxicity in prostate cancer cell lines compared to their 
wt fibre equivalents (vMH4 and vMH6). Since vMH4 and vMH5 contained the same E1A 
modifications, as do vMH6 and vMH7, and all prostate cancer cell lines express moderate 
to high levels of CAR, no difference in cytotoxicity would be expect. However, this also 
shows that introduction of the RGD-retargeted fibre does not have a detrimental effect on 
cytotoxicity in CAR positive cell lines. 
 
Virus 
Cytotoxicity to 
prostate cancer 
TI 
E1A protein 
expression 
E1A RNA 
expression 
Cytotoxicity to 
HEK293 cells 
vMH2 1 6 1 1 1 
vMH4 =2 =3 =2 =2 =2 
vMH5 =2 =3 =2 =2 =2 
vMH6 =5 =1 4 5 =2 
vMH7 =5 =1 5 6 =2 
vNR3 =2 5 Not tested =2 =2 
Table 4-7. Rank scoring from 1 - 7 (most - least) of vMH vectors 
 
Previous studies using E1A CR2 24 vectors, similar to vMH2 but without the transgene, 
have observed increased cytotoxicity in relation to Ad5 wt, in both tumour and non-growth 
arrested non-transformed cells [Bazan-Peregrino et al,  2008]. Currently, the exact reason 
for the increase in lytic activity is still not fully understood. A recent report has 
demonstrated E1A CR2 24 viruses induce a novel non-apoptotic non-necrotic mode of 
cell death, which may be responsible for the increase in cytotoxicity. Speculations have also 
been made that by deleting the CR2 region and preventing the ability to bind to any pRb, 
more E1A is free to perform other functions which increase the rate of replication.  
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Concerns were raised in section 1.2.4.4.2 that replacement the wt E1A promoter with an 
E2F responsive promoter, in the context of a virus with a wt E4 region, may replace the E1-
E4 negative feedback loop with a positive feedback loop, resulting in reduced attenuation in 
non-transformed cells. Contrary to this idea, both ICOVIR-5 and ICOVIR-7 based vectors 
show reduced E1A RNA and protein expression at early timepoints (up to 24 hours post 
infection), compared to Ad5 wt. However, vMH4, 5 and 6 do possibly expresses more E1A 
protein at later timepoints (36 to 60 hours post infection), potentially suggested a positive 
feedback loop at late times of infection.  
 
For all the viruses used the therapeutic index was calculated to give an indication of the 
relative tumour selectivity (summarised in Table 4-7). In all cell lines the ICOVIR-5 and 
ICOVIR-7 based vectors (vMH4, 5, 6 and 7) had higher TI than the wt E1A promoter, E1A 
CR2 24 virus, vMH2, and the E1B-55K virus vNR3. Thus despite reduction of lytic 
activity observed with these vectors, replacement of the wt E1A promoter with the 
ICOVIR-5 or ICOVIR-7 promoter does increase the tumour selectivity. In DU145 and 
22RV1 cells vMH4 had the highest TI, followed by both ICOVIR-7 based vectors. Whereas 
in PC3 cells both ICOVIR-7 vectors had the highest TI, followed by both ICOVIR-5 based 
vectors (shown in Figure 4-3). It is essential to note the TI values used underestimate the 
actual selectivity of the ICOVIR-7 based vectors. A large variation of TI was observed 
across the three prostate cancer cell lines, probably due to the varying p53, pRb and E2F 
status (summarised in Table 4-8) plus the different levels of CAR and integrin expression. 
However there was no direct correlation p53 and pRb status and the lytic activity of the 
CRAd vectors and E2F expression levels are high in all three cell lines. Furthermore, in 
both 22RV1 and DU145 cells Ad5 wt showed higher TI than all other vectors, probably due 
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to the fact the MRC5 cells were not growth arrested. If the fibroblasts were growth arrested 
it would be anticipated the CRAd vectors would show higher TI than Ad5 wt, in both of 
these cell lines. 
 
Cell line 
p53 
status 
pRb 
status 
E2F 
levels 
Surface 
CAR 
Surface 
αVβ3 
Surface 
αVβ5 
Reference 
DU145 Mutant Mutant High High No High 
[Sun et al, 
2007; 
Supiot et 
al, 2008] 
22RV1 wt wt High High Moderate High 
[Sun et al,  
2007; 
Supiot et 
al,  2008] 
PC3 Null wt High Moderate No High 
[Sun et al,  
2007; 
Supiot et 
al,  2008] 
Table 4-8. p53, pRb, E2F and Ad receptor levels of prostate cancer cell lines 
 
Cytotoxicity experiments in HEK293 cells provide wt E1A, constitutively present, thus are 
expected to remove some of the E1A associated reduction in lytic activities and provide a 
more level „playing-field‟. Cytotoxicities of vMH vectors in HEK293 cells show 
replacement of the natural E1A promoter by either the ICOVIR-5 promoter or ICOVIR-7 
promoter results in a slight reduction in lytic activity. However, no significant difference 
was observed in lytic activities between vMH4, vMH5, vMH6 and vMH7. These results 
may suggest the reduction in cytotoxicities observed with ICOVIR-5 and ICOVIR-7 based 
vectors compared to vMH2, was a due to the increase in genome size. Concerns were also 
raised previously, whereby the increase in vector genome size may result in an increase in 
P:I ratio (discussed in section 3.6.2). However, the ICOVIR based vectors contain E1A 
under control of an E2F responsive promoter, not the wt E1A promoter. Normally in Ad 
infection E1A expression is down-regulated at late times, however this would not be the 
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case with either E2F responsive promoter. Therefore despite HEK293 cells supplying wt 
E1A, all the ICOVIR based vectors would be expected to express more E1A than vMH2 in 
HEK293 cells, at late times of infection. Thus the differential cytotoxicities observed in 
HEK293 cells may not be entirely due to the difference in vector genome size. However in 
my opinion it is likely the increase in vector genome size would contribute at least in part to 
the reduction in lytic activities observed with vMH4, 5, 6 and 7, compared to vMH2.  
4.4.2 E1A Expression in vMH Viruses 
Replacement of the natural E1A promoter with the ICOVIR-5 or ICOVIR-7 promoter 
results in reduced E1A expression at both the RNA and protein level (Figure 4-7 and Figure 
4-8, respectively), which was associated with a subsequent reduction in virus cytotoxicity 
(Figure 4-11). Despite this, the tumour specific promoters do increase the tumour 
specificity of the viruses as has been discussed in section 4.4.1. Notably, vMH2 produced 
more E1A RNA and protein than Ad5 wt at early timepoints (4 and 8 hours post infection), 
which may contribute to the increased cytotoxicity observed with vMH2 over Ad5 wt.  
 
Interestingly, the RGD-retargeted virus vMH7 produces less E1A RNA and protein than the 
equivalent wt fibre vector, vMH6, both of which have the E1A promoter replaced with the 
same ICOVIR-7 promoter. Moreover, vMH7 shows an 8-10 hour delay in the onset of 
DNA replication, presumably due to the reduced level of E1A expression, which 
subsequently delayed the start of transgene and late protein expression. This delay can be 
almost completely eliminated in HEK293 cells, further demonstrating the delayed DNA 
replication, late protein and transgene expression, was a result of reduced E1A expression. 
The ICOVIR-7 promoter has been fully sequenced in both vMH6 and vMH7, from 100bp 
upstream of the DM-1 insulator element to 100bp into the E1A ORF, and was shown to be 
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identical to each other, and to the sequence in pICOVIR-7 used for recovery for both 
vectors (see section 4.3.8). Thus the differential E1A expression observed with vMH6 and 
vMH7 was not due to unintentional promoter mutations. Sequence of the ICOVIR-7 
promoter did reveal unexpected differences from the predicted sequence at 5 points within 
the ICOVIR-7 promoter sequence (see appendix 2 for sequence). Analysis of the cloning 
pathway used for construction of pICOVIR-7 demonstrated all of these mutations were at 
the cloning junction between the various promoter components (i.e. the DM-1 insulator 
element, E2F-1 promoter region, and the two additional E2F-1 binding regions) [Majem et 
al,  2006; Rojas et al,  2009], and were therefore likely to be accidently introduced during 
the cloning of pICOVIR-7. It is therefore possible, but in my opinion very unlikely, these 
mutations would affect the promoter activity. Despite this, the promoter regions from 
vMH6 and vMH7 are identical, therefore these mutations would not account for the 
differential E1A expression. The pICOVIR-7 cloning pathway describes the ICOVIR-7 
promoter as having a poly(A) site, followed by the DM-1 insulator and the E2F-1 promoter 
with the two additional E2F-1 binding regions. It is worth noting the ICOVIR-7 promoter 
sequencing results show a AATAAA poly(A) consensus sequence between the E2F-1 
promoter and DM-1 insulator element, i.e. following the DM-1 insulator elements 
(including the CTG repeats sequences and GC rich regions) (as marked in appendix 2). 
Additionally, no clear poly(A) consensus sequence was apparent upstream of the DM-1 
insulator. 
 
The exact reason behind the differential expression observed between vMH6 and vMH7 is 
currently not known. Both vectors were screened by PCR for contaminating wt E1A 
sequences. However it is probably first advisable to screen banded batches of viruses for 
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the presence of wt E1A sequences by Q-PCR. The restriction profiles of both vectors 
showed they contained the correct ICOVIR-7 promoter sequence. However it is worth 
noting no vectors were screened by PCR for the presence of the wt E1A promoter, using a 
primer situated within the deleted promoter region. It is therefore also first advisable to 
screen batches of virus by PCR for the presence of the wt E1A promoter, which could have 
been acquired through recombination with the adenovirus sequences in HEK293 cells (used 
for virus rescue). The differential E1A protein expression observed appeared proportional 
to the observed differences in the E1A RNA levels, suggesting the differential is not due to 
post-translation effects. There are several possible explanations for the difference in E1A 
RNA expression observed. vMH7 could have acquired an unintentional mutation during the 
recovery of this virus which had a detrimental effect on E1A expression. Conversely vMH6 
could have acquired an unintentional mutation which enhanced E1A expression. Such 
mutations could be within; gene(s) that could effect transcription from the ICOVIR-7 
promoter (such as E4orf6/7), the regions surrounding the promoter region which might 
effect transcription (such as with the enhancer elements upstream of the DM-1 insulator 
element) or within regions affecting E1A mRNA stability (such as within the E1A ORF). 
At the end of this study the entire genomes of vMH6 and vMH7 were sent away for 
sequencing, to try and identify a mutation which might explain the difference in E1A 
expression. However, at the time of writing the results from the genome sequencing had not 
yet arrived. If any mutation was observed which could affect E1A expression then specific 
experiments would have to investigate the mutation. Assuming there are no mutations 
within either genome it is possible the differential E1A expression observed was due to a 
direct or indirect interaction between the ICOVIR-7 promoter and the RGD-retargeted 
fibre. No difference in E1A expression was observed between vMH4 (wt fibre) and vMH5 
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(RGD-retargeted fibre). Both of there vectors incorporate the ICOVIR-5 promoter, which is 
very similar to ICOVIR-7. Therefore, in my opinion, it seems unlikely the reduced E1A 
expression observed with vMH7 is due to insertion of the RGD-4C motif. Further 
possibilities exist such as; delayed endosomal escape, virus unpackaging or nuclear 
trafficking with vMH7, however these seem unlikely since the delay in DNA replication 
can be eliminated using HEK293 cells.  
4.4.3 Effect of Transgene Insertion 
At the start of this project no reports were published using either ICOVIR-5 or ICOVIR-7 
based vectors. Since then several reports have been published using an ICOVIR-5 based 
vector [Alonso et al,  2007a; Alonso et al,  2007b; Cascallo et al,  2007] and one report 
using an ICOVIR-7 based vector [Rojas et al,  2009]. The ICOVIR-5 reports generally 
demonstrated a potent anti-glioma effect and low systemic toxicities in in vivo mouse 
models. Furthermore restoration of pRb function led to down-regulation of E1A and a 
dramatic reduction in adenovirus replication. The ICOVIR-7 paper reported greater anti-
tumour potency compared to Ad5 wt in subcutaneous xenografts treated by intravenous 
injection and low liver toxicity in mouse models.  
During this work it was suggested introduction of the eGFP transgene into the ICOVIR-7 
background may result in reduced lytic activity. Direct comparison between vMH vectors 
and vICOVIR-7 were attempted; unfortunately these comparisons were invalidated by the 
discovery that the vICOVIR-7 stock was heavily contaminated with a virus having a 
restriction enzyme profile similar to Ad5 wt, but apparently with the RGD-retargeted fibre. 
In comparison of vMH6 with vPS1393 (an ICOVIR-7 based vector lacking eGFP transgene 
with wt fibre), showed a slight decrease in cytotoxicity in 22RV1 cells (2- to 3- fold), 
associated with transgene insertion, however no significant difference in DU145 cells. 
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Experiments in HEK293 cells also showed approximately a 3-fold reduction in cytotoxicity 
of vMH6 compared to vPS1393, associated with eGFP transgene insertion. These results 
suggest introduction of eGFP does result in a minor reduction of oncolytic activity. There 
are three possible explanations for the reduction in cytotoxicity observed by eGFP 
introduction; the increase in genome size is having a direct negative effect on vector 
cytotoxicity, a direct „toxic‟ effect of the eGFP transgene or the transgene insertion results 
in specific problem for expression of virus proteins such as fibre and the E4 region.  
Unfortunately from the data here it is not possible to identify which of these factors is 
responsible for the reduced cytotoxicity, thus further experiments would be required to 
identify how much each factor is contributing to this observation. 
4.4.4 RGD-Retargeted Fibre 
The RGD-retargeted fibre has been used in multiple studies for nearly 10 years and 
therefore is not novel in this study. This mutation has been well characterised and shown to 
increase binding to cells expressing low amounts of CAR, by directly using αVβ3/5 integrins 
as the primary cell surface attachment receptor [Dmitriev et al,  2002]. I have demonstrated 
that both vMH5 and vMH7 show increased transduction in cells expressing low levels of 
CAR, in comparison to the equivalent wt fibre vectors; vMH4 and vMH6, respectively. 
In all prostate cancer cell lines no growth advantage was observed with the RGD-retargeted 
viruses in comparison to their wildtype fibre equivalents, either in a single replication cycle, 
or in plaque assays which require multiple cycles of replication and cell-to-cell spread. 
Furthermore no transduction advantage was observed with the RGD-retargeted vectors in 
DU145 cells. These observations would fit in line with previous studies that have also seen 
little or no transduction advantage in the PC3 [Work et al, 2004] and DU145 cells [Rajecki 
et al, 2007]. All the prostate cell lines tested in this study express moderate to high levels of 
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CAR on their cell surface, which would probably not be saturated by the range of MOI used 
here. Of all the cell lines tested PC3 express the lowest amount of CAR and are therefore 
most likely to show any advantage with the RGD-retargeted fibre. Indeed with PC3 cells a 
very slight increase in cytotoxicity was observed with the RGD-retargeted vectors, however 
the decrease in EC50 values was not significant. Despite this no specific disadvantage was 
conferred by introduction of the RGD-retargeted fibre in CAR positive cells. Whereas 
previous reports have shown some CAR expression in prostate carcinoma samples, there 
does seem to be a general down-regulation CAR expression compared to normal tissue, 
especially in higher grade tumours [Rauen et al, 2002]. Therefore although the RGD-
retargeted fibre may not confer an in vitro increase in cytotoxicity, a cytotoxic advantage 
may still be observed in prostate cancer patients. 
4.4.5 Virus Dissemination in Monolayers 
Virus spread is an important factor in the in vivo efficacy of gene therapy vectors. An ideal 
gene therapy vector should be able to spread rapidly throughout the tumour tissue but be 
unable to replicate in normal non-carcinoma cells. Of all vMH vectors, vMH2 is clearly the 
quickest at spreading through prostate cancer monolayer cultures. However significant 
normal cell toxicity was also observed, as demonstrate by the rapid spread from MRC5 
cells in infectious centre assays. Little difference was observed in the spread of vMH4, 
vMH5, vMH6 and vMH7 through prostate cancer monolayers. Despite this, vMH6 and 
vMH7 show a reduce spread and plaque formation from MRC5 cells in infectious centre 
assays, at the lowest MOI tested (30 PFU/cell). These two vectors should therefore be able 
to spread throughout tumour tissue as efficiently as vMH4 and vMH5, but stop spreading 
when normal tissue is reached. 
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There was no difference in the speed of virus spread between RGD-retargeted vectors and 
matched wt fibre vectors, probably due to the high levels of CAR expressed on both DU145 
and MRC5. 
4.5 Summary 
I have characterised 6 new CRAd vectors for oncolytic virotherapy of prostate cancer. 
From all vectors tested the ICOVIR-7 vectors possess the highest therapeutic index in 
prostate cancer cell lines. As might be expected, replacement of the wt E1A promoter does 
result in lower E1A expression at both the RNA and protein level. The increase in genome 
size caused by the replacement of the E1A promoter by either the „ICOVIR-5 promoter‟ or 
„ICOVIR-7 promoter‟ may cause a decrease in lytic activity, as does introduction of the 
therapeutic transgene eGFP. However no reduction in lytic activity is observed between 
ICOVIR-5 and ICOVIR-7 based vectors attributed to the increase in genome size. Both 
RGD-retargeted vectors show increased transduction of CAR negative cell lines. 
 
Based on these data the ICOVIR-7 based vectors were selected for the introduction of the 
therapeutic transgene NTR and NTR variants. 
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CHAPTER 5   
 
Characterisation of NTR Expressing 
Vectors 
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5.1 Introduction 
As described in CHAPTER 3 novel oncolytic CRAd viruses expressing eGFP were 
constructed, based on the ICOVIR vectors from Dr R. Alemany‟s lab at the Institut Catalá 
d‟Oncologia. These vectors were expected to be more tumour selective than the E1A CR2 
24 vector with a wt E1A promoter, displaying cytotoxicity in cancer cell lines while 
avoiding toxicity to normal non-transformed cells.  
These vectors were characterised in CHAPTER 4 to identify the most tumour selective 
vectors for the introduction of NTR. The ICOVIR-7 based vectors, vMH6 and vMH7, were 
the most tumour selective, showing no toxicity to primary human fibroblasts, thus the 
ICOVIR-7 backbone was chosen for introduction of the therapeutic transgene NTR. The 
new NTR vectors were constructed prior to full characterisation of vMH6 and vMH7. 
Therefore NTR was inserted into both RGD-retargeted and wt fibre vectors, while bearing 
in mind a potential difference in E1A expression. 
The latest clinical trials with enzyme/prodrug systems utilise mutant enzymes which have 
increased catalytic activity for their specific substrate [Barton et al,  2008]. Two recent 
reports from The University of Birmingham SCS-GT group have identified novel nfsB NTR 
mutants which are catalytically enhanced for CB1954 reduction [Guise et al,  2007; 
Jaberipour et al,  2010]. The double NTR mutant T41L N71S showed a 14-fold increase in 
CB1954 sensitisation over wt NTR when expressed in a replication deficient Ad vector. 
The second variant is the triple NTR mutant T41Q N71S F124T, which showed up to 80-
fold increase in CB1954 sensitisation over wt NTR when expressed in a replication 
deficient Ad vector. It was therefore decided to introduce both NTR mutants, as well as wt 
NTR, into the ICOVIR-7 backbone, in order to improve the NTR mediated cytotoxicity. 
 210 
Six new NTR expressing ICOVIR-7 based vectors were constructed, combining the RGD-
retargeted and wt fibre with the three NTR variants: wt NTR, double mutant NTR and triple 
mutant NTR. 
5.2 Aim of Chapter 
The aim of this chapter was to characterise new ICOVIR-7 based oncolytic vectors 
expressing NTR and NTR mutants. Vectors were compared with vNR6, an E1B-55K 
deleted vector expressing NTR from the pIX virus promoter, in terms of virus replication, 
gene expression and lytic activity, alone or in combination with the prodrug CB1954, to 
identify the optimal vector for the treatment of prostate cancer. 
5.3 Construction of NTR Expressing ICOVIR-7 Vectors 
Figure 5-1 shows a schematic of the 6 NTR expressing ICOVIR-7 based vectors (vPS1361-
vPS1366, collectively referred to as vPS136X), along with the E1B-55K, pIX, NTR 
expressing vector vNR6. All vPS136X vectors contain the E1A CR2 24 deletion and have 
the E1A promoter replaced by the ICOVIR-7 promoter (described in section 3.3), derived 
from the same modified E1A plasmid pICOVIR-7. vPS1361, vPS1363 and vPS1365 
encode the RGD-4C sequence introduced into the fibre knob HI-loop. 
All vPS136X vectors express NTR (wt or mutant) from the MLP via an upstream splice 
acceptor site, inserted directly downstream of the fibre gene, and have a Kozak sequence 
directly before the translation start site. Thus the organisation of NTR expression in 
vPS136X vectors is the same as eGFP expression in vMH vectors. 
vPS1361 and vPS1362 express the wt NTR gene, encoded by the E.coli nfsB gene [Michael 
et al, 1994]. vPS1363 and vPS1364 express T41L N71S double NTR mutant and vPS1365 
and vPS1366 express the T41Q N71S F124T triple NTR mutant.  
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Figure 5-1. Schematic of vPS136X Vectors 
vNR6 has the E1B-55K deletion and has the pIX ORF replaced by the wt NTR ORF. All 
vPS136X vectors have the E1A CR2 24 deletion; the wt E1A promoter replaced by the 
ICOVIR-7 promoter and are designed to express an NTR variant from a splice acceptor site 
downstream of the fibre ORF. vPS1361 and 2 encode wt NTR, vPS1363 and 4 encode 
T41L N71S double mutant (2m) NTR and vPS1365 and 6 encode the T41Q N71S F124T 
triple mutant (3m) NTR. vPS1361, 3 and 5 also have the RGD-4C motif inserted into the 
HI-loop of the fibre knob. 
 
All vPS136X vectors were constructed following the same cloning pathway used for the 
construction of vMH6 and vMH7 (as described in CHAPTER 3 ). Due to time limitations, 
the cloning and recovery of NTR expressing viruses was performed by Dr P. Searle and E. 
Hodgkins. 
Briefly, the entire ORF from NTR (wt and mutants) was amplified by PCR using primers 
PS1300A and PS1300B (described in Table 2-1). Primers PS1300A and PS1300B are 
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similar to MHp001 and MHp002, with the eGFP complementary sequence replaced by 
NTR complementary sequence.  
The purified NTR fragments were cloned into pNKfibreRGD to give pPS1300F, G, H 
before the NTR sequences confirmed by DNA sequencing and all three pPS1300 plasmids 
recombined with pPS1344G8. Since pPS1344G8 contains the wt fibre, whereas pPS1300F, 
G and H contain the RGD-retargeted fibre, the same recombination generated plasmids with 
either wt or RGD-retargeted fibre which were discriminated between via a SacII digest 
(since the RGD-4C insertion introduced an additional SacII site). The resulting plasmids 
with RGD fibre were pPS1300Q1, R1 and S1, while those with wt fibre were pPS1300Q20, 
R20 and S7 (with wt NTR, double mutant and triple mutant NTR, respectively). These 
plasmids were used in virus rescue with pICOVIR-7 via homologous recombination in 
HEK293 cells, to generate 1
o
 seed stocks. All subsequent passages were performed in A549 
cells. 
All vectors were double plaque purified in DU145 cells, and all subsequent passages were 
performed in A549 cells. P1 seed stocks were screened for contaminating viruses which 
may have recovered the wt E1A region (from the HEK293 cells) or rearranged the NTR 
insert. Screening was performed by E. Hodgkins using the methods described in section 3.5. 
Following screening the p1 seed stocks were used to generate p2 seed stocks. The sequence 
of the NTR insert and 50bp of flanking sequence was verified by Dr P. Searle either from 
the p1 DNA or the final CsCl banded stock. 
 
I used p2 seed stocks to infect 20x150cm
2
 tissue culture flasks of A549 cells. Upon 
complete CPE, flasks were harvested and virus CsCl banded. DNA was extracted from each 
p3 banded stock and restriction enzyme profile confirmed with HindIII, BglII, and KpnI 
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(performed by E. Hodgkins, data not shown). Restriction profiles for all viruses were as 
predicted, confirming they had not undergone any major re-arrangements. 
Following restriction enzyme profiling, virus particle concentration was determined by 
PicoGreen assay and infectious virus particles counted by plaque assay. Table 5-1 shows 
the results of virus particle count, plaque count, P:I ratio and the genome size expressed as 
percentage of Ad5 wt. 
All banded virus stocks were greater than 1x10
11
 particles/ml and possessed acceptable P:I 
ratios below 110. These batches of p3 banded viruses were used in all subsequent 
experiments for vPS136X characterisation. 
 
Virus Mutations 
Particle count 
(VP/ml) 
Plaque count 
(PFU/ml) 
P:I ratio 
Percentage 
size of Ad5 
wt genome  
vNR6 
pIX, wt NTR, 
wt fibre 
2.89x10
11
 4.50x10
9
 64.2 93.30 
vPS1361 
wt NTR,  
RGD fibre 
3.41x10
11
 3.70x10
9
 92.2 105.07 
vPS1362 
wt NTR,  
wt fibre 
5.50x10
11
 1.20x10
10
 45.8 105.00 
vPS1363 
2m NTR,  
RGD fibre 
1.62x10
12
 2.60x10
9
 62.3 105.07 
vPS1364 
2m NTR,  
wt fibre 
3.79x10
11
 3.50x10
9
 108.2 105.00 
vPS1365 
3m NTR,  
RGD fibre 
1.41x10
12
 1.33x10
10
 105.4 105.07 
vPS1366 
3m NTR,  
Wt fibre 
1.13x10
12
 3.00x10
10
 34.7 105.00 
Table 5-1. Particle count, plaque count and P:I ratios of NTR expressing vectors 
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5.4 Results 
5.4.1 vPS1361 and vPS1362 DNA replication 
Previous investigations with the ICOVIR-7 based eGFP expressing vectors vMH6 and 
vMH7 showed that the RGD-retargeted version, vMH7, has delayed E1A expression 
resulting in a delay in DNA replication and late gene expression. It was therefore decided to 
investigate the DNA replication of the RGD-retargeted vector vPS1361 and the wt fibre 
vector vPS1362, which contain the same wt NTR transgene, to see if the same delay 
occurred.  
DU145 cells seeded in 24-well plates were infected with vPS1361, vPS1362 or Ad5 wt at 
100 VP/cell (as described in section 2.4.8). At timepoints between 0 and 48 hours post 
infection duplicate wells from each infection were harvested, DNA extracted and Q-PCR 
performed for virus and cell DNA.  
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Figure 5-2. DNA replication profile of vPS1361 and vPS1362 
DU145 cells were seeded at 1x10
5
 cells per well in 24-well plates and duplicate wells were 
infected with Ad5 wt, vPS1361 or vPS1362 at 100 VP/cell as described in section 2.4.8. 
Duplicate wells were harvested at timepoints from 4 to 48 hours post infection, DNA 
extracted, and Q-PCR performed for viral genomes and cellular DNA. Virus genome copies 
were normalised to cellular DNA copies. Graph shows the mean of duplicate wells (n=1), ± 
S.D. (where no error bars are visible S.D. was <5%) 
 
Figure 5-2 shows the virus DNA replication profile, expressed as virus copy number 
normalised to cell number. For both vPS1361 and vPS1362 the virus DNA replication 
profile closely matched that of Ad5 wt, which was similar to that seen previously (Figure 
4-6). DNA replication began between 8 and 16 hours post infection, reaching maximal 
levels of DNA at 36 hours post infection. The delay previously observed with vMH7 is not 
apparent in vPS1361 which expresses RGD-retargeted fibre and wt NTR.  
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5.4.2 Cytotoxicity of vPS136X Vectors 
The oncolytic activity and replication selectivity of vPS136X vectors was assessed in 
prostate cancer cell lines and the primary human fibroblast line MRC5. Work in previous 
chapters has shown ICOVIR-7 based vectors to be the most selective for prostate cancer 
cells. Therefore it was necessary to establish that the same level of selectivity had been 
maintained after replacement of eGFP with the therapeutic transgene NTR. Initial 
experiments were conducted using a wide range of MOI. Based on this data a second round 
of experiments was conducted with a narrower range of MOI which were anticipated to 
show a clear dose response.  
Prostate cancer cells lines DU145, PC3 and 22RV1 and MRC5 human lung fibroblasts 
plated in 96-well plates were infected with 10-fold dilutions of Ad5 wt, Ad-GFP, vNR6 or 
vPS136X vectors between 1x10
-2
 and 3x10
3
 PFU/cell (as described in section 2.4.8). Cell 
survival was measured 5 days post infection by AP assay and data normalised against mock 
infected cells (100% viability) and empty wells (0% viability). Sigmoid dose response 
curves are shown in Figure 5-3, with EC50 values in Table 5-2. 
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(C) PC3
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Figure 5-3. Dose response curves for vPS136X cytotoxicity 
DU145 (A), 22RV1 (B), PC3 (C) were seeded in 96-well plates at 3x10
4
 cells per well and 
MRC5 (D) were seeded in 96-well plates at 1x10
4
 cells per well. Triplicate wells were 
infected with a serial dilution of Ad5 wt, Ad-GFP, vNR6 and vPS136X vectors as described 
in section 2.4.8. Cell survival was measured 5 days post infection by AP assay and 
normalised to mock infected cells (100% survival) and empty wells (0% cell survival). 
Plots show mean cell survival, ± S.D. (where no error bars are visible S.D. was <5%), 
where n=3 for each data point and fitted sigmoid dose response curves. GraphPad software 
was used to calculate error bars, dose response curves and EC50 values. A schematic of 
each NTR expressing CRAd can be seen in Figure 5-1. 
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Virus DU145 22RV1 PC3 MRC5 
Ad5 wt 
3.37 
(3.11 – 3.66) 
0.453 
(0.416 - 0.494) 
14.6 
(11.6 - 18.4) 
236 
(151 – 370) 
Ad-GFP >3000 >3000 >3000 >3000 
vPS1361 
17.5 
(15.8 - 19.4) 
6.38 
(4.94 - 8.23) 
38.7 
(30.6 - 49.1) 
1020 
(657 - 1580) 
vPS1362 
7.85 
(6.75 - 9.12) 
1.77 
(1.25 - 2.51) 
20.5 
(17.9 - 23.5) 
2250 
(1750 - 2910) 
vPS1363 
18.7 
(15.6 - 22.4) 
8.45 
(4.15 - 17.2) 
33.3 
(23.9 - 46.5) 
3180 
(1530 - 6640) 
vPS1364 
3.96 
(3.37 - 4.64) 
0.878 
(0.625 - 1.23) 
11.0 
(9.34 - 12.9) 
1495 
(1120 - 2000) 
vPS1365 
16.5 
(15.1 - 18.2) 
4.97 
(3.74 - 6.61) 
19.5 
(14.2 - 26.6) 
709 
(591 – 851) 
vPS1366 
78.4 
(65.5 - 93.9) 
10.4 
(6.69 - 16.2) 
237 
(122 - 463) 
4160 
(2400 - 7200) 
vNR6 
21.0 
(18.3 - 24.0) 
0.987 
(0.831 - 1.17) 
8.28 
(5.74 - 11.9) 
375 
(262 – 538) 
Table 5-2. EC50 values with 95% C.I. (PFU/cell) for vPS136X induced cytotoxicity  
 
With only one exception, all vPS136X vectors were less cytotoxic than Ad5 wt in all 4 cell 
types, with a range of EC50 values 2- to 23-fold fold lower than Ad5 wt. This wide range of 
cytotoxicity is unexpected, as they all have the same oncolytic backbone (i.e. the same E1A 
modification). However, a pattern of cytotoxicity can be observed in all prostate cancer cell 
lines, whereby vPS1364 is the most oncolytic and vPS1366 is the least oncolytic vector. 
Lytic activity of the remaining vPS136X vectors fall in-between vPS1364 and vPS1366, 
however vPS1362 and vPS1365 are consistently more cytotoxic than vPS1361 and 
vPS1363. The cytotoxicity of vNR6 is equivalent to that of vPS1364 in 22RV1 and PC3 
cells, but is almost 10-fold less lytic than vPS1364 in DU145 cells. 
In MRC5 cells vPS1365 was the most lytic vector (3-fold lower than Ad5 wt), followed by 
vPS1361, vPS1364, vPS1362 and vPS1363 (4-, 6-, 9- and 13-fold lower than Ad5 wt, 
respectively); with vPS1366 is the least cytotoxic to MRC5 cells, with an EC50 value 18-
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fold lower than Ad5 wt. All vPS136X vectors were significantly more cytotoxic to both 
prostate and MRC5 cells than would be anticipated from the equivalent data with vMH6 
and vMH7 (see section 4.3.2).  
The therapeutic index of each vector was calculated to assess the tumour selectivity (Figure 
5-4). 
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Figure 5-4. Therapeutic index values for vPS136X vectors 
The therapeutic index for each virus was calculated in DU145, 22RV1 and PC3 cells by 
dividing the MRC5 EC50 value by the target prostate cell line EC50 value.  
 
A large variation in TI can be observed across the range of vPS136X vectors. However in 
all three prostate cell lines vPS1364 had the highest therapeutic index, followed by 
vPS1362, both of which were the only vectors to have TI consistently higher than vNR6 
and Ad5 wt.  
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Since each vector has the same oncolytic backbone, i.e. the same E1A modifications, it was 
anticipated that all RGD-retargeted vectors would have similar oncolytic activities and TI 
values, as would all wt fibre vectors. Only vPS1366 showed EC50 values similar to those 
previously observed with vMH6 and vMH7, while the other vPS136X vectors were 
significantly more cytotoxic. Furthermore, whereas no vMH vector had TI greater than Ad5 
wt in DU145 and 22RV1 cells (see Figure 4-3), both vPS1362 and vPS1364 show TI higher 
than that of Ad5 wt.  
5.4.3 vMH6/7 vs vPS136X Vectors 
If cytotoxicity was entirely due the lytic activity of the virus, all vPS136X vectors would be 
expected to show lytic activities similar to that of vMH6 and vMH7. However all vPS136X 
vectors, with the exception of vPS1366, demonstrated EC50 values lower than were 
previously observed with vMH6 and vMH7. To directly compare the lytic activities of 
vPS136X vectors with vMH6 and vMH7, virus induced cytotoxicity was measured in 
DU145. Cells in 96-well plates were infected with 1x10
-2
 to 3x10
2
 PFU/cell of Ad5 wt, Ad-
GFP, vMH6, vMH7 and vPS136X vectors (as described in section 2.4.8) and cell survival 
measured 5 days post infection by AP assay. Dose response curves are shown in Figure 5-5 
and EC50 values in Table 5-3. 
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Figure 5-5. Cytotoxicity of vPS136X vs vMH6 and vMH7 in DU145 cells. 
DU145 cells were seeded in 96-well plates at 3x10
4
 cells per well. Triplicate wells were 
infected with serial dilutions of Ad5 wt, Ad-GFP, vMH6, vMH7 and vPS136X vectors as 
described in section 2.4.8. Cell survival was measured 5 days post infection by AP assay 
and normalised to mock infected cells (100% survival) and empty wells (0% cell survival). 
Plots show mean cell survival from triplicate wells (n=1), ± S.D. (where no error bars are 
visible S.D. was <5%), and fitted sigmoid dose response curves. Dose response curves were 
used to calculate EC50 values. 
 
Virus EC50 values (95% C.I.) 
Ad5 wt 2.37 (2.18 - 2.57) 
Ad-GFP >3000 
vMH6 55.4 (42.6 - 71.9) 
vMH7 80.8 (62.0 – 106) 
vPS1361 25.6 (23.5 - 27.9) 
vPS1362 11.2 (9.64 - 13.1) 
vPS1363 9.67 (8.19 - 11.4) 
vPS1364 5.73 (4.88 - 6.72) 
vPS1365 8.46 (7.36 - 9.72) 
vPS1366 83.6 (62.8 – 111) 
Table 5-3. EC50 values with 95% C.I. (PFU/cell) for vPS136X vs vMH6 and vMH7 
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As was previous observed in section 4.3.2, vMH6 and vMH7 show a greater than 20-fold 
reduction in lytic activity compared to Ad5 wt. vPS1366 shows cytotoxicity equivalent to 
vMH6 and vMH7, with no significant difference in the EC50 values. All other vPS136X 
vectors have EC50 values between that of vMH7 and Ad5 wt, with a range of EC50 values 
2-10 fold lower than vMH6 and vMH7. 
5.4.4 vPS136X NTR Expression 
The experiments above demonstrated the vPS136X vectors were significantly more 
cytotoxic than equivalent eGFP expressing vectors vMH6 and vMH7. This observation 
could be explained by high levels of NTR expression, resulting in additional „background‟ 
cytotoxicity. It was therefore decided to investigate the level of NTR expression in 
vPS136X vectors and vNR6 by western blot. 24-well plates of DU145 cells were infected 
with 10 PFU/cell of vNR6 or vPS136X vectors as described in section 2.4.8. Total protein 
was harvested at 16, 24 and 48 hours post infection and prepared for western blotting. Blots 
were probed for NTR and β-tubulin (loading control) using unconjugated primary 
antibodies with appropriate species-specific HRP-labeled secondary antibodies (all 
described in section 2.8). Recombinant purified NTR produced in E.coli (kindly donated by 
Dr S. Vass) was analysed alongside to act as a positive control and reference sample.  
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Figure 5-6. Western blot of NTR expression in vPS136X and vNR6  
DU145 cells seeded at 1x10
5
 cells per well in 24-well plates were infected with 10 PFU/cell 
of vNR6 or vPS136X vectors as described in section 2.4.8. Total protein was harvested 
from wells at 24 (A) and 48 (B) hours post infection, 2.5ng of each sample separate by 
SDS-PAGE and western blotted, as described in section 2.8. Blots were probed for NTR 
and β-tubulin expression (loading control).  
 
No NTR expression was observed with any vector at 16 hours post infection (data not 
shown). Figure 5-6 shows the western blots at 24 and 48 hours post infection for all 
vPS136X vectors and vNR6. Clear NTR expression was observed with vNR6 at 24 hours 
post infection, but not with the vPS136X vectors. At 48 hours post infection NTR was 
detected with all vectors, with a range of expression levels evident from the vPS136X 
vectors. Of all the vPS136X vectors, vPS1365 and vPS1366 expressed the most NTR, 
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followed by vPS1361, vPS1362, vPS1364, with vPS1363 expressing the least amount of 
NTR. Furthermore, at 48 hours post infection, NTR expression from vNR6 was greater than 
from vPS1361-4, and similar to that of vPS1365 and vPS1366.  
 
All vPS136X vectors express NTR from the same splice acceptor site, the presence of 
which was confirmed by PCR sequencing (data not shown), and therefore were expected to 
express equivalent amounts of NTR. No correlation was observed between NTR expression 
and P:I ratios. Furthermore, there was no clear correlation between oncolytic cytotoxicity 
and NTR expression.  
5.4.5 vPS136X E1A Expression 
Each vPS136X vector demonstrated different cytotoxicities and NTR expression, despite 
the fact they were all derived from the same left end plasmid. Both virus lytic activity and 
transgene expression are related to E1A expression levels thus both of these observations 
could be explained by difference in E1A levels. It was therefore decided to investigate E1A 
protein expression of the 6 vPS136X viruses.  
DU145 cells plated in 24-well plates were infected with 10 PFU/cell of vPS136X vectors or 
Ad5 wt as described in section 2.4.8. At 8, 16 and 24 hours post infection total protein was 
harvested and prepared for western blotting. Blots were probed for E1A and β-tubulin 
(loading control) using unlabelled primary antibodies with HRP-labelled species-specific 
secondary antibodies and detected using an ECL kit (as described in section 2.8.4). 
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Figure 5-7. Western blot for E1A expression in vPS136X vectors 
DU145 cells seeded at 1x10
5
 cells per well in 24-well plates were infected with 10 PFU/cell 
of Ad5 wt or vPS136X vectors as described in section 2.4.8. Total protein was harvested at 
8, 16 and 24 hours post infection, 2.5g of each sample separate by SDS-PAGE and 
western blotted, as described in section 2.8. Blots were probed for E1A and β-tubulin 
expression (loading control).  
 
Figure 5-7 shows the E1A expression from each vPS136X vector and Ad5 wt at 8, 16 and 
24 hours post infection. E1A expression was clearly seen with Ad5 wt at all three 
timepoints. No E1A expression was detected for vPS1361, 3 and 6 at any of the timepoints, 
even after prolonged exposure (data not shown). In contrast E1A expression was observed 
for vPS1362, 4 and 5. vPS1364 had a detectable level of E1A 16 hours post infection, 
which was maintained at 24 hours. For vPS1362 and vPS1365, E1A was only detectable at 
24 hours post infection, with vPS1362 expressing significantly more than vPS1365. 
The different levels of E1A expression between vPS136X vectors is somewhat unexpected, 
as all vectors have E1A driven by the same ICOVIR-7 promoter. There was no clear 
correlation between E1A expression and NTR expression or P:I ratio. However, the 
differential E1A expression does correlate with the oncolytic activity; the vectors 
expressing the most E1A have the lowest EC50 values in prostate cancer cell lines (see 
Table 5-2 for EC50 values).  
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5.4.6 vPS136X ICOVIR-7 Promoter Sequencing 
All vPS136X vectors were created by homologous recombination using the same batch of 
the left end plasmid pICOVIR-7, which was also used for construction of vMH6 and 
vMH7. All vPS136X vectors were shown to be free of contaminating wt E1A sequences by 
PCR screening (performed by Dr P. Searle and E. Hodgkins, data not shown). Despite this, 
the vPS136X vectors expressed different levels of E1A protein. To investigate whether this 
difference was a result of unintentional mutations acquired within the region controlling 
E1A expression, the ICOVIR-7 promoter region in each vPS136X virus was sequenced. 
Sequencing was performed as described in section 4.3.8.  
All vPS136X vectors were shown to have an ICOVIR-7 promoter sequence identical to that 
found in vMH6 and vMH7 (see section 4.3.8 and appendix 2). This sequence includes the 
base changes identified in vMH6, vMH7 and the plasmid pICOVIR-7, located at the 
cloning junctions in the construction of pICOVIR-7 (discussed in section 4.4.2). Therefore 
the differential E1A expression was not due to a mutation within the ICOVIR-7 promoter 
insertion. However the possibility of unintentional mutations elsewhere in the vectors 
genome still exists (discussed in section 5.5.3). 
5.4.7 Cytotoxicity of vPS136X Vectors with CB1954 
To investigate the NTR/CB1954 mediated cytotoxicity with the vPS136X vectors, DU145 
cells plated in 96-well plates were infected with Ad-GFP, vNR6 or vPS136X at 3 or 10 
PFU/cell (as described in section 2.4.8). 48 hours post infection the medium was replaced 
with 200µl of fresh infection medium containing 1-1000µM of CB1954. Cells were 
incubated with prodrug for 16 hours before the CB1954 was removed and replaced with 
200µl of fresh infection medium. At 120 hours post infection (96 hours after prodrug 
exposure) cell survival was measured by AP assay. The data was normalised to empty wells 
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(0% viability) and infected cells with no CB1954 (100% viability) to assess the 
NTR/CB1954 mediated cytotoxicity. Dose response curves are shown in Figure 5-8 with 
EC50 values in Table 5-4. 
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Figure 5-8. Dose response curves for 16 hour CB1954 exposure 
DU145 seeded in 96-well plates at 3x10
4
 cells per well before infection with Ad-GFP, 
vPS136X vectors or vNR6 at 3 PFU/cell (A) or 10 PFU/cell (B), as described in section 
2.4.8. 48 hours post infection the virus was removed and replaced with 200µl of infection 
medium containing 1-1000µM CB1954. Cells were incubated with prodrug for 16 hours at 
37
o
C before the CB1954 was removed, wells washed and replaced with 200l of fresh 
infection medium. Cell survival was measured 5 days post infection by AP assay and 
normalised to infected cells with no prodrug (100% survival) and empty wells (0% cell 
survival). Plots show mean cell survival from triplicate wells (n=1), ± S.D. (where no error 
bars are visible S.D. was <5%), and fitted sigmoid dose response curves. Dose response 
curves were used to calculate EC50 values.  
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Virus 
3 PFU/cell 
16 hour CB1954 
10 PFU/cell 
16 hour CB1954 
Ad-GFP 254 (205 - 315) 289 (254 - 329) 
vPS1361 67.6 (50.8 - 89.8) 33.7 (30.5 - 37.2) 
vPS1362 29.2 (18.9 - 45.1) 15.1 (12.5 - 18.4) 
vPS1363 46.3 (40.7 - 52.6) 17.1 (15.9 - 18.4) 
vPS1364 9.39 (7.91 - 11.2) 7.76 (5.28 - 11.4) 
vPS1365 15.4 (7.98 - 29.9) 3.74 (2.53 - 5.51) 
vPS1366 21.0 (14.1 - 31.2) 12.8 (11.8 - 13.9) 
vNR6 6.92 (4.37 - 11.0) 6.25 (4.72 - 8.29) 
Table 5-4. EC50 values with 95% C.I. (PFU/cell) after 16 hours CB1954 exposure 
 
Greater sensitisation to CB1954 was observed at the higher MOI of 10 PFU/cell. At 3 
PFU/cell (Figure 5-8A), vNR6 showed the greatest sensitisation to CB1954, closely 
followed by vPS1364 (double mutant NTR, wt fibre vector). Both triple mutant viruses, 
vPS1365 and vPS1366, showed the third greatest sensitisation to CB1954, followed by 
vPS1363 and finally vPS1361.  
At 10 PFU/cell (Figure 5-8B), vPS1365, vNR6 and vPS1364 showed the greatest 
sensitisation to CB1954, with no significant difference between the three vectors. vPS1366, 
vPS1362 and vPS1363 are next and showed similar levels of sensitisation. Again vPS1361 
showed the least sensitisation to CB1954. 
The data above is normalised to infected cells with no CB1954 and therefore only assesses 
the NTR/CB1954 mediated cytotoxicity, not taking into account the intrinsic oncolytic 
activity of the virus. To investigate the combined oncolytic activity and NTR/CB1954 
mediated cytotoxicity of each vector, the same data was normalised to empty wells (0% 
viability) and mock infected cells (100% viability); the results are shown in Figure 5-9.  
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Figure 5-9. Dose response curves for combined cytotoxicity with 16 hour CB1954 
exposure 
The same data is presented as in Figure 5-8, but normalised to mock infected cells (100% 
survival) and empty wells (0% survival), to assess the combined oncolytic and 
NTR/CB1954 mediate cytotoxicity. Plots show mean cell survival from triplicate wells 
(n=1), ± S.D. (where no error bars are visible S.D. was <5%), and fitted sigmoid dose 
response curves.  
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At both MOIs, vPS1364 showed more cytotoxicity in the absence of prodrug compared to 
all the other vectors, which achieved <20% cell death in the absence of prodrug. 
Looking at the combined effect, vPS1364 was the most cytotoxic vector at both MOIs, 
followed by vPS1365, which showed less lytic activity in the absence of prodrug, but gave 
a greater sensitization to prodrug. vPS1361 showed the least combined cytotoxicity at both 
MOIs, requiring the highest prodrug concentration of all NTR expressing vectors to reach 
100% cell death. 
 
The above experiments used a 16 hour prodrug exposure. A recent phase I/II clinical trial 
using the NTR/CB1954 enzyme/prodrug system in a replication deficient Ad vector, 
observed the concentration of CB1954 in patient plasma peaked 6 minutes post 
administration (mean peak concentration of 7.8M, S.D. 3.1M) and had completely 
cleared after 4-6 hours [Patel et al,  2009]. Thus, a 16 hour prodrug exposure time is far 
greater than the maximum prodrug exposure time observed physiologically. It was therefore 
decided to investigate the NTR/CB1954 mediated cytotoxicity after a shorter (4 hour) 
prodrug exposure. The experiment as described above was repeated infecting the cells with 
10 PFU/cell of Ad-GFP, vNR6 or vPS136X vectors, with a 4 hour prodrug exposure (1-
1000µM). Cell survival was measured 5 days post infection by AP assay. The data was 
normalised to empty wells (0% survival) and infected cells with no prodrug (100% 
survival) to analyse the NTR/CB1954 mediated cytotoxicity. Dose response curves are 
shown in Figure 5-10, with EC50 values in Table 5-5.  
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The same data was also normalised to mock infected cells (100% survival) and empty wells 
(0% survival) to ascertain the combined oncolytic activity and NTR/CB1954 mediated 
cytotoxicity (Figure 5-11).  
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Figure 5-10. Dose response curves for 4 hour CB1954 exposure 
DU145 were seeded in 96-well plates at 3x10
4
 cells per well before infection with Ad-GFP, 
vPS136X vectors or vNR6 at 10 PFU/cell, as described in section 2.4.8. 48 hours post 
infection the virus was removed and replaced with 200µl of infection medium containing 1-
1000µM of CB1954. Cells were incubated with prodrug for 4 hours at 37
o
C before the 
CB1954 was removed, wells washed and replaced with 200l of fresh infection medium. 
Cell survival was measured 5 days post infection by AP assay and normalised infected cells 
with no prodrug (100% survival) and empty wells (0% cell survival). Plots show mean cell 
survival from triplicate wells (n=1), ± S.D. (where no error bars are visible S.D. was <5%), 
and fitted sigmoid dose response curves. Dose response curves were used to calculate EC50 
values.  
 
Virus 
10 PFU/cell 
4 hour CB1954 
Ad-GFP >1000 
vPS1361 535 (490 - 585) 
vPS1362 149 (120 - 184) 
vPS1363 >1000 
vPS1364 71.8 (47.1 - 110) 
vPS1365 58.4 (43.4 - 78.5) 
vPS1366 137 (119 - 158) 
vNR6 68.8 (52.2 - 90.6) 
Table 5-5. EC50 values with 95% C.I. (PFU/cell) for 4 hour CB1954 exposure 
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Figure 5-11. Dose response curves for combined cytotoxicity with 4 hour CB1954 
exposure 
The same data is presented as in Figure 5-10 but normalised to mock infected cells (100% 
survival) and empty wells (0% survival), to assess the combined oncolytic and 
NTR/CB1954 mediate cytotoxicity. Plots show mean cell survival from triplicate wells 
(n=1), ± S.D. (where no error bars are visible S.D. was <5%), and fitted sigmoid dose 
response curves.  
 
Looking at the NTR/CB1954 mediated cytotoxicity (Figure 5-10), vPS1365, vPS1364 and 
vNR6 showed the greatest cytotoxicity, all with no significant difference between the EC50 
values, ranging from 58-72µM (Table 5-5). These are followed by vPS1362 and vPS1366, 
both with EC50 values of approximately 140µM, and finally vPS1361 and vPS1363 with 
EC50 values of 500µM and 1000µM respectively. 
The same pattern of virus oncolytic activity was observed, with only vPS1364 
demonstrating 45% cell death and all other vectors showing <25% cell death in the absence 
of prodrug (Figure 5-11). vPS1364 also showed the greatest combined effect, with 50% cell 
death at 1µM CB1954, however most of this cytotoxicity was from virus oncolytic activity. 
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vPS1365 was the second most cytotoxic vector, with 50% cell death achieved at 
approximately 18µM CB1954. vPS1361 and vPS1363 were the least cytotoxic vectors, 
requiring 450µM and >1000µM CB1954 to achieve 50% cell death, respectively. 
 
At both MOIs and both prodrug exposure times vPS1364 showed the greatest combined 
cytotoxicity; followed by vPS1365 and vNR6. By looking at the NTR/CB1954 mediated 
cytotoxicity alone it was clear the additional cytotoxicity observed with vPS1364 over 
vPS1365 and vNR6 was due to a greater oncolytic activity as opposed to a greater 
NTR/CB1954 mediated cytotoxicity. vPS1362 and vPS1366 gave the next greatest 
combined cytotoxicity, with little difference between them. At both MOI and prodrug 
exposure times vPS1363 and vPS1361 showed the least combined cytotoxicity. 
With respect to the NTR/CB1954 associated cytotoxicity, a clear pattern was observed, 
with vPS1365 and vPS1364 showing the greatest toxicity of all vPS136X vectors, equal to 
that of vNR6. This was followed by vPS1361 and vPS1366 and finally vPS1361 and 
vPS1363, both of which showed little sensitisation to CB1954 at the lower MOI and shorter 
CB1954 exposure time.  
5.5 Discussion 
5.5.1 Construction of vPS136X Vectors and P:I Ratios 
Six new oncolytic Ad vectors expressing NTR or NTR mutants (vPS131-6) were 
constructed based on the ICOVIR-7 oncolytic backbone. All vectors possessed acceptable 
P:I ratios ratios in the range of 10-110, comparable to that of the E1B-55K deleted NTR 
expressing vector vNR6. Previous attempts to recover replication defective Ad vectors 
expressing some of the triple NTR mutants from the CMV promoter have been 
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unsuccessful, probably because high level expression of the mutant NTR affected virus 
growth, resulting in low yield and high P:I ratios (Dr P. Searle, personal communication). 
However the late transgene expression in the vPS136X vectors did not have any significant 
detrimental effect on virus production. 
Work in CHAPTER 3 with eGFP expressing vectors found a positive correlation between 
increasing genome size and increasing P:I ratio with all batches of the ICOVIR-7 based 
vectors (vMH6 and vMH7) having the largest genomes and P:I ratios of approximately 100. 
One explanation is that the increase in genome size may lead to a reduction in virus 
packaging efficiency, resulting in lower infectious vector concentrations and higher P:I 
ratios (discussed in section 3.6.2). Three vP136X vectors (vPS1361, 4 and 5) have P:I ratios 
at the upper limit of the acceptable range, of approximately 100, whereas vPS1362, 3 and 6 
have P:I ratios between 35 and 62. Figure 5-12 plots the vector P:I ratio against the vector 
genome size, combining the observations with all batches of vMH and vPS136X vectors 
plus Ad5 wt. 
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Figure 5-12. Scatter plot of vector size vs P:I ratio 
The P:I ratio of the banded stocks of Ad5 wt, vMH vectors and vPS136X vectors was 
plotted against the vector genome size relative to Ad5 wt. For each data point n=1. 
GraphPad software was used to perform Spearman rank analysis (Spearman rank = 0.9762 
and p=0.0004)  
 
Spearman rank analysis of the combined vMH and vPS136X vector observation shows a 
positive correlation between increase in virus genome size and P:I ratio (Spearman rank = 
0.9762, p value = 0.0004), similar to the previous observations for the vMH vectors 
(discussed in section 3.6.2). Bett et al previously suggested a relatively tight Ad packaging 
limit between 104.6% and 105.4% of Ad5 wt [Bett et al,  1993]. All ICOVIR-7 based 
vectors (vMH6, vMH7 and vPS136X vectors) have genomes between 105% and 105.25% 
of Ad5 wt and it is tempting to speculate the increase in P:I ratio is a result of reduced 
packaging efficiency, thus reducing the infectious virus yields. However there does not 
appear to be any hard limit as all ICOVIR-7 vectors could be easily grown and worked 
with. It also important to remember this study was not designed to investigate viral 
packaging limits and a more detailed study would be required to make a full correlation 
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between virus genome size and packaging efficiency. Furthermore, if virus genome 
packaging was a problem it would be anticipated the vectors would undergo rearrangements 
and deletions to reduce genome size, possibly within regions not required for in vitro 
culture, such as the E3 region. However all vectors had the predicted restriction profile, 
demonstrating they had not undergone any major rearrangements or deletions, however 
these may become apparent at higher passage number. It is therefore possible the increase 
in P:I ratios observed is not entirely due to vector genome size, however in my opinion it is 
likely the packaging limit contributes to the higher P:I ratio of the viruses with larger 
genomes. It is also essential to note all plaque assays were performed on DU145 cells and 
up to a 5-fold greater number in plaques has been observed with the vPS136X vectors on 
HEK293 cells (data not shown). For a more rigorous comparison of P:I ratios between vMH 
or vPS136X vectors and any replication deficient vector, HEK293 cells should be used, not 
the DU145 values presented in this study. 
5.5.2 vPS136X Cytotoxicity and Therapeutic Index 
All vPS136X vectors are based around the same oncolytic ICOVIR-7 backbone and were 
therefore expected to show similar levels of cytotoxicity and tumour cell selectivity. The 
eGFP expressing ICOVIR-7 based vectors, vMH6 and vMH7, show similar cytotoxicities 
to both tumour cells and fibroblasts, with a 3-, 20- and 30- fold reduction in lytic activity 
relative to Ad5 wt in PC3, 22RV1 and DU145 cells respectively, and no toxicity to MRC5 
cells.  
In contrast to this expectation, lytic activity with vPS136X vectors ranged from equal to 
Ad5 wt to a 28-fold reduction in lytic activity. In addition, there was no clear correlation 
between RGD-retargeted and equivalent wt fibre vectors. Table 5-6 shows the vPS136X 
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vectors and vNR6, ranked 1-7 for oncolytic activity, tumour selectively, relative E1A and 
NTR expression, NTR/CB1954 mediated cytotoxicity and combined cytotoxicity. 
 
Virus 
P:I 
ratio 
E1A NTR 
Oncolytic 
Activity 
TI 
NTR/CB1954 
Cytotoxicity 
Combined 
Cytotoxicity 
vNR6 64.2 n/d = 1 4 = 4 = 1 3 
vPS1361 92.2 Neg 4 = 5 = 6 6 7  
vPS1362 45.8 2 5 = 2 2 = 4 = 4 
vPS1363 62.3 Neg 7 = 5 3 6 6 
vPS1364 108.2 1 6 1 1 = 1 1 
vPS1265 105.4 3 = 1 = 2 = 6 = 1 2 
vPS1366 34.7 Neg = 1 7 = 4 = 4 = 4 
Table 5-6. Rank scoring from 1 - 7 (most - least) of vPS136X vectors 
 
A clear pattern of lytic activity can be observed with the vPS136X vectors, with vPS1364 
being most lytic in all prostate cancer cell lines, followed by vPS1362 and vPS1365. This 
pattern is slightly different in MRC5 cells, with vPS1365 being most lytic, followed by 
vPS1364 and then vPS1362. Both vPS1361 and vPS1363 show similar lytic activities in all 
cell lines, and vPS1366 is consistently the least lytic vector.  
The TI was used to give an indication of vector tumour selectivity. Once again it was 
anticipated the three RGD-retargeted vectors would show a similar therapeutic index, as 
would the three wt fibre vectors. However a wide range of TI was observed across the panel 
of vPS136X vectors. vPS1364 (wt fibre, double mutant NTR) was shown to be the most 
selective vector in all the prostate cancer cell lines tested. This was followed by vPS1362 
(wt fibre, wt NTR) and vPS1363 (RGD-retargeted fibre, double mutant NTR). In addition 
these are the only three vectors which had TIs greater than vNR6 in all prostate tumour cell 
lines. Furthermore, vPS1364 and vPS1362 showed TIs greater than Ad5 wt in all prostate 
cell lines, whereas no vMH vector showed TI greater than Ad5 wt in DU145 and 22RV1 
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cells (discussed in section 4.4.1). No consistent pattern could be observed with the 
remaining vectors; vPS1361, 5 and 6. 
 
It is not clear why a range of lytic activities was observed with the vPS136X vectors, nor 
why they showed cytotoxicity greater than vMH6 or vMH7. As has been previously 
discussed, both vector genome size and the replacement of eGFP with NTR may result in 
the additional cytotoxicity observed with vPS136X vectors, compared with vMH6 and 
vMH7. However, there was a direct correlation between vPS136X oncolytic activity and 
E1A expression, whereby vPS1364 was the most oncolytic and expressed the most E1A, 
followed by vPS1362 which expressed the second highest amount of E1A and was the 
second most oncolytic, and finally vPS1365 being the third most oncolytic and the only 
other vPS136X vector to have detectable levels of E1A. No E1A was detected with 
vPS1361, 3 and 6 which were the least cytotoxic. The differential E1A expression is 
discussed fully in section 5.5.3 below. 
From the data presented in this thesis it is not possible to ascertain to what extent these 
factors contribute to the range of oncolytic activities observed with the vPS136X vectors or 
the additional cytotoxicity over vMH6 and vMH7. Cytotoxicity experiments with HEK293 
cells may help to eliminate some variation in the E1A expression between vPS136X 
vectors, thus elucidating more information regarding the NTR associated cytotoxicity.  
Ideally for a direct comparison with vMH6 and vMH7 to assess the NTR associated 
increase in cytotoxicity, each vPS136X virus would have been constructed by reverse 
engineering, directly replacing the eGFP ORF in the vMH vectors with that of NTR or NTR 
mutants. This would allow assessment of any additional cytotoxicity directly from the NTR, 
as any base changes in vMH vectors would be transferred into all the vPS136X vectors. 
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However this method is substantially more time consuming and the vectors would still have 
to be cultured and plaque purified, allowing opportunity for additional mutations to be 
accumulated.  
5.5.3 E1A Expression and Promoter Sequencing 
All vPS136X vectors are based on the ICOVIR-7 left end backbone, and thus have the wt 
E1A promoter replaced by the tumour-specific ICOVIR-7 promoter. Furthermore, all 
vPS136X vectors were recovered using the same stock of left end plasmid, pICOVIR-7, as 
were vMH6 and vMH7. It was therefore expected that all vPS136X would express similar 
levels of E1A protein. As shown in Figure 5-7, a range of E1A protein expression levels 
was detected in the panel of vPS136X vectors, summarised in Table 5-6, with vPS1364 
showing the highest level of E1A expression, followed by vPS1362 and vPS1365. No E1A 
was detected with vPS1361, 3 and 6. All vPS136X vectors were screened by PCR to 
confirm the absence of contaminating wt E1A sequences. In addition the restriction profiles 
have been confirmed with HindIII, BglII and KpnI, demonstrating that all the banded stocks 
consisted predominantly of a virus with the correct ICOVIR-7 left end. 
A clear positive correlation was observed between vPS136X oncolytic activity and E1A 
expression (discussed in section 5.5.2 above). However, the reason behind the differential 
E1A expression observed with vPS136X vectors is unknown. The promoter region 
controlling E1A expression (including the first 50bp of the E1A ORF) were sequenced and  
shown to be identical in all vPS136X vectors and identical to vMH6 and vMH7.  
In CHAPTER 4 vMH7 was shown to produce less E1A RNA and protein than vMH6, 
resulting in delays in DNA replication and late gene expression. Several reasons were 
suggested for this difference including minor contamination with wt E1A sequences not 
detectable by standard PCR, an unintentional mutation introduced with vMH6 increasing 
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E1A expression, an unintentional mutation in vMH7 reducing E1A expression, or a direct 
interaction between the RGD-retargeted fibre and the ICOVIR-7 promoter (for a full 
discussion see section 4.4.2). All vectors were shown to be free of contaminating wt E1A 
CR2 region by PCR, but they were not PCR screened for the presence of the wt E1A 
promoter. Restriction enzyme profiling demonstrated the majority of the banded stocks 
contained the ICOVIR-7 left end; however this method is not as sensitive as PCR. It is 
therefore possible that low level contamination with virus containing the wt E1A promoter 
was responsible for the differential E1A expression. It would therefore in my opinion be 
informative to screen all vMH and vPS136X vectors for the presence of the wt E1A 
promoter by PCR. Since no delay in E1A RNA expression was observed with the other 
RGD-retargeted vector vMH5, it seems unlikely this delay was the result of an interaction 
between the RGD-retargeted fibre and the ICOVIR-7 promoter (for example, the RGD-
fibre may activate an intracellular signalling pathway which is detrimental to ICOVIR-7 
promoter activation). If the delay observed with vMH7 was due to an interaction between 
the RGD-retargeted fibre and ICOVIR-7 promoter it would be predicted that the same delay 
would be observed with other RGD-retargeted ICOVIR-7 based vectors. However no 
significant difference was observed in the DNA replication profiles of the RGD-retargeted 
vector vPS1361 and wt fibre vector vPS1362, both of which contain the same wt NTR 
transgene. This would suggest the delay in E1A expression and thus DNA replication 
observed with vMH7 is not common for all RGD-retargeted ICOVIR-7 vectors, and is 
probably not due to an interaction between the ICOVIR-7 promoter and the RGD-retargeted 
fibre. It is possible mutations have also arisen in vPS1361, 3 and 6 resulting in aberrant 
E1A expression, or in vPS1362, 4 and 5 resulting in increased E1A expression. If the 
results of vMH6 and vMH7 genome sequencing clearly indicate a mutation which would 
 244 
explain the difference in E1A expression, it would perhaps be worth investigating vPS136X 
vectors for further mutations. 
5.5.4 NTR Expression and NTR/CB1954 Mediated Cytotoxicity 
As would be expected increasing the virus MOI (from 3 to 10 PFU/cell) and increasing the 
prodrug exposure time (from 4 to 16 hours) reduced cell survival. At both prodrug 
exposures, vPS1364 was the most cytotoxic combined therapy, followed by vPS1365 and 
vNR6 (see Table 5-6 for ranking). vPS1362 and vPS1366 showed combined cytotoxicity 
slightly lower than vNR6. vPS1363 and vPS1361 demonstrated the lowest cytotoxicity with 
combined therapy, which was most evident at lower MOI (3 PFU/cell with 16 hour prodrug 
exposure) and shorter prodrug exposure (10 PFU/cell with 4 hour prodrug exposure). 
Normalisation of cell survival to virus infected cells in the absence of prodrug allows 
assessment of the NTR/CB1954 mediated toxicity alone, disregarding the virus oncolytic 
activity. By this criterion, vNR6, vPS1364 and vPS1365 gave the greatest sensitisation, as 
indicated by the lowest EC50 value (see Table 5-4 and Table 5-5) with no significant 
differences between them. vPS1363 and vPS1361 gave the least sensitisation to CB1954, 
which was barely above the negative control (Ad-GFP) at 10 PFU/cell and a 4 hour prodrug 
exposure or 3 PFU/cell and a 16 hour prodrug exposure. Taking into account these 
observations it can be concluded that the additional combined cytotoxicity observed with 
vPS1364 over vPS1365 and vNR6 originates from increased oncolytic activity. In contrast, 
vNR6 and vPS1365 show less oncolytic activity but possibly a slightly greater 
NTR/CB1954 mediated cytotoxicity. A recent phase I/II clinical trial using intravenous 
delivery of CB1954 showed a mean peak concentration of 7.8M (S.D. 3.1M) in patient 
serum, suggesting the local tumour concentration can not be greater than approximately 
7.8µM [Patel et al,  2009]. With this in mind, the NTR/CB1954 mediated EC50 values for 
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vPS1364, vPS1365 and vNR6, which showed the greatest sensitisation to CB1954 
following a 4 hour CB1954 incubation, were approximately 10-fold greater than the peak 
concentration observed in patients. Furthermore, at the CB1954 concentrations observed in 
patient serum these vectors only show about a 20% increase in cell death. It is therefore 
worth considering whether any of these CRAd vectors would provide any additional 
therapeutic benefit at clinically relevant prodrug concentrations compared to the oncolytic 
virus alone.  
When looking specifically at the NTR/CB1954 mediated cytotoxicity it is also possible to 
assess the increase in sensitisation to CB1954 conferred by the NTR mutants relative to wt 
NTR. Previous in vitro studies by The University of Birmingham SCS-GT group, using the 
double and triple NTR mutants have demonstrated a 14- and 80-fold increase in sensitivity 
to CB1954 over wt NTR using replication defective vectors for gene delivery [Guise et al,  
2007; Jaberipour et al,  2010]. With all vPS136X vectors the maximum increase in CB1954 
sensitivity observed was approximately 10-fold, when comparing the EC50 values of 
vPS1361 (RGD-fibre, wt NTR) to vPS1365 (RGD-fibre, triple mutant NTR) at 10 PFU/cell. 
Furthermore, no vPS136X vector demonstrated significantly greater sensitisation to 
CB1954 than vNR6. Work in section 4.3.3 with the equivalent eGFP expressing vectors 
demonstrated, at 48 hours post infection, vMH6 and vMH7 expressed >10-fold more eGFP 
than vNR3, an E1B-55K deleted vector expressing eGFP from the pIX promoter. All 
vPS136X vectors were therefore expected to express more NTR than vNR6 at 48 hours post 
infection and consequently show greater sensitisation to CB1954 than vNR6. Contrary to 
this prediction, western blot analysis demonstrated no vPS136X vectors express more NTR 
than vNR6 at 48 hours post infection (see Table 5-6 for ranking of NTR expression), thus 
helping to explain the reduced efficacy in comparison to vNR6. It is also likely the range of 
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NTR expression observed contributes to the lower than expected increase in sensitisation to 
CB1954 observed with NTR mutant vectors, compared to their wt NTR expressing 
equivalents. However, there was no direct correlation between increased NTR expression 
and increased CB1954 sensitisation, (for example, vPS1362 expresses less NTR than 
vPS1366, but vPS1362 shows a >10-fold sensitisation to CB1954 compared to vPS1366, 
despite the fact vPS1366 contains the catalytically enhanced triple mutant NTR). It is 
important to note that the western blot and CB1954 sensitisation assays were performed at a 
single timepoint (48 hours post infection) and it is therefore possible that the level of NTR 
expression differs between the vPS136X viruses with time. 
 
Two major questions remain; why did each vPS136X virus express a different level of NTR 
and why was the level of NTR expression lower than vNR6 at 48 hours post infection? 
There is no clear correlation between NTR expression and either vector P:I ratio or E1A 
expression (see Table 5-6). There was no significant difference between the DNA 
replication profiles of vPS1361 and vPS1362, suggesting the difference was not related to 
DNA replication. However it would be worth investigating the DNA replication profiles of 
the other vPS136X vectors. Jaberipour et al have previously observed lower expression 
levels with some NTR mutants compared to wt NTR, despite expression from an identical 
Ad vector [Jaberipour et al,  2010]. It was suggested that the mutations may affect mRNA 
stability or translation, and or reduced protein stability of the mutants as possibly 
contributing to the lower level of mutant NTR expression. It is possible that such factors 
play a role in the lower level expression observed with the double mutant NTR compared to 
wt NTR. However in contradiction, the triple NTR mutant shows the highest NTR 
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expression, thus other factors must be playing a role in the differential NTR expression 
observed between the vPS136X vectors.  
There is no clear reason why vPS136X vectors express less NTR than vNR6. However, 
taking into account the above suggestions by Jaberipour et al a comparison can only be 
made between vPS1361/2 and vNR6, which express wt NTR: vPS1361 and vPS1362 
expressed significantly less NTR than vNR6, at 48 hours post infection. The sequence of 
the NTR insert in all of these vectors has been confirmed by PCR sequencing, ruling out 
unintentional mutations in the insertion.  
Gene expression from the Ad MLP is a complicated multi-factorial process, which is 
regulated by several host and viral proteins via promoter activation, RNA splicing, mRNA 
export and translation (discussed in section 1.2.2.1.4 and 1.2.2.3). Thus there are several 
levels at which NTR expression in vPS136X vectors could be controlled. Over-expression 
of NTR (and particularly NTR mutants) in Ad vectors is known to be somewhat toxic to the 
virus, causing low infectious virus titres and high P:I ratios (Dr P. Searle, personal 
communication). It is therefore possible, and in my opinion likely, that the culture and 
plaque purification of vPS136X vectors selected viruses with lower NTR expression, 
without affecting overall late protein expression. It would be interesting to screen plaques 
from the original 1
o
 seed stocks for NTR protein expression and compare the level of NTR 
expression to other late viral proteins such as hexon or fibre. However, to prove this theory 
and find at which level NTR expression is controlled, detailed investigations into late RNA 
expression and protein production would be required. It is also worth noting that NTR 
expression in vPS136X vectors (or eGFP expression with vMH vectors) has not been 
directly demonstrated to be under MLP control or exactly how these transgenes are spliced 
from the MLTU. Since transgenes are inserted downstream of fibre it is possible for 
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splicing to include x, y and z leader sequences as well as the compulsory 1, 2 and 3 
sequences, introducing the possibility of multiple splice variants and alternative pathways 
for mRNA maturation. However there were no indications from any experiments conducted 
with vPS136X or vMH vectors that transgene expression is not controlled by the MLP, and 
the timing of eGFP transgene expression with vMH vectors was similar to that of other Ad 
proteins expressed from the MLP, such as protein V (see Figure 4-4 and Figure 4-7 for 
eGFP and protein V expression, respectively).  
5.6 Summary 
Six new oncolytic CRAd vectors were constructed, based on the ICOVIR-7 backbone, 
which expressed either wt NTR, double mutant NTR or triple mutant NTR. These vectors 
have been characterised in terms of tumour selectivity, NTR/CB1954 mediated 
cytotoxicity, combined cytotoxicity, transgene and E1A expression. Of all these vectors 
vPS1364, expressing double mutant T41L N71S NTR with a wt fibre, demonstrated the 
highest tumour selectivity and greatest cytotoxicity, alone and in combination with the 
prodrug CB1954. Furthermore, this vector was more selective than vNR6, an E1B-55K 
vector expressing wt NTR, and demonstrated greater cytotoxicity in combination with the 
prodrug CB1954. 
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CHAPTER 6   
 
Summary and Future Work 
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The work presented in this study has investigated oncolytic adenoviruses, in particular the 
ICOVIR based vectors from Dr R. Alemany‟s lab, armed with nitroreductase and in 
combination with the prodrug CB1954, for the treatment of prostate cancer.  
 
The use of oncolytic adenoviruses carrying NTR has been explored over the past several 
years primarily by The University of Birmingham SCS-GT group. Drs Chen and Roesen 
previously constructed two E1B-55K deleted oncolytic vectors carrying NTR, CRAd-NTR 
and vNR6; the latter was shown to have greater cytotoxicity at low MOI and no NTR-
associated toxicity to virus replication [Chen et al,  2004; Roesen 2006]. Unfortunately 
vNR6 also demonstrated significant cytotoxicity to non-transformed human fibroblasts. Dr 
R. Alemany‟s lab at the Institut Català d'Oncologia designed a series of oncolytic 
adenoviruses vectors, the latest two of these, ICOVIR-5 and ICOVIR-7, contain the E1A 
CR2 24 deletion and have the wt E1A promoter replaced by one of two insulated tumour 
specific E2F-1 promoter. These vectors were potential oncolytic backbones for the 
introduction of the therapeutic transgene NTR; however at the beginning of this study no 
data was published on either vector. In order to assess which vector provided the most 
suitable backbone for introduction of therapeutic transgenes it was decided to construct and 
characterise ICOVIR-5 and ICOVIR-7 based vectors expressing the marker transgene 
eGFP. The transgene was inserted downstream of fibre and utilised a splice acceptor site for 
expression from the MLP. Equivalent vectors were constructed containing the wt fibre or 
the RGD-retargeted fibre, to investigate whether the RGD-retargeted fibre conferred any 
cytotoxic advantage in prostate cancer cell lines. An equivalent E1A CR2 24 vector was 
also constructed which retained the wt E1A promoter and wt fibre to investigate the effect 
of insertion of the insulated E2F-1 promoter. 
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The E1A CR2 24 vector vMH2 with the wt E1A promoter and wt fibre, consistently 
showed the greatest cytotoxicity in all prostate cancer cell lines but also showed the greatest 
cytotoxicity to non-transformed human fibroblasts and as a result showed the lowest tumour 
selectivity (as measured by the therapeutic index) of all vMH vectors. No significant 
toxicity was observed with either ICOVIR-7 based vector, vMH6 and vMH7, in non-
transformed human fibroblasts and it was therefore deemed these vectors were the most 
tumours selective. However they also demonstrated the lowest cytotoxicity to prostate 
cancer cell lines, compared to all other vMH vectors. Transgene expression was generally 
observed from approximately 24 hours post infection, which coincided with the end of virus 
DNA replication and the start of late virus protein expression. No significant increase in 
cytotoxicity was observed with RGD-retargeted viruses compared to the wt fibre 
equivalents, probably because all prostate tumour cells used expressed moderate to high 
levels of CAR. However the presence of the RGD-retargeted fibre was shown to increase 
transduction of SKOV3 and MZ2-MEL3.0 cells which expressed no detectable levels of 
CAR.  
Unexpectedly, the RGD-retargeted ICOVIR-7 based vector vMH7 demonstrated a delay in 
E1A RNA and protein expression compared to the equivalent wt fibre vector vMH6, which 
subsequently delayed DNA replication, late virus protein and eGFP expression. The 
ICOVIR-7 promoter from both vectors and the original pICOVIR-7 promoter were 
sequenced and shown to be identical.  
In comparison to vNR3, ICOVIR-5 and ICOVIR-7 based vectors showed greater tumour 
selectivity in all prostate cancer cell lines and demonstrated up to a 10-fold greater 
transgene expression. 
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There is much scope for further work to be done on the ICOVIR-5 and ICOVIR-7 based 
vectors. More investigation is required to identify why vMH7 expresses less E1A than 
vMH6. Based on the observations with other RGD-retargeted viruses (vMH4 vs. vMH5 and 
vPS1361 vs. vPS1362) it would in my opinion seem unlikely this difference was due to a 
specific effect of inserting the RGD-4C motif. The genomes of both vMH6 and vMH7 are 
currently being sequenced, which may identify a sequence difference explaining the 
difference in E1A expression. Neither ICOVIR-5 or ICOVIR-7 vectors were shown to be 
directly pRb dependent in these experiments. Furthermore, in PC3 and 22RV1 cells that 
express wt pRb lower EC50 values were observed with ICOVIR-5 and ICOVIR-7 based 
vectors, in comparison to the mutant pRb cell line DU145. This does not rule out mutations 
at other points within the pRb pathway and the observations are further complicated by 
other factors such as varying cell surface receptor expression. However vICOVIR-5 was 
shown to be pRb/E2F responsive by our collaborators [Alonso et al,  2007a]. Additionally 
eGFP has not been directly shown to be expressed from the MLP, or whether insertion of 
transgenes affects viral gene expression (such as fibre or E4). It would therefore be 
interesting to investigate in further detail the mechanism of transgene expression and any 
effect of transgene insertion, before such insertions were used in future vectors. Finally, it is 
worth considering whether the ICOVIR-7 vectors provide sufficient oncolytic cytotoxicity 
to tumour cell lines to confer a significant anti-tumour effect in prostate cancer patients, 
thus in vivo animal experiments would be required to investigate oncolytic activity. 
 
Based on the fact the ICOVIR-7 based vectors were shown to be most tumour selective, 
with no significant cytotoxicity to non-transformed human fibroblasts, the ICOVIR-7 
backbone was chosen for the introduction of NTR. One of three NTR variants was inserted; 
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wildtype, double mutant or triple mutant NTR, each with either the wt fibre or RGD-
retargeted fibre, thus creating a panel of 6 vectors (vPS1361-6). Each vPS136X vector was 
subsequently characterised in terms of cytotoxicity, tumour selectivity, E1A and NTR 
expression, NTR/CB1954 mediated cytotoxicity and combined cytotoxicity. Contrary to 
expectations each vPS136X vector showed differential virus-induced cytotoxicity and all 
vectors except vPS1366 were significantly more cytotoxic than the equivalent eGFP 
expressing vectors vMH6 and vMH7. This differential cytotoxicity resulted in a wide range 
of tumour selectivity with both vPS1362 and vPS1364 consistently showed the highest 
therapeutic indices, even greater than vNR6 and Ad5 wt. Whereas the differential 
cytotoxicity was not fully explained there was some correlation with E1A expression, 
whereby the higher the E1A expression the more cytotoxic the vector. However, the 
differential E1A expression was also unexpected, as all vPS136X vectors have E1A under 
control of the same ICOVIR-7 based promoter, which was shown by DNA sequencing to be 
identical in all vPS136X vectors. Each vPS136X showed a different level of NTR 
expression, which did not correlate with either the vector P:I ratio or E1A expression. 
Furthermore, the wt NTR expressing vPS136X vectors, vPS1361 and vPS1362, were 
shown to produce less NTR than vNR6 at 48 hour post infection. This observation was 
contradictory to that using equivalent eGFP expressing vectors, where vMH6 and vMH7 
showed 10-fold higher transgene expression compared to vNR3. vPS1364 demonstrated the 
greatest combined cytotoxicity, both at 3 PFU/cell and 10 PFU/cell, and a 16 or 4 hour 
prodrug exposure. Looking at just the NTR/CB1954 mediated cytotoxicity vPS1364, 
vPS1365 and vNR6 all demonstrated equivalent sensitisation to CB1954, thus it would 
appear the additional combined cytotoxicity observed with vPS1364 was the result of 
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greater virus induced cytotoxicity. It is however clear vPS1364 shows both greater 
cytotoxicity and selectivity than the best previous vector vNR6. 
 
With vPS136X vectors two essential questions remain; what is the cause of the differential 
E1A expression and what is the cause of the differential and lower than anticipated NTR 
expression. A reduction in E1A expression was previously observed with the RGD-
retargeted fibre vector vMH7 compared to the wt equivalent vMH6, however there was no 
correlation between RGD fibre and E1A expression with vPS136X vectors. Further 
investigations with vMH6 and vMH7 may elicit some explanation to the difference in E1A 
expression observed with these vectors and it would be interesting to see if the same 
difference was found in any vPS136X vector. There are many possible explanations for the 
differential NTR expression observed, which was also lower than anticipated, such as 
variations in mRNA and protein stability. Additionally, MLP expression is controlled at 
multiple points including RNA splicing, mRNA export and translation, and it is not 
unconceivable transgene expression is downregulated by the MLP at one of these points. 
Investigations into exactly how eGFP expression is controlled in vMH vectors may be used 
to identify how NTR expression is controlled and potentially downregulated in vPS136X 
vectors. Furthermore, it may be beneficial to understand exactly how transgene expression 
is controlled in vMH and vPS136X vectors, before using the same splice acceptor sites for 
the expression of potentially toxic transgenes. Alternatively, other mechanisms to achieve 
late transgene expression could be investigated, such as the use of IRES (internal ribosome 
entry sites) sequences [Cody and Douglas 2009] or 2A sequences (which use a process 
called „ribosome skipping‟) from picornaviruses [Funston et al, 2008] which could be used 
to directly link expression of transgenes to virus genes such as fibre.  
 255 
Many various ways have been investigated to express transgenes in CRAd vectors, and it is 
debatable as to which mechanism is preferable, particularly where potentially toxic 
transgenes are required and a balance needs to be found between virus spread and 
enzyme/prodrug efficacy [reviewed by Cody and Douglas 2009]. Furthermore, the 
packaging limit of the virus must be considered, especially when designing CRAds with 
multiple inserts and exogenous promoters. Transgene expression from constitutive 
promoters such as the CMV immediate early promoter yield high levels transgene 
expression, conferring a good therapeutic affect. However this way can result in reduced 
virus yields in combination with the prodrug [Roesen 2006]. The key concern with using 
constitutively active promoters, such as the CMV promoter, is that transgene expression 
could be allowed in non-tumour tissue causing additional unwanted toxicity. However, by 
using tumour-specific or endogenous virus promoters reduces this risk. Exogenous tissue-
specific promoters have been investigated extensively to drive transgene expression [Cody 
and Douglas 2009]. Such promoters are advantageous as they can give good levels of 
transgene expression and transgene expression is tissue targeted reducing the risk to non-
target tissue types. However these promoters can again be expressed at early times post 
infection making them no ideal for CRAd vectors. Typically, insertion of exogenous 
promoters requires deletion of some viral genes to allow enough space in the genome to 
accommodate both the promoter and transgene. Generally these deletions were made within 
the E3, which removes gene involved in immune evasion and the ADP, neither of which 
may be required. However the E3B has been retained to keep some immune evasion 
functions and more importantly ADP. 
Various strategies have been investigated for expression of transgenes from endogenous 
viral promoters. Such strategies can reduce the transgene mediated toxicity to the virus as 
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the timing of expression within the virus lifecycle can be controlled, for example expression 
of NTR from the pIX ORF showed no toxicity to the virus in combination with prodrug 
[Roesen 2006]. However expression from the pIX promoter is significantly lower than other 
virus promoters, which resulted in low level transgene expression and a poor therapeutic 
potential, demonstrating that the virus promoter used for transgene expression needs to be 
carefully chosen. Ideally therapeutic transgene expression should be higher but only 
activate at late times of infection, to give a good therapeutic potential but no toxicity to 
virus DNA replication, and it would seem expression from the E3 region or Ad MLP would 
be ideally suited for this. Multiple studies have inserted transgenes in the E3 region as well 
as replacing the interval E3 proteins and in doing so mimicking transgene expression to that 
of the replaced viral gene in terms of timing and levels. Several E3 genes are expressed at 
low level early in infection, however greatly upregulated in late Ad infection (post DNA 
replication). Therefore insertion of NTR into the E3 region deserves consideration as this 
may demonstrate both low toxicity to the virus and a good therapeutic potential.  
In this study transgene expression is from a splice acceptor site inserted downstream of the 
fibre gene. Previous studies have used a similar system for expression of transgene from the 
Ad MLP both downstream of fibre and within the L3 region [Carette et al, 2005; Guedan et 
al, 2008; Robinson et al, 2008]. These studies identify high and late transgene expression as 
would be expected and a more strict dependence on initiation of DNA replication, which 
would be ideally suited for expression of potentially toxic transgene. Non of these studies 
identify any unintentional toxicity or reduced expression due to transgene insertion. 
However an older study by Fuerer and Iggo expressing the yCD gene downstream of fibre 
from the Ad41 long fibre demonstrated lower than anticipated transgene expression, which 
was inferior to that of an IRES behind the fibre gene  [Fuerer and Iggo, 2004]. These 
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observations coincide with those made in this study, where toxic transgene expression from 
the MLP is downregulated, and may also suggests further investigations are required into 
the control of transgenes expression using this system.  
An interesting study by Jin et al, used a transposon-based system to scan the Ad genome for 
insertion sites that did no compromise the viral life cycle. In this study a reporter gene 
(eGFP or luciferase) was linked via a splice acceptor site so that expression was dependent 
on endogenous promoters [Jin et al, 2005]. Using this method a variety of insertion sites 
were discovered, primarily between the E3 and L5 regions and around the E4 region, and in 
every case the transcripts originated from the MLP. This study would suggest a fair amount 
of flexibility in the locations of transgene insertion, but also demonstrate there are some 
regions where the virus will not accept any transgene insertion. Thus, the transgene 
insertion site still needs to be well considered as to not unintentionally disrupt expression of 
viral gene. This includes both well characterised virus transcription units and potentially 
new or novel transcription units such as the U exon. Currently the exact promoter region 
driving UXP expression has not been identified and deletion of UXP was shown to cause a 
mild growth defect [Tollefson et al,  2007]. Thus for transgene insertion downstream of 
fibre conversations need to be made to fibre, E4 and UXP expression, as not to disrupt 
expression and virus production.  
 
It is difficult to accurately compare the cytotoxicities of vPS136X vectors with similar Ad 
vectors expressing transgenes reported previously. Singleton et al have reported on a 
similar study in which they inserted wt NTR into the E3B region of ONYX-411, an E1A 
CR2 24 deleted virus with E1 and E4 expression controlled by the E2F-1 
promoter[Singleton et al,  2007]. The resultant vector, termed ONYX-411
NTR
, showed no 
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reduction in lytic activity compared to the parental vector and typically resulting in EC50 
values of 1-10 PFU/cell in PC3 and DU145 cells. It is impossible to compare EC50 values 
between studies due to the variation in experimental procedure and the authors did not 
include Ad5 wt as an internal reference which would have enabled some of a comparison. 
The study goes on to show high level NTR expression occurs post initiation of DNA 
replication and ONYX-411
NTR
 shows a moderate increase in sensitisation to CB1954 but a 
greater increase in sensitisation using an alternative prodrug SN27686. It would therefore 
be interesting to investigate the use of alternative prodrug, such as SN27686, with the 
vPS136X vectors as well as perform direct comparisons between vPS136X vectors and 
similar oncolytic Ad vectors, such as ONYX-411
NTR
. The results of such investigations 
may help to identify the optimal vector and prodrug combination for prostate cancer gene 
therapy.  
 
The work presented in this study has developed novel oncolytic adenovirus vectors for 
combined oncolytic virotherapy and NTR/CB1954 mediated suicide gene therapy. One 
vector, vPS1364 expressing double mutant NTR and wt fibre, was identified which 
demonstrates both greater tumour cell selectivity and combined cytotoxicity than the E1B-
55K deleted NTR expressing vector vNR6. Therefore vPS1364 may warrant further 
investigation in in vivo animal models to assess any potential anti-tumour activity. 
 
 
 i 
Appendix 1 
The tables below show the predicted HindIII, BglII and KpnI restriction enzyme profiles for each vMH vector. Distinctive bands are 
highlighted in bold text. Gels showing the restriction enzyme digests for each vMH vector are shown on the next page. Separate gels were 
run for each vMH vector, alongside Fermentas 1kb+ DNA ladder (300bp, 400bp, 500bp, 650bp, 1kb, 1.5kb, 2kb, 3kb, 4kb, 5kb, 7kb, 
10kb, 20kb) for size determination with 1.5kb and 5kb bands labelled. Distinct bands marked by an *. 
 
 
 
 
KpnI 
vMH2 vMH4 vMH5 vMH6 vMH7 
6485 6485 6485 6485 6485 
5753 5753 5753 5753 5753 
    5609   5609 
5582 5582   5582   
5120 5120 5120 5120 5120 
3646 3646 3646 3646 3646 
2949 2949 2949 2949 2949 
2337 2337 2337 2337 2337 
2028         
      1864 1864 
  1738 1738     
1696 1696 1696 1696 1696 
  1281 1281 1281 1281 
1086 1086 1086 1086 1086 
BglII 
vMH2 vMH4 vMH5 vMH6 vMH7 
6182 6182 6182 6182 6182 
5586 5586 5586 5586 5586 
5178 5178 5178 5178 5178 
      4421 4421 
  4295 4295     
3304         
2943 2943 2943 2943 2943 
    2423   2423 
2396 2396   2396   
2334 2334 2334 2334 2334 
2151 2151 2151 2151 2151 
1672 1672 1672 1672 1672 
1548 1548 1548 1548 1548 
1497 1497 1497 1497 1497 
1268 1268 1268 1268 1268 
351 351 351 351 351 
272 272 272 272 272 
HindIII 
vMH2 vMH4 vMH5 vMH6 vMH7 
8010 8010 8010 8010 8010 
5665 5665 5665 5665 5665 
5324 5324 5324 5324 5324 
4597 4597 4597 4597 4597 
    3735   3735 
3708 3708   3708   
3437 3437 3437 3437 3437 
      3142 3142 
  3016 3016     
2780         
2081 2081 2081 2081 2081 
1005 1005 1005 1005 1005 
 ii 
 
 vMH2         vMH4    vMH5   vMH6   vMH7 
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Appendix 2 
The following page shows the results from the ICOVIR-7 promoter DNA sequencing. All 
numbers refer to the positions within the vMH6/vMH7/vPS136X genomes. Mutations are 
shown in red with the nucleotides inserted or deleted in capitals. The DM-1 insulator 
element is underlined in black and the E2F-1 promoter region is underlined in blue. The 
region containing the two additional E2F binding regions is underlined in pink. Nucleotides 
in blue represent the E2F binding sites, each consisting of two imperfect palindromes.  
The E1A ATG is shown in capitals and underlined in green and the primers used for 
sequencing are shown in grey. A list of the primers used for sequencing can be found in 
table Table 2-1.  
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